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Abstract 
Respiratory disease is an important cause of wastage in the Australian horse racing 
industry and viruses are frequently suspected as aetiological agents of respiratory 
disease or poor performance by clinicians and trainers but confirmation is seldom 
attempted.  This thesis deals with the potential role of equine herpesvirus types 1, 2, 
4 and 5 in upper respiratory disease and poor performance in horses in Western 
Australia. 
The methodology selected for the identification of equine herpesviruses in tissues of 
horses was polymerase chain reaction (PCR) and therefore individual PCR assays 
were developed for the detection of each herpesvirus, and then a nested multiplex 
PCR was developed to detect all four viruses.  There was good correlation between 
the multiplex PCR for the detection of EHV and the detection of virus by isolation in 
cell culture, although a combination of the 2 techniques provided greater sensitivity 
than either technique alone.  The multiplex PCR described appeared equally 
sensitive as specific PCR assays using a single set of primers for each individual 
virus but reduced labour and reagent costs.   
As latency is a well recognised phenomenon in the equine herpesviruses and the 
horse is subjected to  a number of stresses which might induce reactivation of latent 
infections, it was hypothesised that there would be a background level of replication 
of the equine herpesviruses in clinically normal horses.  Nasal swabs and peripheral 
blood leukocytes (PBL) were obtained from 282 clinical normal horses and examined 
for EHV.  The results clearly demonstrated the widespread occurrence of EHV in the 
clinically healthy horses.  The rate of detection of different types of EHV varied, as 
did the prevalence in young and adult horses.  The most common EHV detected was 
EHV5: in 83.2% of 131 of horses <2 years of age; in 40% of horses >2 years of age.   
A prospective clinical study was conducted whereby respiratory tract samples and 
PBL from adult horses with respiratory disease and/or poor performance were ii   
examined for equine herpesviruses; the aim was to determine a possible association 
between equine herpesvirus infection and respiratory disease and/or poor 
performance.  The relative incidence of factors identified in the history, signalment, 
physical and laboratory evaluation of horses in the study population was compared 
between horses from which EHV was identified in respiratory samples and horses 
negative for equine herpesvirus.  The results indicated that equine herpesviruses 
were important causes of respiratory disease in the study population, and that 
haematological and cytological data were a poor indicator of such equine herpesvirus 
infection.   
The occurrence of equine herpesvirus in nasal swabs and PBL of weaned or 
unweaned foals from Thoroughbred breeding establishments was determined and 
provided data on the occurrence of EHV in association with respiratory disease.   
EHV5 was detected in nasal swabs and/or PBL at a high prevalence rate in healthy 
foals and yearling horses but its occurrence was not associated with clinical signs of 
respiratory disease.  In contrast, EHV2 was detected more commonly in nasal swabs 
and/or PBL from foals with respiratory disease than in similar samples from healthy 
horses.  Experimental infection of 8 horses with EHV2 was attempted and induced 
clinical signs of respiratory disease, but less severe than observed in the 
epidemiological studies.  The results suggested that EHV2 is associated with mild 
upper respiratory tract infection in young horses. 
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Chapter 1.  Introduction 
This thesis deals with an investigation of the potential role of equine herpesvirus 
in respiratory disease and poor performance in horses in Western Australia, in 
both Thoroughbred and Standardbred horses.  Respiratory disease is an 
important cause of wastage in the Australian horse racing industry (Bailey et al., 
1997) and viruses are frequently suspected as aetiological agents of respiratory 
disease or poor performance by clinicians or trainers but confirmation is seldom 
attempted and so-called “viral” respiratory disease is therefore often assumed in 
horses that may be suffering from other disease syndromes.  As a clinical 
diagnosis of respiratory disease may be difficult, and there is similarity in the 
clinical signs induced by various aetiological agents, confirmation of the role of 
viruses in respiratory disease can only be achieved with laboratory support and 
a good understanding of the epidemiology and pathogenesis of all four equine 
herpesviruses that have been associated with respiratory disease in the horse. 
Upper respiratory tract disease in the horse is complex in causation and many 
agents or factors may be involved, including viral and bacterial infections, and 
various non-infectious causes (Mumford & Rossdale, 1980).  Viruses associated 
with respiratory disease include the alphaherpesviruses equine herpesvirus type 
1 (EHV1) and type 4 (EHV4), the gammaherpesviruses equine herpesvirus type 
2 (EHV2) and type 5 (EHV5), equine rhinoviruses, equine influenza virus, equine 
arteritis virus, parainfluenza-3 virus, equine adenovirus and Hendra virus 
(McChesney, 1975; Sherman et al., 1977; Coggins, 1979; Reif, 1979; McAllister, 
1982; Colahan et al., 1992; Mumford et al., 1998).  
Research reported in this thesis has concentrated on the role of equine 
herpesviruses in upper respiratory tract disease.  A critical analysis of the 
literature dealing with herpesviruses was therefore undertaken, concentrating on 2   
the equine herpesviruses, but also examining comparative aspects of 
herpesviruses in other species, for which there was usually more information 
available; this is provided in Chapter 2.  As persistence of herpesviruses 
probably throughout life is a feature of all herpesviruses, including the equine 
herpesviruses (Studdert, 1996; Baxi et al., 1996), the events and mechanisms 
by which latency is established were included in the review.  An understanding 
of latency was considered critical to the interpretation of the results of this thesis 
as it is generally recognised that not all horses infected with the equine 
herpesviruses necessarily have clinical disease, and it was hypothesised that 
latency or reactivation of latent virus may be one explanation for the occurrence 
of equine herpesviruses in some horses.   
Prior to commencing epidemiological or pathogenesis studies it was deemed 
critical to develop rapid, sensitive and specific methods of detecting the equine 
herpesviruses present in sampled horses.  Until recently, cell culture has been 
the gold standard technique but this technique is time consuming, expensive 
and, therefore, not really suited to large scale epidemiological investigations.  
The recent advances in molecular biology, enabling the sequence analysis of 
most equine herpesvirus types, have  led to the development of PCR based 
techniques for the detection and differentiation of the alphaherpesviruses EHV1 
and EHV4 (Borchers et al., 1993; Carvalho et al., 2000), and the 
gammaherpesviruses EHV2 and EHV5 (Reubel et al., 1995).  Rather than 
conducting individual PCR assays for each virus, it was hypothesised that it 
should be possible to develop a multiplex one-step or two-step PCR for the 
simultaneous detection of all four equine herpesviruses associated with 
respiratory disease, and the results of this investigation and the method finally 
developed is reported in Chapter 3. 3   
As latency is a well recognised phenomenon in the equine herpesviruses 
(Studdert, 1996; Baxi et al., 1996), and the horse is subjected to  a number of 
stresses such as weaning, sales, transportation and training during its pre-racing 
career which might induce reactivation of latent infections, it was hypothesised 
that there would be a background level of replication of the equine 
herpesviruses in clinically normal horses.  A better understanding of the virus 
population in clinically normal horses was considered important for the 
interpretation of results from the examination of horses with respiratory disease.  
An examination of the virus population of normal horses was therefore 
undertaken, utilising the multiplex PCR that was developed.  These results are 
reported in Chapter 4. 
An examination of horses with respiratory disease was then undertaken, again 
concentrating on determination of the potential role of equine herpesviruses as 
aetiological agents in the affected horses, and these results are reported in 
Chapter 5.   
While there is unequivocal evidence that the alphaherpesviruses EHV1 and 
EHV4 are pathogens and major causes of acute respiratory disease of horses, 
the evidence that the gammaherpesviruses EHV2 and EHV5 are a cause of 
respiratory disease is more tenuous.  In Australia, both EHV2 and EHV5 were 
detected in a high percentage of horses, including normal horses (Reubel et al., 
1995), but there are no reports definitively associating either gammaherpesvirus 
with disease.  During the examination of normal horses (Chapter 3) a high 
prevalence of EHV5 was detected, and only a low prevalence of EHV2.  
However, during the course of the investigation of young horses with respiratory 
disease it was determined that EHV2 was occasionally present in a high 
proportion of the affected horses, which suggested that it may be a cause of 
respiratory disease in these younger horses.  The results of the epidemiological 4   
survey suggesting EHV2 was associated with respiratory disease are reported in 
Chapter 6, as are the results of attempts to reproduce respiratory disease in 
foals experimentally infected with the isolated virus. 
A general discussion of the results and their significance is provided in the final 
Chapter 7. 5   
Chapter 2:  Literature review 
2.1 General introduction 
Equine respiratory disease is a common and important disease in many countries, 
including Australia (Studdert et al., 1970; Allen & Bryans, 1986; Studdert, 1996), 
New Zealand (Fu et al., 1986), the United States of America (Murray et al., 1998), 
Canada (Sherman et al., 1977), England (Mumford et al., 1998, Mumford & 
Edington, 1980), the Netherlands (de Boer et al., 1979), Germany (Schroer et al., 
2000), France and Ireland; (Bryans, 1980), Spain (Ruiz et al., 1998), Brazil 
(Carvalho et al., 2000a,b), Argentina (Galosi et al., 2001), Namibia (Borchers & 
Frolich, 1997), Nigeria (Adeyefa, 1992) and India (Singh et al., 1995).  It is the 
second most common cause of lost training days (Powell et al., 1974; Burrell et al., 
1996). 
In Australia there are about 1.2 million horses used for racing or recreational sport, it 
is a significant industry, and respiratory disease has been ranked as the highest 
research priority by surveys conducted within the industry.  All sectors of the 
industry, including the Thoroughbred Breeders Association, the Australian 
Racehorse Trainers Association, and equine veterinarians considered further 
understanding of respiratory disease to be of paramount importance (Five Year 
Strategic Plan, RIRDC Equine Research and Development Committee, 1996). 
Equine respiratory disease may affect the upper and/or lower respiratory disease 
(Ainsworth & Biller, 1998).  The causes are varied and include allergic conditions, 
infectious conditions caused by viruses, bacteria, fungi or parasites, and non-
infectious conditions such as exercise-induced pulmonary haemorrhage and chronic 
obstructive pulmonary disease.  The clinical signs of equine respiratory disease are 
therefore variable and frequently non-specific. 6   
Equine respiratory disease is an important cause of wastage in the Australian horse 
racing industry (Bailey et al., 1997).  It can cost the equine industry millions of 
dollars each year, associated with loss of weight, loss of training days, cost of 
antibiotics for treatment, and in severe cases even death (Mumford et al., 1998).  
Horses with respiratory disease show variable signs that may include an acute or 
chronic cough, abnormal respiratory noise with exercise, nasal discharge, 
decreased exercise tolerance, finishing a race in respiratory distress, and poor 
performance. 
As this thesis deals primarily with the role of equine herpesviruses (EHV) in 
respiratory disease in Australia, this literature review therefore focuses on the EHV, 
their role in respiratory disease and poor performance, and methods for the 
diagnosis of viral respiratory disease and the detection of herpesviruses. 
2.2 Respiratory disease and poor performance 
Poor performance can be defined as less than expected or anticipated performance 
based on a level which has been previously observed, affecting an individual or 
sometimes a whole stable population (Pilsworth et al., 1998).  Poor performance in 
racehorses is a subject that is at the forefront of concerns affecting owners, trainers 
and the betting public.  Respiratory problems caused by viruses have been 
incriminated on many occasions as a cause of poor performance but other causes 
such as nutrition, allergies and the environment, including climatic influences, 
exercise regimes and prior infections, may also play significant roles (Seeherman 
et al., 1990; Freeman et al., 1993, Burrell et al., 1996). 
2.3 Viruses as causes of equine respiratory disease  
Viruses may be suspected as aetiological agents of respiratory disease or poor 
performance by clinicians or trainers, but confirmation of the viral aetiology is 
seldom attempted and so-called “viral” respiratory disease is often assumed in 7   
horses that may be suffering from other disease syndromes.  A clinical diagnosis of 
respiratory disease may be difficult; there is a similarity in the clinical syndrome 
induced by a number of aetiological agents, as well as difficulty in identifying the 
primary aetiological agents.  One survey in the UK indicated that the causes of 68% 
of respiratory disease outbreaks over a one-year period were not identified (Dixon 
et al., 1995).  It is necessary in the case of suspected viral disease that further 
investigations be conducted, using samples such as bronchoalveolar lavage (BAL), 
tracheal washes (TW) and nasal swabs (NS), and peripheral blood leukocytes 
(PBL) (Beech, 1991b) to detect infectious agents. 
Ten viruses have been associated with respiratory disease or isolated from the 
respiratory tract in the horse: the alphaherpesviruses EHV1 (equine abortion virus) 
and EHV4 (rhinopneumonitis virus), the gammaherpesviruses EHV2 and EHV5, 
equine rhinoviruses (now reclassified as aphthoviruses and erboviruses), equine 
influenza virus, equine arteritis virus, parainfluenza-3 virus, equine adenovirus and 
Hendra virus (McChesney, 1975; Sherman et al., 1977; Coggins, 1979; Reif, 1979; 
McAllister, 1982; Colahan et al., 1992; Mumford et al., 1998).  
There is unequivocal evidence that the alphaherpesviruses EHV1 and EHV4 are 
pathogens and major causes of acute respiratory disease of horses, although not all 
horses infected with these 2 viruses necessarily develop a recognised clinical 
disease.  In contrast, although numerous reports have associated EHV2 with 
disease, primarily respiratory disease, there is no definitive evidence that the 
gammaherpesviruses EHV2 and EHV5 are a cause of respiratory disease.  For 
example, EHV2 was detected in pulmonary macrophages from horses with lower 
respiratory tract disease (Schlocker et al., 1995; Murray et al., 1996) but as EHV2 
was also detected in (albeit a lower percentage) of samples from clinically normal 
horses (Schlocker et al., 1995), the interpretation of this result is uncertain.  Most of 
the reports associating EHV2 with disease generally precede the ability to 8   
differentiate EHV2 from EHV5; therefore, to avoid confusion in this thesis, where it 
is apparent that there is no distinction between EHV2 and EHV5, the viruses will be 
referred to as “EHV2”.   
The role of the equine rhinoviruses in respiratory disease in Australia has been 
investigated although the extent of their involvement is poorly defined.  Only 
serotype 1 (now reclassified as equine rhinitis A virus in genus Apthovirus) has 
been isolated in Australia (Studdert & Gleeson, 1978; Studdert & Gleeson, 1977; Li 
et al., 1997) and serological surveys have indicated there is a high equine rhinitis A 
seroprevalence rate of 48% (Li et al., 1997).  Sero-epidemiological data also 
indicated that equine rhinovirus type 2 (now renamed as equine rhinitis B virus and 
reclassified in genus Erbovirus) infection of horses may be common in Australia and 
a 24% seroprevalence rate was reported (Huang et al., 2001). 
Equine influenza virus is highly contagious and spreads rapidly in horses stabled 
together.  Infection is associated with a rapid onset of acute fever that persists 4-5 
days, a concurrent serous or mucopurulent nasal discharge, and a harsh dry cough 
persisting for up to 3 weeks.  Infection is usually self-limiting, with improvement 
seen within 5-7 days of onset provided no complications, such as pneumonia and 
secondary bacterial infection, occur.  Equine influenza is endemic in many countries 
including Europe and America, but has not occurred in Australia.  Influenza virus 
A/equine/2 is the most common virus associated with acute infectious upper 
respiratory tract disease (Mumford et al., 1998).  
Although never reported in Australia, sero-epidemiological surveys have revealed 
that equine arteritis virus is prevalent in most European countries (Glaser et al., 
1996) and North America (Del Piero, 2000).  The virus causes sporadic cases of 
respiratory disease and abortion in horses, the incidence of which has increased in 
recent years.  Mares and geldings eliminate virus after acute infection, but 30% to 
60% of stallions become persistently infected.  In these animals, equine arteritis 9   
virus is maintained within the reproductive tract and is shed continuously in the 
semen (Holyoak et al., 1993; Glaser et al., 1996). 
Parainfluenza-3 virus has been associated with equine upper respiratory disease 
but its importance in the production of epizootics of respiratory disease in horse is 
not known.  Parainfluenza-3 infection of young horses was reported in Canada by 
Ditchfield et al. (1965) associated with clinical signs that included mild fever, 
anorexia, dyspnoea, nasal discharge and conjunctivitis.  The absence of other 
subsequent reports of its occurrence suggests it is an unusual infection in horses.  
Equine adenovirus has been isolated from clinically normal horses and from horses 
with respiratory disease in Australia but it is not a major cause of equine respiratory 
disease (Wilks & Studdert, 1973; Harden, 1974; Harden et al., 1974b). 
Hendra virus is a recently identified member of the family Paramyxoviridae which is 
the type species of a new genus within the sub-family Paramyxovirinae, which also 
contains another newly identified zoonotic bat virus, Nipah virus (Wang et al., 2000).  
Hendra virus was originally recognised as a cause of a severe respiratory disease in 
horses in association with encephalitis and pneumonia in humans (Madic, 2001).  
The virus is a zoonotic agent able to cause natural disease in humans and horses, 
and 3 human cases have been recognised, all in association with equine cases: 
there have been 2 human fatalities, one due to respiratory failure and the other from 
delayed-onset encephalitis (Barclay & Paton, 2000).  Infected horses can develop a 
severe and often fatal respiratory disease characterised by dyspnoea, vascular 
endothelial damage and pulmonary oedema; nervous signs may also occur.  
Hendra virus is not contagious in horses and transmission appears to require close 
contact with body fluids, such as froth from infected lungs (Hooper et al., 2000; 
Williamson et al., 2000).  There is no evidence for widespread subclinical infection 
of horses (Barclay & Paton, 2000). 10   
Experimentally, Hendra virus has produced a fatal respiratory disease in cats, 
guinea pigs and mice.  Fruit bats, especially Pteropus species, are the natural and 
reservoir hosts of Hendra virus, wherein it produces a mainly subclinical infection.  
The method of transmission from bats to horses is unknown.  It is assumed that 
contact with bats has led to the transfer of Hendra virus to horses on each of the 3 
separate incidents reported in the last 5 years (Westbury, 2000).  
In summary, influenza and equine arteritis viruses (the former being a major cause 
of respiratory disease in endemic countries) have, to date, been successfully 
excluded from Australia.  Parainfluenza viruses and adenovirus infections in the 
horse appear to be uncommon and of minor clinical significance.  Serological 
studies suggest that rhinoviruses (now reclassified as aphthoviruses and 
erboviruses) may be widespread in the horse population in Australia but there is 
minimal evidence that they are significant causes of respiratory disease, although 
this should be investigated further.  The EHV, therefore, are the major known and 
potential viral pathogens of the equine respiratory tract in Australia.  While the 
pathogenicity of the alphaherpesviruses has been extensively investigated there is 
minimal information on the occurrence or pathogenicity of the equine 
gammaherpesviruses in the horse population in Australia, or elsewhere. 
2.4 Characteristics of Herpesviridae 
The family Herpesviridae, although divided into 4 subfamilies Alphaherpesvirinae, 
Betaherpesvirinae, Gammaherpesvirinae and an un-named subfamily comprising 
the channel catfish herpesvirus-like viruses (Van Regenmortel et al., 2000), all have 
a number of features in common.  The common features include aspects of their 
structure, biological properties including a propensity to form latent infections in 
infected animals, similar genomic structure and mode of replication.  There is, 
however, a considerable degree of variation between the more than 100 species 
identified from most animal species (White & Fenner, 1994). 11   
2.4.1.  General features of the structure of herpesviruses 
The Herpesviridae have distinct virion architecture and all possess similar structural 
components.  There is a torus-shaped inner fibrous spool-like core about 75 nm in 
diameter (Knopf, 2000) surrounding the DNA genome, which is contained within an 
icosahedral capsid of about 125 nm diameter (Knopf, 2000) with 162 hollow 
capsomers, which is surrounded by an amorphous tegument, in turn enclosed in an 
outer envelope (Figures 2.1 and 2.2).  The size of herpesvirus virions has been 
reported to vary from 120 to nearly 300 nm (Roizman et al., 1992), the variability 
due to the variability in the thickness of tegument and the state of the envelope 
(Knopf, 2000). 
 
Figure 2.1.  Schematic representation of the composition and structure of a typical 
herpesvirus.  
 
   
Figure 2.2.  Electro-micrographs depicting the feature of a typical herpesviruses. A, 
Enveloped particles showing internal icosahedral nucleocapsid; B, Icosahedral nucleocapsid 
without envelope .  (From: A, http://www.uct.ac.za/depts/mmi/stannard/emimages.html, 19 
July 2002; B, http://www.virology.net/Big_Virology/Special/EHV1/EHVpage.html, 19 July 
2002). 12   
Electro-microscopic studies of thin sections of infected cells have shown that the 
envelope has a trilaminar appearance (Roizman et al., 1992), which is to be 
expected as it is derived from membranes of the host cell (Mettenleiter, 2002).  The 
envelope contains protrusions or spikes, which are more numerous and shorter than 
those appearing on the surface of many other enveloped viruses; the spikes consist 
of glycoproteins, the number and relative amounts of which vary in different 
herpesvirus species (Roizman et al., 1992).  These glycoproteins play an important 
role in the infection process, mediating both entry of the virion into the host cell and 
cell-to-cell spread of virus (Spear, 1985).  This will be discussed further in Section 
2.4.6. 
The tegument is the structure between the capsid and envelope.  It has no 
distinctive features in thin sections but may appear fibrous in negatively-stained 
preparations.  It is frequently distributed asymmetrically and has varying thickness 
depending on the location of the virion within the infected cell, a factor affecting 
virion diameter (Roizman & Furlong, 1974). 
The icosahedral capsid, approximately 100 nm in diameter, is composed of 162 
morphological subunits (capsomers), 150 of which are hexameric and 12 of which, 
at the apices of the triangular facets on the icosahedron, are pentameric.  The 
structure of the hexameric and pentameric structures (Trus et al., 2001) is shown in 
Figure 2.3.   
The core located in the capsid of mature herpesvirus particles contains the genome 
consisting of double-stranded DNA ranging in size from 124-235 kbp in association 
with viral proteins, and may assume a torus (doughnut) shape.  In some herpesvirus 
species, the torus appears to be suspended by a proteinaceous spindle extending 
from the inside surface of the capsid (Roizman & Sears, 1996).  The arrangement of 
the DNA in the torus is unknown (Roizman & Sears, 1996) . 
 13   
 
Figure 2.3.  The hexon morphology for Kaposi’s sarcoma herpesvirus (KSHV), simian 
cytomegalovirus (sCMV), and herpes simplex virus type 1 (HSV1) (From Trus et al., 2001).  
In each case, the hexon on the icosahedral two-fold axis, is viewed from the outside (A, C, 
and E) and inside (B, D, and F).  In the outside views, 6 triplexes surround each hexon.  The 
mutual resemblance of the KSHV and sCMV protrusions is evident.   
 
2.4.2.  Common biological properties of herpesviruses 
Herpesviruses share a number of significant biological properties: 
(1) Transmission is generally associated with mucosal contact, but droplet infection 
is also common (Van Regenmortel et al., 2000).  Either method of transmission 
would require close contact between individuals. 
(2) The genome is double-stranded and linear, in the range of 125-235 kbp in size 
(Van Regenmortel et al., 2000). 14   
(3) They encode a large number of enzymes (DNA polymerase, helicase, primase, 
an origin binding protein) involved in nucleic acid metabolism, DNA synthesis and 
protein processing, although the number and type of enzymes varies for every 
herpesvirus.  They encode at least one protease and a variable number of protein 
kinases (Roizman, 1992; Roizman & Sears, 1996). 
(4) DNA replication occurs with sequential transcription and translation of immediate 
early (IE) or α, early (E) or β, and late (L) or γ genes producing α, β and γ proteins 
respectively.  The earlier transcripts regulate transcription of the later genes, and 
then encapsidation, which occurs in the nucleus (Van Regenmortel et al., 2000).  
The envelope is acquired by budding through the nuclear membrane.  
(5) Many of the alphaherpesviruses produce irreversible damage to the host cell 
during replication, often producing intranuclear inclusions, sometimes cytomegalic 
cells or syncytia.  They are frequently associated with focal or localised lesions, 
particularly in the skin or in the mucosae of the respiratory and genital tracts (Van 
Regenmortel et al., 2000).  In contrast to the alphaherpesviruses, the 
betaherpesviruses and gammaherpesviruses are not highly lytic for infected cells 
and they typically cause chronic infections lasting several months before clinical 
recovery.  Tumours are produced by some species within the Gammaherpesvirinae 
and by the alphaherpesvirus Marek’s disease virus, the latter possessing an 
oncogene similar to some retroviruses (Van Regenmortel et al., 2000) 
(6) All herpesviruses produce life-long persistent infections of the natural host, with 
persistence of the virus in a latent form after recovery from the initial acute disease.  
During latency, the viral genome circularises within specific cells, sometimes within 
neurons, sometimes within PBL, during which only a small subset of genes is 
expressed in the nucleus of the latently infected neurons or lymphocytes (Gleeson & 
Coggins, 1985).  Reactivation, sometimes associated with stress, triggers active 
virus replication and recurrence of clinical disease and further shedding of infectious 15   
virus (White & Fenner, 1994).  The mechanism of latency is described in greater 
detail below. 
2.4.3.  Classification of the herpesviruses 
Herpesviruses exhibit great diversity in their pathogenetic behaviour in cells and 
animals but are grouped into 3 sub-families based on the type of disease produced, 
cellular tropism and the nature of the latent infection.  Classifications based on 
these properties have in general accorded well with molecular properties including 
nucleotide sequence and phylogenetic analyses (Van Regenmortel et al., 2000).   
Alphaherpesvirinae exhibit a wide host cell range, have a relatively short 
reproductive cycle, spread rapidly from cell to cell in culture, cause widespread 
destruction of infected cells, and establish latent infections in sensory ganglia.  Even 
at a low multiplicity of infection (MOI) of 0.1, in cell culture they will produce 100% 
cytopathology within 24-48 h (Studdert, 1996).  The cytopathic effect (CPE) is 
characterised by focal rounding and aggregation of cells, after which the cells lyse 
and detach into the medium.  This subfamily includes human herpesvirus types 1 
and 2 (herpes simplex virus 1 and 2; HSV1 and HSV2), EHV1 and EHV4, and 
varicella-zoster virus (VZV) (Roizman & Sears, 1996).  EHV4 was initially 
differentiated from EHV1 based on significant genomic differences indicated by 
restriction endonuclease patterns (Sabine et al., 1981). 
Betaherpesvirinae have a more restricted host range than the alphaherpesviruses, a 
longer reproductive cycle, and spread slowly from cell to cell in culture.  Infected 
cells frequently become enlarged (cytomegalic) and carrier cultures are readily 
established.  Betaherpesviruses are normally latent in secretory glands, 
lymphoreticular cells, kidneys and other tissues (Roizman & Sears, 1996).  Included 
in the Betaherpesvirinae is the genus Cytomegalovirus (human herpesvirus 5 or 16   
 
 
Figure 2.4.  Phylogenetic dendrogram of herpesvirus major capsid proteins (adapted from 
Trus et al., 2001).  The 3 subfamilies are indicated by α, β and γ, and the notation for 
subgroupings (α1, α2, etc.) is that of McGeoch & Davison (1999).  Among the 
gammaherpesviruses, which include KSHV, the major capsid proteins of alcelaphine 
herpesvirus 1 and murine herpesvirus 4 appear distinct from the rest of the γ2 group.   
 
human cytomegalovirus, and cercopithecine herpesvirus 5), genus 
Muromegalovirus (murid cytomegalovirus 1 or mouse cytomegalovirus 1, and murid 
herpesvirus 2 or rat cytomegalovirus) and genus Roseolavirus (human herpesvirus 
6 or roseola virus). 
Gammaherpesvirinae have a restricted host range and are specific for either T or B-
lymphocytes (Drummer et al., 1996) in which they may establish latency and in 
some cases produce transformation of these cells without the production of progeny 
virus.  Gammaherpesviruses can establish latency in multiple cell types: murine 
gammaherpesvirus 68, for example, will establish latency not only in B cells but also 
in macrophages (Weck et al., 1999) including alveolar macrophages, and lung 
epithelial cells (Stewart et al., 1998; Wu et al., 2000).  Epstein-Barr virus (EBV) will 17   
establish latency in both B cells and epithelial cells (Robertson et al., 1996).  EHV2 
is latent in B lymphocytes (Drummer et al., 1996).  In vitro, gammaherpesviruses 
replicate in lymphoblastoid cells and will cause lytic infection in some types of 
epithelioid and fibroblastoid cells.   
Gammaherpesvirinae comprises 2 genera, Lymphocryptovirus (the gamma 1-
herpesviruses) including the baboon herpesvirus, cercopithecine herpesvirus 14 
and human herpesvirus 4 (Epstein-Barr virus), and Rhadinovirus (the gamma 2-
herpesviruses) including alcelaphine herpesvirus (wildebeest-associated malignant 
catarrhal fever virus), bovine herpesvirus 4, the 2 equine gammaherpesviruses 
EHV2 and EHV5, an equid herpesvirus 7 (asinine herpesvirus 2) isolated from a 
donkey (Browning et al., 1988b), human herpesvirus 8 (Kaposi's sarcoma-
associated herpesvirus), ovine herpesvirus 2 (sheep-associated malignant catarrhal 
fever virus) and saimirine herpesvirus 2 (herpesvirus saimiri).  Originally, the equine 
gammaherpesviruses were included in the Betaherpesvirinae due to similarities in 
their biological properties to cytomegaloviruses, but the 2 viruses were recently 
differentiated and reclassified as gammaherpesviruses based on genomic 
differences (Browning & Studdert, 1987b; Agius et al., 1992; Telford et al., 1993).  
EHV5 isolates exhibit a high degree of genetic heterogeneity (Dunowska et al., 
2000).  
In summary, there are currently 8 equid herpesviruses: 5 Alphaherpesvirinae and 3 
Gammaherpesvirinae.  The horse is the natural host of the alphaherpesviruses 
EHV1 (equine abortion virus), EHV 3 (equine coital exanthema virus) and EHV4 
(rhinopneumonitis virus) (Roizman, 1996).  Alphaherpesviruses in donkeys are 
asinine herpesvirus type 3 (AHV3) and an EHV3-homologue (asinine herpesvirus 
type 1, AHV1) (Browning et al., 1988b).  EHV2 and the related EHV5 are 
Gammaherpesvirinae of horses (Telford et al., 1993) whereas asinine herpesvirus 18   
type 2 (AHV-2) represents a related virus of donkeys, which was recovered from 
leukocytes of a clinically normal animal (Browning et al., 1988b). 
2.4.4.  Herpesvirus replication 
Herpesvirus replication occurs during a series of events (Figure 2.5) which can be 
divided into the following stages: (i) attachment of the virus to the host cell and 
penetration of the virus into the host cell (involving fusion of the virion envelope with 
the cell membrane), (ii) transport of the viral nucleocapsid to the nuclear pores, (iii) 
uncoating of the nucleocapsid and entry of the core into the nuclear compartment, 
where viral transcriptional events take place, (iv) viral DNA replication and 
recombination, (v) assembly of capsids and cleavage and packaging of viral DNA 
into preformed capsids, and (vi) maturation of virions (envelopment of 
nucleocapsids) by budding through the nuclear membrane and egress and release 
of the mature infectious virions (Knopf, 2000). 
After inhalation of a herpesviruses affecting the respiratory tract, the virus must first 
attach to the host mucosal epithelial cells of the nasal passages, pharynx and 
tonsillar tissue, and it does this via an interaction of the envelope glycoproteins gB 
and gC with glycosaminoglycan receptors, often heparan sulfate, on the cell surface 
(Riggio et al., 1989; Kasamatsu & Nakanishi, 1998; Knopf, 2000).  Mannose-6-
phosphate receptors and the complement receptor C3b appear to participate in the 
initial binding (Kasamatsu & Nakanishi, 1998).  This initial interaction of the virus 
with the cell is referred to as “attachment”.  After attachment, fusion of the viral 
envelope with the cell membrane is mediated by an interaction between viral 
glycoprotein gD with specific cellular receptor molecules; the nature of these 
receptors varies considerably with different species of herpesvirus (Knopf, 2000).    19   
 
Figure 2.5.  Schematic diagram illustrating the major features of the replication cycle of a 
typical alphaherpesvirus.  (1) virion attaches to host cell via complexing of envelope 
glycoprotein (gC) with heparan sulfate moieties of cellular proteoglycans. Viral gD is 
believed to bind to a secondary cellular receptor.  (2) The viral envelope fuses to the plasma 
membrane in a pH-independent fashion such that the nucleocapsid enters the cytoplasm. 
Glycoproteins gB, gD, and gH are instrumental for this process.  (3) The capsid travels along 
the cytoskeleton to a nuclear pore where the viral DNA is released.  The linear genome 
enters the nucleus and circularises.  (4) Once in the nucleus, the viral DNA is transcribed 
into mRNA by cellular RNA polymerase II.  In herpesviruses, viral gene expression is tightly 
regulated and divided into 3 kinetic classes of expression.  First, a tegument protein 
associates with cellular proteins, and the complex transactivates transcription of immediate-
early (IE or α) genes.  IE genes generally encode regulatory proteins.  Second, an IE protein 
initiates transcription of the early (E or β) genes.  These gene products are enzymes needed 
to increase the pool of nucleotides and for viral replication.  Lastly, late (L or γ) genes are 
activated for production of viral structural proteins.  (5) After transcription in the nucleus, all 
mRNA transcripts are translated into protein in the cytoplasm.  Subsequently, the proteins 
can go to the nucleus, stay in the cytoplasm, or become a part of the membrane bilayer.  (6) 
Capsid proteins assemble in the nucleus to form empty capsids.  (7) Full-length viral DNA is 
packaged to form nucleocapsids.  (8) The nucleocapsids associate with segments of the 
nuclear membrane where tegument and glycosylated envelope proteins have bound.  This 
association triggers envelopment by budding through the nuclear membrane.  (9) Enveloped 
virions accumulate in the endoplasmic reticulum (ER).  (10) Mature virions are released by 
exocytosis.  (11) Virus-specific proteins are also found on the plasma membrane of infected 
cells.  (From http://www.stanford.edu/group/virus/1999/inesicle/replication.html; 19 July 
2000) 
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Subsequent penetration through the cell membrane is assisted by 2 other viral 
glycoproteins, gH and gL (Peng et al., 1998).   
Five of 8 viral glycoproteins are dispensable for virus growth in cell culture (gC, gE, 
gG, gI, gJ) but 3 (gB, gD and gH) are essential and represent the minimal set of 
surface proteins necessary to sustain and carry out the flow of the above events 
(Knopf, 2000).  
After fusion, viral nucleocapsid associated with tegument proteins is deposited in 
the cytoplasm of the cell, and this process seems to involve an interaction with the 
cellular cytoskeleton (Kristensson et al., 1986).  It was suggested by Izaurralde et al. 
(1999) that migration of HSV1 to the cell nucleus occurs along the microtubules 
possibly by the dynein- transporter and is transported along the microtubules 
towards their negatively charged end to the centriole.  The nucleocapsid binds to 
the nuclear pore, and subsequently, probably triggered by the tegument protein 
UL35 in the case of HSV1, the viral core together with some adherent tegument 
proteins is released into the nucleus (Knopf, 2000). 
In HSV1 infection, 2 important proteins having late gene functions are liberated 
during the subsequent uncoating process, the vhs (viral host shutoff) protein 
encoded by the UL41 gene, and a trans-inducing factor (α-TIF) UL48 gene product 
also called VP16.  The vhs is responsible for the shut off of host macromolecular 
synthesis (Kwong et al., 1988), and the α-TIF induces transcription of the very early 
viral protein functions by binding to a motif of the promoter regulatory domain of the 
IE genes (Knopf, 2000).   
In herpesviruses, transcription of the large complex viral genome is sequential, with 
sequential transcription of 3 distinct mRNA classes: initially (i) the immediate early 
or αtranscripts that in HSV1 are translated to 5 trans-acting regulators of virus 
transcription; then (ii) early or βtranscripts from which enzymes, non-structural 21   
regulatory and a subfraction of structural proteins are derived; then (iii) late or γ 
transcripts that produce additional regulatory and most of the structural proteins 
(Knopf, 2000).  The γ transcripts are dependent on DNA synthesis but there are 2 
classes of γ transcripts and γ2 expression is most stringently dependent on on-going 
viral DNA synthesis. 
The mechanism of viral DNA replication remains largely unexplored (Knopf, 2000).  
Viral DNA replication requires both α and β genes, and there is also a special role of 
specific nuclear matrix-associated domains in DNA replication.  These domains are 
referred to as ND10 sites (nuclear dots that occur at an average of 10 per nucleus), 
and various other designations (Knopf, 2000) which are probably sites for virus DNA 
accumulation.  The initiation of DNA synthesis takes place at specific palindromic 
sequences that function as ORIs: the HSV1 genome contains 3 of these cis-acting 
signals and the presence of at least one is required and sufficient for DNA 
replication.  There is evidence in HSV1 and the related EHV1 of a complex pattern 
of herpesvirus DNA replication (Bataille & Epstein, 1997; Slobedman & Simmons, 
1997).  It is likely that after nuclear entry and circularisation of the viral genome that 
DNA replication proceeds in 2 distinct phases: an initial phase characterised by bi-
directional (theta) replication initiated at one or more ORIs with bidirectional fork 
movement, and a latter phase a rolling-circle mode of DNA replication.  Both 
replication modes can actually lead to the generation of branched concatameric 
DNA, that constitutes a major fraction at both early and late times of HSV1 
replication (Knopf, 2000).  After completion of viral DNA synthesis, resulting in 
concatameric DNA, unit-length genomes are cleaved, translocated and packaged 
into preformed capsids, a process requiring UL15 and UL28 (Knopf, 2000). 
Concomitantly with the onset of viral DNA replication (about 2-4 h after infection), 
the synthesis of the true late gene products (γ2) takes place.  These comprise most 
of the glycoproteins and membrane associated proteins.  At about the same time, 22   
capsid proteins and proteins required for DNA packaging and cleavage are 
produced and transported to the DNA replication compartments.  In HSV1, the 
major capsid protein VP5 (UL19), and the scaffolding protein pre-VP22a (UL26.5), 
condense to form structures that are extended into procapsids by the addition of 
VP19c (UL38) and VP23 (UL18), which mature into robust polyhedral capsids 
(Spencer et al., 1998).  Transport of the procapsids and capsid proteins to the 
replication compartments seems to involve UL17, a tegument protein, and the DNA 
packaging protein UL32 (Lamberti & Weller, 1998; Taus et al., 1998).  After 
association of the capsid shell with UL35 (VP26) which binds to UL19 yielding a 
hexameric ring on the top of the hexons (vertices of the icosahedral facets), and 
proteolytic processing of the scaffolding protein, the virus genome is packaged into 
the procapsids (Knopf, 2000).  Three genes UL6, UL25 and UL encode proteins 
required for reeling of the cleaved and translocated DNA (above) and the final 
stages of the packaging process (Knopf, 2000). 
While the process of capsid formation in the nucleus is reasonably well understood, 
the final stages of assembly (acquisition of the tegument and envelope) is not so 
well understood and it appears that egress of virus from the cell is a rather complex 
process (Mettenleiter, 2002).  Mature nucleocapsids coated with tegument proteins 
are exported from the nucleus by budding through the inner lamella of the nuclear 
membrane, and become enveloped.  Electron microscopic observations by 
Granzow et al. (2001) indicate that egress of the alphaherpesviruses, EHV1, HSV1, 
infectious laryngotracheitis virus (ILTV), and pseudorabies virus (PrV) occur in a 
morphologically similar manner.  After intranuclear assembly, nucleocapsids bud at 
the inner leaflet of the nuclear membrane, resulting in enveloped particles in the 
perinuclear space that contain a sharply bordered rim of tegument and a smooth 
envelope surface.  Egress from the perinuclear cisterna primarily occurs by de-
envelopment: fusion of the primary envelope with the outer leaflet of the nuclear 23   
membrane resulting in intracytoplasmic naked nucleocapsids.  Final tegumentation 
(acquisition of tegument) occurs in the cytoplasm and tegumented capsids acquire 
their final envelope by budding into vesicles of the trans-Golgi network.  Fusion of 
the vesicle membrane with the plasma membrane then leads to release of mature 
virions.  These events are summarised in Figure 2.6. 
 
Figure 2.6.  Summary diagram of the proposed pathway of herpesvirus egress from cells 
(from Mettenleiter, 2002).  There is a rather complex process of herpesvirus maturation 
including primary envelopement of capsids by budding at the inner leaflet of the nuclear 
membrane and translocation of capsids into the cytoplasm after loss of the primary envelope 
by fusion with the outer leaflet of the nuclear membrane.  Subsequently, final tegumentation 
occurs in the cytoplasm and tegumented capsids obtain their final envelope by budding into 
vesicles of the trans-Golgi network.  Final endocytosis from the plasma membrane and 
directional budding of virions results in release of virus from the cell. 
 
The enveloped infectious virions can either remain cell-associated and spread to 
uninfected cells via virus-induced cell fusion, or can be released from the cell via 
exocytosis or cell lysis (Kasamatsu & Nakanishi, 1998).   24   
A large number of proteins and glycoproteins are associated with the final 
maturation and egress of virus from the cell.  These are reviewed by Mettenleiter 
(2002) and their complexity is illustrated in Figure 2.7.  None of the glycoproteins 
that play essential roles in fusion of the virion envelope and cellular plasma 
membrane during entry is required for virus egress, suggesting that fusion during 
entry and fusion during egress may be fundamentally different.   
 
Figure 2.7.  Diagram of the interactions of gene products of HSV1 involved in the final 
stages of virion formation and maturation (From Mettenleiter, 2002).  Solid lines or direct 
contacts between the rectangles representing the designated gene products indicate 
physical interaction, whereas arrows indicate functional effects.  Dotted lines and question 
marks denote suggested, but not firmly established interactions or involvement of proteins.  
Between proteins, only direct contacts resulting in complex formation are depicted.  Steps: 1, 
primary envelopment; 2, de-envelopment; 3, secondary (final) envelopment.  Abbreviations: 
NUC, nucleus; CYT, cytoplasm; the gene designations are in accordance with the genome 
of HSV1.   
 
2.4.5.  The structure of the herpesvirus genome  
The herpesvirus DNA is linear and double-stranded, but circularises immediately 
upon release from capsids into the nuclei of infected cells.  Many of the 
herpesviruses have now been sequenced, including some of the EHV.  The 
genomes of EHV1 and 4 have been completely sequenced (Telford et al., 1992; 25   
Telford et al., 1998), as has the genome of EHV2 (Telford et al., 1995), but only the 
sequence of the gB gene of EHV5 has been published (Holloway et al., 1999). 
In the typical herpesvirus genome, there are reiterated sequences dividing the 
genome into 2 stretches of unique sequence, a unique long (UL) region and a short 
(US) region (Van Regenmortel et al., 2000).  This basic structure is illustrated in 
Figure 2.8.  In the case of the 138 kbp genome of HSV, the inverted repeats 
flanking UL (ab and b’a’, 9 kbp each) and those  flanking US (a’c’ and ca), (>6 kbp 
each) together account for about 10% of the genome.  When the orientation of the 
reiterated sequences are inverted, the unique long and short sequences can invert, 
relative to one another, during replication, giving rise to 2 or 4 different isomers of 
the genome, present in equimolar proportions.  Further intragenomic and 
intergenomic recombination events can also alter the number of a reiterated 
sequence, creating polymorphism (Van Regenmortel et al., 2000).  
There is a large degree of variation in the composition, size and structure of 
herpesvirus DNA (White & Fenner, 1994).  The percentage of guanine plus cytosine 
(G + C ratio) varies from 31-75 %, a range exceeding that found in DNAs of all 
eukaryotes (Van Regenmortel et al., 2000).  The genome size ranges from 124-235 
kbp and may also vary in each species (Roizman et al., 1992).  The differences in 
genome size of independent isolates of the same virus species may be up to 10 
kbp, and this variability reflects the number of internal and terminal indirect repeat 
sequences (IR and TR) (Roizman & Sears, 1996).  
The complexity of the herpesvirus genome is illustrated by the schematic diagram of 
the genomes of the alphaherpesvirus EHV4 and the gammaherpesvirus EHV2 
(Figures 2.9 and 2.10) and described by Telford et al. (1998 and 1995) respectively.   26   
 
Figure 2.8.  Diagram illustrating the basic structure of herpesvirus genomes (from 
http://www.uct.ac.za/microbiology/cann/335/Herpesviruses.html).  Each herpesvirus has a 
unique long (UL) and a unique short (US) region, bounded by inverted repeat sequences (IR) 
or terminal repeat sequences (TR).  Genome size of various isolates of a particular virus can 
vary by up to 10kbp, depending on the number of repeated sequence.  Abbreviations: HSV, 
herpes simplex virus; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, Epstein-Barr 
virus; HHV-6, human herpesvirus type 6. 
 
The herpesvirus genome contains a large number of open reading frames (ORFs) 
varying from 68 for VZV to over 200 for HCMV (Studdert, 1996) although these are 
not all thought to encode proteins.  However, the number of encoded proteins is 
large, and in the case of HSV, at least 84 of the ORFs identified in the genome are 
expressed (Roizman, 1999).  
The location of the gene classes within the HSV genome is of interest.  The IE or α 
genes map at the termini of the long and short components and tend to cluster 
together.  In particular, IE genes surround the HSV origin of replication in the short 
region.  Each IE gene has its own promoter-regulatory region and transcription 
initiation and termination sites.  The β and γ genes are scattered in both the long 
and short components.  Studies of both the EHV1 and HSV1 IE1 promoters 
demonstrated that the product of gene 12 is a potent transactivator of immediate-
early gene expression of both viruses, which requires sequences in the upstream 
HSV1 promoter for activity.  The EHV1 immediate-early transactivator may not be  27   
 
 
Figure 2.9.  Predicted EHV4 gene arrangement (from Telford et al., 1998).  The genome is 
shaded, the thinner and thicker portions denoting the unique regions (UL, US) and inverted 
repeats (TRL/IRL, TRS/IRS), respectively.  The scale is in kbp.  Protein-coding regions are 
shown as open arrows within the shaded genome above the gene nomenclature.  ORFs 44 
and 47 are predicted to be expressed as a spliced mRNA.  Candidate polyadenylation sites 
are indicated by vertical arrows in the appropriate strand.  Reiterated sequences are shown 
as small filled rectangles and the centre of palindromes associated with putative origins of 
replication are denoted by vertical lines between genes 39 and 40 and genes 64 and 65.  
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Figure 2.10.  Predicted EHV-2 gene arrangement (from Telford et al., 1995).  The genome is 
shaded, the thinner and thicker portions denoting the unique region and terminal direct 
repeats, respectively.  The scale is in kbp.  Protein-coding regions are shown as white 
arrows with ORF nomenclature below.  ORF 17.5 is shown by a thinner arrow to reveal the 
overlap with ORF 17.  ORF2 29a and 29b are shown in black and are presumed to be 
expressed as spliced mRNA.  Vertical arrow indicate candidate polyadenylation signals in 
the appropriate strand.  The location of reiterations (black bars) and short inverted repeats in 
the unique region (IR1 and IR2) are indicated above the genome.   29   
functionally co-linear with VP16, with transactivation requiring both the C terminus 
and another region(s) present within the N-terminal portion (Elliott, 1994).  
2.4.6.  Herpesvirus proteins and glycoproteins   
The immediate early (IE or α), early (E or β) and late (L or γ) genes encode a 
number of proteins (Stokes et al., 1996). 
(1) In HSV1, 5 IE genes have been identified that express ICPs (infected cell 
proteins).  These are ICP0, ICP4, ICP22, ICP27 and ICP47 (Chen et al., 1996).  
Their peak synthesis occurs 2-4 h post-infection (p.i.), but they continue to 
accumulate until late in infection.  All IE gene-encoded proteins appear to function 
as transacting regulators of virus transcription (Zhao et al., 1992; Rice & Lam, 1994; 
Knopf, 2000), with the possible exception of ICP47 which interferes with antigen 
presentation (York et al., 1994).  The IE protein ICP4 is essential for the 
transcription of early and late genes, acting through the basal cellular transcription 
machinery (Preston, 2000).  ICP27 is also required for virus replication, operating at 
post-transcriptional levels to regulate splicing, termination and nuclear export of viral 
transcripts (reviewed by Phelan & Clements,1997).  The other proteins, ICP0 and 
ICP22 are not essential but are required for efficient replication of HSV1; the HSV1 
ICP0, also a major transactivator, stimulates the onset of virus infection, is required 
for efficient reactivation of virus from latency, and is probably also involved in 
blocking of the HSV1 infected cell in the G1 phase (Knopf, 2000).  
Transcription of the IE genes is activated by VP16, a major component of the 
tegument (reviewed by O'Hare & Williams, 1992).  VP16 and an additional cell 
protein HCF bind to an Oct-1/TAATGARAT (R is a purine nucleotide) sequence 
which is present in at least one copy in all HSV IE promoters.  This suggests that 
the availability of the HCF and Oct-1 cellular factors might influence the initiation of 
the HSV lytic cycle (Preston, 2000). 30   
Four high molecular weight IE polypeptides have been identified in EHV1-infected 
cells.  These 4 molecules are related and are products of a single 6 kb mRNA 
molecule encoded by viral gene 64 located in the large repeat structures of the viral 
genome (Figure 2.9) and showing homology to HSV1 ICP4 (Crabb & Studdert, 
1995). 
(2) E genes are not expressed in the absence of α proteins and their expression is 
enhanced in the presence of drugs that block DNA synthesis.  They reach peak 
rates of synthesis 5-7 h p.i.  The genes have been divided into 2 subclasses. β1 
genes, such as the large component of ribonucleotide reductase and the major DNA 
binding protein (ICP8), appear early after infection.  β2 genes include viral thymidine 
kinase (TK) and viral DNA polymerase.  The β genes are expressed immediately 
preceding the onset of viral DNA synthesis.  Most viral genes involved in viral 
nucleic acid metabolism appear to be β genes (Spear, 1985). 
(3) L genes are separated into 2 groups. γ 1 genes are expressed early in infection 
and are only minimally affected by inhibitors of DNA synthesis. These genes encode 
the major capsid proteins. γ 2 genes are expressed later in infection and are not 
expressed in the presence of inhibitors of viral DNA synthesis (Spear, 1985). 
As discussed above, the glycoproteins of herpesviruses play important roles in 
pathogenicity, mediating both entry of the virion into the host cell, via adsorption and 
penetration, and cell-to-cell spread of virus (Spear, 1985).  The known capsid and 
envelope proteins/glycoproteins of HSV1 are shown in Tables 2.1 and 2.2, 
respectively. 
The EHV1 genome contains at least 76 unique genes likely to encode proteins 
(Crabb & Studdert, 1995) .  EHV1 homologues for 10 of 11 recognised HSV1 31   
Table 2.1.  Capsid proteins of HSV1 (from Knopf, 2000). 
Capsid protein  Gene  Mr Function 
NC1, VP5  UL19  155 kDa  Penton and hexon formation 







Scaffolding proteins (interacting with themselves and VP 5) 
released from mature B capsids by protease (VP24) cleavage 
at C-terminus 
NC5, VP23  UL18  33 kDa  Forms triplexes with VP19C 
NC6, VP24  UL26  26 kDa  Maturation protease, its self-cleavage generates VP21 
NC7, VP26  UL35  12 kDa  Vertex protein, basic phosphoprotein 
 
glycoproteins (Table 2.3) have been identified from DNA sequence analyses and 
the remaining glycoprotein gJ of HSV1 has a positional counterpart in the US region 
of EHV1, gene 71 (Figure 2.9) although these 2 genes show no significant 
homology  
(Telford et al., 1992).  EHV1 also possesses 3 other glycoproteins, designated gp2 
(gene 71) and gp21/22a, which have no HSV homologue, and gp10, which is the 
homologue of the HSV1 tegument protein VP13/14.  The EHV1 glycoproteins gp2, 
gp10, gC, gB, gD and gp21/22a have been definitively identified by SDS-PAGE, as 
have EHV4 glycoproteins gp2, gp10, gC, gB, gD and gG (reviewed in Crabb & 
Studdert, 1995).   
EHV1 glycoprotein gp14, the homologue of gB of herpes simplex virus may be 
important for the induction of neutralizing antibodies.  Studies with recombinant 
gp14 expressed in both bacteria and insect cells indicated that gp14 expressed in 
insect cells induced antibodies with virus-neutralizing activity, whereas a gp14 
expressed by E. coli failed to elicit neutralizing antibodies, and that post-
translational modification (presumably glycosylation) of the EHV1 gp14 was 32   
important for the expression of epitopes necessary for the induction of neutralizing 
antibodies (Osterrieder et al., 1994b).   
 
Table 2.2.  Envelope proteins of HSV1 (from Knopf, 2000).   
Protein Gene  Features 
Glycoproteins 
gB UL27  syn plaque phenotype, attachment and cell fusion 
gC UL44  Attachment,  penetration 
gD  US6  Attachment, penetration, strongest immunogenicity 
gE  US8  IgG Fc-receptor binding, complexed with gI, cell-to-cell spread, 
plaque size, virulence, phosphorylated by UL13, acylated 
gG US4  Subtype-specific  antigen 
gH  UL22  Complexed with gL, penetration 
gI  US7  Complexed with gE, modulates IgG binding, cell-to-cell spread 
gJ US5  ? 
gK UL53  syn plaque phenotype, envelopment, egress 
gL  UL1  Complexed with gH, syn plaque phenotype 
gM  UL10  Cell-to-cell spread, plaque size, complexed with UL49.5 
Unglycosylated membrane-associated proteins 
 UL11  Myristylated 
 UL20  syn plaque phenotype, virus egress 
 UL24  syn plaque phenotype 
 UL43  ? 
 UL45  syn plaque phenotype, associated with endoplasmic reticulum 
  UL49.5  Complexed by disulfide bond to gM 
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Table 2.3.  Herpes simplex virus glycoproteins and their homologues in EHV1 and EHV4 
(from Crabb & Studdert, 1995). 
HSV glycoprotein      Homolog 
Designation Gene
a  Identified function  E or N  EHV1  EHV4 
Amino acid 
identity (%) 
gB UL27  Penetration,  fusion  E  gp14  gp14  88 
gC UL44  Adsorption,  C3b 
receptor 
N gp13  gp13  79 
gD US6  Penetration,  fusion  E  gp18  gp18  83 
gE  US8  Fc receptor (with gI)  N  gE  gE  - 
gG US4  Unknown  N  gG  gG  58 
gH UL22  Penetration,  fusion, 
complexes with gG 
E gH  gH  85 
gI  US7  Fc receptor (with gE)  N  gI  -  - 
gJ US5  Unknown  N  US5  US5  - 
gK UL53  Fusion  N  gK  -  - 
gL UL1  Penetration,  fusion, 
complexes with gH 
E gL  -  - 
gM UL10  Unknown  N  gM  -  - 
a HSV1 gene assignments are according to Hutchinson et al. (1992a, b), Baines & Roizman 
(1993) and McGeoch & Davison (1999). 
 
2.4.7.  Mechanisms of herpesvirus latency and reactivation of latent infection 
Persistence of the virus probably throughout life is a feature of all herpesviruses, 
including the EHV (Roumillat et al., 1979; Browning et al., 1988a; Field et al., 
1992;.Gibson et al., 1992b; Ostlund, 1993; Edington et al., 1994; Slater et al., 1994; 
Baxi et al., 1995; Crabb & Studdert; 1995; Strelow & Leib, 1995; Baxi et al., 1996; 
Studdert, 1996).  The events and mechanisms by which latency is established are 
not well understood (Wagner & Bloom, 1997).  It is, however, well recognised that 
herpesviruses of all types undergo an initial cycle of active virus infection in the 34   
host, which in the case of HSV1 usually begins in the skin or mucosal epithelium 
and is associated with clinical disease.  The virus then undergoes a period of 
latency, which in the case of HSV1 occurs in the sensory ganglia whose nerve 
processes supply the primary site of infection.  Once within these sites of latency, 
there is initial replication of virus which is presumed to lead to post-synaptic spread 
of the virus to a reproducible series of sites within the nervous tissue, but within a 
few days there is profound restriction of viral gene expression so that the cytopathic 
results of productive infection do not occur, and the virus expresses only a limited 
number of genes.  During the period of latency there remains one active 
transcription unit known as the latency associated transcription unit, the products of 
which are termed latency associated transcripts (LATs) under the control of a 
latency-associated promoter.  Subsequent reactivation of the latent virus infection 
may result in further replication of the virus, anterograde transport of the virus back 
along the peripheral nerves, and recurrence of clinical disease (Jarman et al., 1999; 
Smith et al., 2000).  
Alphaherpesviruses 
The mechanism of latency is best understood in the alphaherpesviruses and the 
following review of latency relates primarily to this subfamily, and particularly to 
HSV1.  After HSV1 has gained entry to the axonal termini from the primary site of 
replication in the skin or mucosal epithelium, it is transported retrogradely along the 
axon to the neuronal cell body (Holland et al., 1999).  Cook & Stevens (1973) 
showed that after primary infection in mice, HSV1 was retrogradely transported in 
axons as non-enveloped nucleocapsids.  This was confirmed by in vitro experiments 
in a rat model (Lycke et al. 1984)   
Once transported to the site of latency, in the neurons of the sensory ganglia 
supplying the site of initial replication in the case of HSV, HSV replication may be 
detected initially but within a few days no free virus can be detected within ganglia 35   
and latency is established (Preston, 2000).  Multiple copies of the HSV1 genome 
are sequestered in the non-replicating state in the neuronal nucleus, and there is a 
wide variation in the copy number in individual neurons (Preston, 2000).  The virus 
DNA probably exists in the neuron as a circular episome until signals which induce 
reactivation are received.  During latency all the lytic virus genes are switched off, 
but the LATs accumulate to high levels.  The major products are 2 kb and 1.5 kb 
RNAs, which are predominantly localised to the neuronal nucleus and are 
transcribed antisense to and partially complementary to the coding sequences for 
ICP0.  These RNAs represent stable introns cleaved from a longer precursor that 
extends across the a’ sequence and into the short repeat region and is 
complementary to all of the ICP0 coding sequences.  The reason for the continuing 
transcription of the LATs in an otherwise inactive genome is not known in detail, but 
it is clear that sequences located downstream of the promoter, and in the 
transcribed region, are important (reviewed by Preston, 2000). 
The function of LATs during latency remains elusive.  Confounding the issue are the 
accumulated masses of data indicating that LATs are not absolutely required for the 
establishment or maintenance of latency or for the reactivation of latent virus.  No 
gene or sequence tested has been identified as being essential for maintenance of 
latency.  The reason for the production of LATs is unknown but it is known that the 
production of LATs is a marker of latency and that their presence unequivocally 
denotes the existence of latent HSV in a neuron (Preston, 2000).  
The hypothesis that latency and lytic infection are alternative, mutually exclusive, 
outcomes after infection of neurons with HSV underlies most current thinking on 
latency (Preston, 2000).  HSV LATs can be quantitated by analysing ganglion RNA 
on blots or by RT-PCR, and the proportion of neurons expressing LATs can be 
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more neurons in the ganglia contain viral DNA than express LATs that can be 
detected by in situ hybridisation (Sawtell, 1998). 
Although the mechanism of reactivation is poorly understood, in general the known 
stimuli are linked by the ability to cause stress, either to the whole organism or 
directly to the neuron (Preston, 2000). Herpesviruses are often reactivated in 
immunosuppressive states, such as during immunosuppressive therapy, during 
immunosuppressive infections such as human immunodeficiency virus induced 
AIDS, during physical or emotional stress, following peripheral tissue damage or 
intake of certain hormones, and associated with hormonal imbalance and 
menstruation (White & Fenner, 1994; Roizman & Sears, 1996).  The result of 
reactivation may be clinically apparent disease that may or may not resemble that 
associated with the primary infection, and it is not uncommon for either the initial or 
reactivated infection to be inapparent.  HSV1 is periodically reactivated with 
infectious virus being carried back to peripheral tissues by axonal transport, usually 
to cells at or near the site of initial infection.  Depending on the host immune 
response, the resulting lesion may vary considerably in severity, from barely visible 
vesicles to rather severe, debilitating lesions in immunosuppressed individuals 
(Roizman & Sears, 1996).  
The mechanism of anterograde transport of HSV from the site of latency was 
studied in cultured dissociated human and rat dorsal root ganglion neurons.  The 
neurons were infected with HSV1 to examine the distribution of capsid (VP5), 
tegument (VP16), and glycoproteins (gC and gB) at intervals after infection.  After 
activation, focal accumulations of VP5 (nucleocapsid protein) and VP16 (tegument 
protein) were detected in axons.  Glycoproteins gB, gC, and gD were diffusely 
distributed in axons and rarely associated with VP5 or VP16. This suggested that 
nucleocapsids coated with tegument proteins were transported by different 
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enveloped virus occurs at the axon terminus (Holland et al., 1999).  This can 
proceed despite the loss of most VP16 (Miranda-Saksena et al., 2000).  
While the site of latency of the alphaherpesviruses, including HSV and PrV, is within 
the nervous system, particularly sensory neurons that innervate the primary site of 
infection (Lachmann et al., 1999; Preston, 2000), the site of latency of the 
alphaherpesviruses is not restricted to this site.   
In the horse, latent alphaherpesvirus (EHV1 and EHV4) infection is common in the 
equine population, apparently in PBL, in lymphoid tissue and in neural tissue, and 
EHV1 and EHV4 have been experimentally reactivated from the latent state by high 
doses of corticosteroids and mild nasal trauma (Edington et al., 1985).  
Scott et al. (1983) proposed that EHV1 (which at that time would not have been 
differentiated from EHV4) replicated in and could establish latency in T 
lymphocytes. Edington et al. (1994) then reported that EHV1 and 4 were detected 
most commonly in the bronchial lymph nodes of horses examined at slaughter; they 
cultured these viruses from the lymph nodes draining the respiratory tract of 60% of 
40 horses and demonstrated viral DNA in 87.5% of bronchial lymph nodes.  The 
presence in PBL of a putative LAT of EHV1 (antisense to and overlapping the 3’ end 
of homologs of the HSV1 IE gene 64) was demonstrated by Chesters et al. (1997).  
Smith et al. (1998) demonstrated that CD5
+ and CD8
+ T lymphocytes were the 
predominant cell that harboured EHV1, and by co-cultivation demonstrated that 
virus could be reactivated from these cells by the mitogens phytohaemagglutinin 
and poke weed mitogen, possibly indirectly by causing the release of mediators 
from adherent cells that reactivated EHV1 from co-cultivated T cells.  Co-cultivation 
demonstrated that the reactivated virus was infectious (Smith et al., 1998).  van der 
Meulen et al. (2001) hypothesised that mitogen stimulation may initiate specific cell 
cycle events and by inducing formation of clusters, facilitate transmission of virus 
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While Edington et al. (1994) detected EHV1 most commonly in the bronchial lymph 
nodes of horses, they were also able to detect virus by PCR in the trigeminal 
ganglia of a similar proportion of horses.  This result was confirmed by Slater et al. 
(1994) who were able to isolate virus from the trigeminal ganglia and detect viral 
DNA in the ganglia by PCR 3.5 months after EHV1 infection and 2 months after 
attempted reactivation of virus, in the absence of virus in other tissues.  Baxi et al. 
(1995) also detected EHV1 LATs (RNA antisense to gene 63) by in situ 
hybridisation in a small number of neurons of trigeminal ganglia.  Similarly, in a 
mouse model of EHV1 infection, Baxi et al. (1996) demonstrated that while there 
was little or no transcription of virus in neural tissues during the 'latent phase', 
following a reactivation stimulus infectious virus was not isolated from any tissues 
but EHV1 DNA was detected on the first round of nested PCR in olfactory bulb, 
trigeminal ganglia and PBL.  Similarly, Marshall & Field (1997) demonstrated EHV1 
latency in the olfactory bulbs of mice by in situ PCR and in vitro protein synthesis 
methods.   
Conflicting results have been reported on the site of latency of EHV4.  While it has 
been shown to establish latency in lymph nodes of the respiratory tract and in PBL 
(Welch et al., 1992; Edington et al., 1994), strong evidence of the occurrence of 
latent EHV4 in trigeminal ganglia was provided by Borchers et al. (1999b) who 
detected EHV4 DNA in 11 (65%) of 17 horses.  EHV4-specific putative LATs of 
homologues of HSV1 gene 63 (ICP0) and 64 (ICP4) were detected in 6 of 10 
trigeminal ganglia.  They used type-specific primers of gene 33 (encoding gB) to 
detect transcripts expected during productive EHV4 infection, and these were 
detected in only one of the 6 ganglia in which the LATs were detected.  In order to 
define the transcriptional activity, RNA preparations of 10 EHV4 DNA-positive 
ganglia were investigated by nested RT-PCR.  EHV-4-specific transcripts derived 
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homologue) were detected in 6 trigeminal ganglia.  In one other case, only gene 64-
specific transcripts were present.  All of the transcripts proved to be antisense 
orientated when a strand-specific RT-PCR was applied.  Type-specific primers for 
gene 33 (encoding glycoprotein B) served to detect transcripts of an acute EHV4-
infection, which were found in only one of the 6 ganglia positive for gene 63- and 
gene 64-specific transcripts (Borchers et al., 1999b).  Overall, these studies 
demonstrated conclusively that EHV4 is latent in trigeminal ganglia. 
Betaherpesviruses 
The mechanism of latency of the betaherpesviruses (recently reviewed by Grzimek 
et al., 2001), has focused on the human CMV (hCMV) in haematopoietic progenitors 
of the myeloid differentiation lineage, where the existence of sense and antisense 
latency-associated transcripts derived from the major immediate-early (MIE) region 
have been detected.  The sense latency-associated transcripts, while transcribed in 
the same orientation, are distinct from the productive cycle IE1/2 transcripts by 
usage of alternative transcription start sites located in the enhancer upstream of the 
IE1/2 transcription start site.  There is increasing evidence to suggest that cytokine-
triggered transcription factors which bind to regulatory modules of the enhancer 
initiate virus reactivation.  Cytokines implicated in allogeneic immune responses and 
proinflammatory cytokines in general are candidates for inducing hCMV 
reactivation. Specifically, tumor necrosis factor alpha (TNF-α) signaling activates 
NF-κB, which then binds to the enhancer resulting in MIE promoter activity. 
Murine CMV (mCMV), like hCMV, can establish a latent infection in cells of the 
myeloid lineage.  Since the mCMV genome remains present in various organs after 
resolution of the latent infection of haematopoietic lineage cells in bone marrow and 
blood, there must exist one or more widely distributed further cell type(s) 
representing the cellular site(s) of enduring latency (Grzimek et al., 2001).  
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capillary endothelial cells in various organs are likely candidates (Grzimek et al., 
2001).  Latent viral DNA is present in lung tissue in a high load that corresponds to 
a high risk of recurrent infection (Reddehase et al., 1994; Soderberg-Naucler et al., 
1997).  Notably, episodes of focal transcriptional activity restricted to the generation 
of spliced IE1 transcripts were detected in latently infected lungs in a frequency of 
about 10 events at any moment (Kurz et al., 1999; Kurz & Reddehase, 1999).  Gene 
IE1 of mCMV represents exons 1 to 4 of the IE1/3 MIE transcription unit (Keil et al., 
1987; Messerle et al., 1992), which corresponds to IE1/2 of hCMV (Meier & Stinski, 
1996; Stenberg, 1996) and is controlled by a specific promoter, P1/3, and by a 
strong upstream enhancer (Dorsch-Hasler et al., 1985).  Exons 2 to 4 specify the 
IE1 protein (Keil et al., 1985; Keil et al., 1987), which is a cotransactivator of early-
phase gene expression (Messerle et al., 1992), induces cellular thymidylate 
synthase gene expression promoting mCMV replication in quiescent cells (Gribaudo 
et al., 2000), and plays a role in CD8 T-cell-mediated immunity (Reddehase, 2000).  
Transcripts of IE3 are generated by differential splicing and encompass exons 1 to 3 
and exon 5, of which exons 2, 3, and 5 specify the E-gene transactivator protein IE3 
(Messerle et al., 1992), the functional analog and amino acid sequence homolog of 
hCMV IE2 (Reddehase, 2000; Spector, 1996).  Very recent work on IE3- deficient 
mCMV has proven that IE3 is indeed essential for viral replication (Angulo et al., 
2000).  Accordingly, the absence of spliced IE3 mRNA in latently infected lungs 
explains why latency is maintained in spite of the sporadic activity of P1/3 that is 
indicated by the random and focal occurrence of spliced IE1 mRNA (Kurz et al., 
1999).  In mCMV, the enhancer controls also gene IE2 that possesses its own 
promoter and is transcribed in a direction opposite to IE1/3 (Messerle et al., 1991).  
Gene IE2 has no counterpart in hCMV and, according to deletion mutagenesis, the 
IE2 protein of mCMV is dispensable (Cardin et al., 1995).  By binding transcription 
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for the observed stochastic episodes of P1/3 activity during pulmonary latency 
(Grzimek et al., 2001). 
Because interstitial pneumonia is a critical manifestation of primary as well as 
recurrent hCMV disease in immunocompromised patients, in particular after bone 
marrow transplantation, many recent studies have concentrated on latency in the 
lungs (Grzimek et al., 2001).  In the murine model, the lungs are a major organ site 
of mCMV pathogenesis (Reddehase et al., 1985) and, after resolution of productive 
infection, the load of latent viral genomes is particularly high in the lungs.  In a 
murine BALB/c model of mCMV infection, acute infection of the lungs lasted for 4 to 
6 weeks and was confined to inflammatory foci and is finally resolved by lung-
infiltrating antiviral CD8 T cells (Holtappels et al., 2000; Podlech et al., 2000).  
Latency of mCMV in the lungs is defined by maintenance of the viral genomes after 
resolution of acute, productive infection and by their ability to reestablish productive 
viral gene expression upon induction, which results in the recurrence of infectious 
virions (Kurz et al., 1997).  The criterion of absence of infectious virions during 
latency, originally proposed for latency of herpes simplex viruses (Roizman & Sears, 
1987), had previously raised a debate on whether CMVs establish true molecular 
latency or rather a low-level productive infection below the detection limit.  
The absence of infectious virus does not imply that the viral genome is 
transcriptionally silent during latency, because there exist numerous possibilities by 
which the highly coordinated viral replication program could be interrupted before 
the assembly of progeny virions.  In fact, earlier reports had noted the presence of 
IE1 RNA, but since IE1 transcripts were then falsely considered as transcripts 
defining the initiation of the productive cycle, the finding was misinterpreted as being 
indicative of low-level persistent productive infection (Henry & Hamilton, 1993; 
Yuhasz et al., 1994).  In 2 recent reports the existence of sequential checkpoints in 
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et al., 1999; Kurz & Reddehase, 1999).  Specifically, latency in the lungs was 
maintained in the presence of IE1 transcripts because of the absence of IE3 
transcripts (Kurz et al., 1999).  That protein IE3 instead of IE1 is the key 
transactivator of mCMV E-gene expression was concluded from earlier work by 
Messerle et al. (1992), who had demonstrated in reporter gene assays an efficient 
activation of the E1 promoter by IE3 alone but not by IE1 alone, whereas IE1 did 
enhance the activity when co-expressed with IE3.  More recently, the replication 
deficiency of an IE3 gene (exon 5 of IE1/3) deletion mutant of mCMV and its trans-
complementation in IE3-expressing cells confirmed the essential role of IE3 in viral 
replication (Angulo et al., 2000).  Thus, in conjunction with the presence of 
functionally competent genomes, the absence of IE3 transcripts is presently the 
best criterion for mCMV latency. 
Gammaherpesviruses 
The discovery of the murine gammaherpesvirus 68 (MHV68) has provided an 
animal model which has allowed latency in a gammaherpesvirus to be investigated 
in more detail, and there appear to be some differences regarding latency in this 
system compared to the alphaherpesviruses.  After MHV68 infection there is also a 
progressive shutdown of gene expression, to an extent that depends on the cellular 
basis of latency and the events involved (recently reviewed by Nash et al., 2001).  
Four cell types are implicated in maintaining the latent state: B cells, dendritic cells, 
macrophages and epithelial cells in the lung.  As with the other 
gammaherpesviruses the MHV68 has a number of genes unique to the virus, 
located at the 5’ end of the genome and including the genes M1 to M4 and 8 
vtRNAs (virus-encoded transfer RNA-like structures).  The vtRNAs are transcribed 
during virus latency and although the function of these products has not been 
determined, they serve as a useful marker for latently infected cells.  During MHV68 
infection, in the lymph node and spleen M2 gene expression seems to be transient, 43   
lasting for about 2 weeks.  M3 is expressed for up to 10 months in the spleen and it 
is also highly expressed during the productive infection.  Other latency-associated 
genes expressed include gene 73 (homologous to the latent nuclear antigen of 
KSHV), ORF 74 (G-protein-coupled receptor) and M11 (Bcl-2 homologue).  These 3 
genes are expressed in lung epithelial cells for well over 100 days p.i., which argues 
strongly in favour of the respiratory tract as a major site of persistence for this virus. 
The gammaherpesviruses may persist in leukocytes or epithelial cells (Roizman, 
1999).  The gammaherpesvirus EBV predominantly replicates in the epithelium of 
the respiratory tract but persists latently in B lymphocytes (Favoreel et al., 2000; 
Robertson et al., 1996) although other sites may also harbour latent 
gammaherpesvirus infection.  MVH68, is thought to maintain latency in B cells, 
dendritic cells, macrophages and epithelial cells in the lung (Nash et al., 2001).   
Latency of the equine gammaherpesviruses appears to occur also in neurological 
and lymphoid tissue.  Rizvi et al. (1997) examined the distribution of EHV2 DNA 
within neurological and lymphoid tissues from 12 EHV2/EHV5 seropositive Welsh 
mountain ponies by PCR.  The lymphoid sites were almost universally PCR positive, 
thus confirming existing virus co-cultivation data that suggested lymph nodes 
draining the respiratory tract are the main reservoirs of EHV2 DNA.  In addition, 
EHV2 DNA was detected, albeit with lower frequency, within both the peripheral and 
central nervous systems of these animals: the trigeminal ganglion proved PCR-
positive in 50% of the animals tested.  In a murine (Balb/C) model of EHV2 
infection, Rizvi et al. (1997) detected EHV2 DNA in the trigeminal ganglia and 
olfactory bulbs from the first day after inoculation and these tissues remained 
positive for EHV2 DNA for at least 30 days, by which time EHV2 DNA had been 
cleared from all other tissues. 
Recent reports of the isolation of EHV5 from a high percentage of clinically healthy 
horses (Dunowska et al., 1999) raise the question of whether the virus detected is 44   
present mainly in a latent state in these horses, or possibly a mix of lytic and latent 
infection.  Both EHV2 and EHV5 have been recovered most frequently from PBL 
(Kemeny & Pearson, 1970) but also from a variety of other tissues, including the 
respiratory tract (Blakeslee et al., 1975; Palfi et al., 1978; Fu et al., 1987).  Drummer 
et al. (1996) reported that the B-lymphocyte was the site of latency for EHV2.  It is 
unknown if the reports of the isolation of EHV2 (which may have included EHV5) 
from more than 75% (Edington et al., 1994), 90% (Kemeny & Pearson, 1970), and 
100 % (Murray et al., 1996; Borchers et al., 1997a) of horses sampled, especially 
from lymph nodes draining the respiratory tract and PBL, represented productive 
virus infection of cells or rescue of latent virus, but PBL do not appear to harbor 
EHV2 indefinitely after infection (Borchers et al., 1997a).  Interestingly, 
alphaherpesviruses were isolated by Edington et al. (1994) only in the presence of 
EHV2/EHV5, although this may be associated with the high prevalence of the 
gammaherpesviruses.  However, it was assumed that EHV2 could play a role in the 
transactivation and possibly reactivation of latent EHV1 and EHV4 (Drummer et al., 
1996; Borchers & Agius, 1997; Dunowska et al., 1999) and play an aetiological role 
in recurring respiratory disease of foals (Fu et al., 1986).  
2.4.8.  Transmission of equine herpesviruses 
The mode of transmission of herpesviruses (excluding EHV3) between susceptible 
horses is through the respiratory system.  The incubation period for infection via the 
respiratory route is 3 to 7 days.  After inhalation the virus attaches, enters and 
replicates in the mucosal epithelial cells of the nasal passages, pharynx and 
tonsillar tissue.  The virus is then transported to other organs by mononuclear cells.  
The CD8+ T lymphocyte is the predominant cell that harbours the infective EHV1 
particles (Allen et al., 1995; O'Neill et al., 1999; van der Meulen et al., 2000).  
It is suggested that transmission of EHV to foals is horizontal, from mare to foal and 
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studies conducted by Gilkerson et al., (1999b) on large Thoroughbred stud farms in 
the Hunter Valley of NSW, where there was clear serological evidence of EHV1 
infection in foals as young as 30 days of age.  Serological evidence suggested that 
these foals were infected with EHV1 from their dams or from other lactating mares 
in the group, with subsequent foal-to-foal spread of infection prior to weaning.  Their 
data indicated that the mare and foal population was a reservoir of EHV1, from 
which new cases of infection propagated through the foal population both before 
and after weaning.  
In mice infected intranasally with EHV1, virus was detectable within a few hours 
after infection; virus was detected in nasal and olfactory epithelium and sub-
epithelial cells of the respiratory mucosa, but antigen-specific immune cells were 
never detected (Bartels et al., 1998).  EHV1 was transmitted early after infection to 
the brain, both via the olfactory route and the trigeminal nerve, but traces of 
degenerative or inflammatory processes were not detected in the brain.  In the lung, 
the immune cells residing or invading the parenchyma did not contain viral DNA or 
proteins.  The primary immune response in the lungs was alveolar and interstitial 
inflammation, dominated by the sequential appearance of neutrophils and 
macrophages, while the number of T and B lymphocytes remained unaltered.  
Within 24 hr after re-infection, lymphocytes accumulated around the blood vessels, 
outnumbering monocytes more than 2-fold, without neutrophils appearing.  There 
were more B than T cells and the T cells were predominantly CD8+ cells.  The T 
lymphocytes and B cells infiltrated the parenchyma also.  These results show the 
route of virus distribution and demonstrate the lack of antigen-specific immune cells 
in the lungs of mice after primary intranasal infection with EHV1 (Bartels et al., 
1998). 
Sequential sampling of the same horse for EHV2 by restriction endonuclease DNA 
fingerprinting (Browning & Studdert, 1987b) suggests there is a complex pattern of 46   
transmission of this virus, with multiple genotypes circulating in a single group of 
horses and up to 5 different viruses detectable over a period in the same horse.  
Multiple concurrent local infections were demonstrated by the isolation of 2 or more 
viruses from the same nasal swab.  
2.5.  Pathogenesis of equine herpesvirus infections  
2.5.1.  Pathogenesis of alphaherpesviruses  
The 2 equine alphaherpesviruses EHV1 and EHV4 are unequivocally pathogens, 
associated with respiratory disease, abortion, perinatal disease, and 
myeloencephalitis in horse populations (Allen & Bryans, 1986).  EHV1 and EHV4 
are of considerable economic importance worldwide (Sherman et al., 1977; 
Mumford & Edington, 1980;  Studdert et al., 1981; Allen & Bryans, 1986; Fu et al., 
1987; Studdert 1996; Mumford et al., 1998; Murray et al., 1998; Ruiz et al., 1998; 
Carvalho et al., 2000b; Galosi et al., 2001; Schroer et al., 2000).   
EHV1 was reported for the first time in Australia in 1968 (Duxbury & Oxer, 1968) 
and the characterisation of the virus was subsequently reported in 1970 (Studdert 
et al., 1970).  In the early literature, EHV4 was not recognised and all equine 
alphaherpesviruses were considered EHV1.  Recognition of the distinction between 
EHV1 and EHV4 was due to 2 Australian groups.  Initial restriction endonuclease 
analysis of EHV1 by Sabine et al. (1981) revealed significant genomic differences, 
and then studies by Studdert et al. (1981) that demonstrated the concurrence of 
endonuclease patterns with the separation of the isolates into abortigenic and 
respiratory strains, and resulted in the recommendation that EHV1 strains should be 
separated into 2 distinct types, the predominantly abortigenic EHV1 and the 
predominantly respiratory EHV4.   47   
Rhinopneumonitis  
Rhinopneumonitis of clinical EHV infection can be caused by EHV1 or EHV4, but 
EHV4 has been suggested as the more common cause of clinical disease in young 
horses.   
Initial EHV4-associated respiratory disease in younger animals is characterised 
clinically by fever, anorexia and profuse serous nasal discharge which later 
becomes mucopurulent.  Virus may reach the lungs, especially in young horses, 
and cause bronchopneumonia, but this lesion is often in association with a 
secondary bacterial infection (Crabb and Studdert, 1995).  The incubation period is 
usually 3-4 days, and infection can spread rapidly through a group of animals.  The 
severity of clinical signs can vary from subclinical disease to fatal 
bronchopneumonia and is perhaps primarily determined by the dose of infectious 
virus (Crabb & Studdert, 1995).  EHV4 infection, however, does not always appear 
to produce clinical disease and in many instances the infection may go unnoticed 
unless the horses are under close supervision (Burrell et al., 1996).  Infection of 
older animals is mostly subclinical (Burrell et al., 1996). 
EHV1 can also be responsible for epizootic respiratory diseases in racehorses in 
the winter but in contrast to EHV4, EHV1 does not appear to produce severe 
respiratory signs (Matsumura et al., 1992).  Chong & Duffus (1992) infected 
specific-pathogen-free foals at 3 to 4 months of age by intranasal inoculation with 
EHV1.  Clinical signs observed included depression, fever, inappetence and 
intermittent coughing.  Clinical recovery was complete by 7 days but high titres of 
virus were detected in nasal mucus for at least 10 days after inoculation.  EHV1 
infections were also described in EHV1-seronegative pony foals by Sutton et al. 
(1998).  They infected with EHV1 using a nebuliser through a face mask.  The 
infected foals demonstrated a febrile response, nasal discharge, enlarged 
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the large airways revealed hyperaemia.  Indirect immunoperoxidase staining of 
respiratory tract samples utilizing monoclonal antibodies specific for EHV1 
demonstrated viral antigen associated with cellular debris, primarily in the 
nasopharyngeal samples 3-9 days p.i.  Similar results were obtained by Gibson 
et al. (1992b) in specific-pathogen-free foals inoculated intranasally with EHV1.  All 
foals showed signs of a mild, self-limiting upper respiratory tract infection, with a 
concurrent leucopenia comprising both a lymphopenia and neutropenia.  Virus was 
isolated from nasal mucus and buffy coat cells over several days during the clinical 
episode and after the animals became clinically normal.  Notwithstanding the 
mildness of the clinical disease, they observed that virus was not eliminated 
completely and intravenous administration of dexamethasone resulted in 
reactivation of latent EHV1 in animals which had received only a single dose of the 
virus.  
Abortion 
EHV1 is recognised as the most common cause of virus-induced abortion in 
pregnant mares, occurring in the final trimester of gestation (Allen & Bryans, 1986; 
Wolff et al., 1986).  EHV4 has only rarely been isolated from the tissues of aborted 
fetuses (Crabb & Studdert, 1995).  
Abortion is considered a sequel to respiratory infection and may occur as early as 4 
months but most commonly in the last 4 months of pregnancy (Crabb & Studdert, 
1995).  EHV1 abortion occurs without premonitory signs and there are usually no 
complications for the mare.  The fetus is usually delivered dead, but fetuses aborted 
close to term may survive for a variable time period before succumbing  to interstitial 
pneumonia and viral damage to the liver, lymphoreticular system and adrenal 
glands, as well as complications by secondary bacterial infection (Crabb & Studdert, 
1995).  EHV1 seropositive mares when challenged with EHV1 may abort fetuses 
from which the virus cannot be isolated; the cause of abortion is thought to be 49   
related to widespread vasculitis, thrombosis, and secondary ischemic damage to 
the endometrium due to replication of EHV1 within cells of the vascular 
endothelium, and the formation of antibody-antigen complexes in the walls of 
endometrial blood vessels , a pathogenesis similar to that for EHV1 
myeloencephalitis (Crabb & Studdert, 1995).   
Myeloencephalitis 
Myleoencephalitis has been associated with EHV1 and while it is usually associated 
with outbreaks of abortion and/or respiratory disease, this is not invariably the case.  
The evidence suggests that only certain strains of EHV1 cause myeloencephalitis 
(Crabb & Studdert, 1995).  
EHV1 myeloencephalopathy (EHM) is typically associated with an acute onset of 
hind limb paresis, but the forelimbs and cranial nerves may also be affected.  The 
clinical signs are rapid in onset, non-progressive.  The prognosis is generally good, 
although recovery may be slow and incomplete (Kohn & Fenner, 1987) and horses 
with EHM that become recumbent have a poor prognosis for survival (Donaldson & 
Sweeney, 1997).  While xanthochromic cerebrospinal fluid (CSF) with a high protein 
concentration and normal or only slightly high CSF nucleated cell count are 
common in horses with EHM, the results of CSF analysis were not associated with 
outcome (Donaldson & Sweeney, 1998).  The incubation period is typically 4 to 7 
days but may extend up to 2 weeks, it may affect animals of any age or gender, 
although cases are seen most often in pregnant or recently lactating or foaled 
mares (Thorsen & Little, 1975; Donaldson & Sweeney, 1997). 
The clinical EHM syndrome results from ischaemic damage to the central nervous 
system secondary to vasculitis (rather than from direct viral infection of neurons).  
The disease is immunologically-mediated and the pathogenesis involves both virus 
infections of the central nervous system endothelium and immune response to this 
infection (Donaldson & Sweeney, 1997).  The pathogenesis is distinctly different 50   
from encephalitis caused by other herpesviruses, in which there is clear evidence of 
primary neurotropism with virus multiplication in neurons and neuronophagia.  
2.5.2.  Pathogenesis of gammaherpesviruses 
Viruses designated as EHV2 were only recently been distinguished into 2 separate 
types, designated EHV2 and EHV5 (Browning & Studdert, 1987b; Agius et al., 1992; 
Telford et al., 1993) and the lack of distinction between these 2 viruses prior to this 
time has led to confusion about the association of EHV2 with disease.  Frequently, 
reports of viruses designated as EHV2 have not differentiated between the 2 
viruses.   
“EHV2” (used to describe early reports where there was no distinction between 
EHV2 and EHV5) has been commonly isolated from the leukocytes of a high 
percentage of apparently normal horses (Kemeny & Pearson, 1970; Roeder & 
Scott, 1975) and also horses with respiratory disease (Palfi et al., 1978; Murray 
et al., 1996; Dunowska et al., 1999).  Sites of isolation have included the upper 
respiratory tract, trachea and conjunctiva as well as the vagina, mammary gland, 
bone marrow, spleen and kidney (Plummer & Waterson, 1963; Kono & Kobayshi, 
1964; Karpas, 1966; Studdert et al., 1970; Turner & Studdert, 1970; Harden et al., 
1974a; Browning & Studdert, 1987a; Collinson et al., 1994; Murray et al., 1996). 
As these viruses are frequently isolated from disease-free horses, their exact role  in 
causing, or predisposing to, respiratory disease remains to be elucidated (Collinson 
et al., 1994).  Further investigation is needed to determine their importance as 
primary pathogens, co-factors in mixed infections or possible contribution to poor 
performance.(Schlocker et al., 1995; Crabb & Studdert, 1995; Murray et al., 1996; 
Dunowska et al., 1999; Dunowska et al., 2000).  Interpretation of previous and 
future investigations must allow for differentiation of EHV2 and EHV5 and must also 
recognise that considerable genetic heterogeneity of both EHV2 and EHV5 has 
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and/or pathogenic potential.   Restriction fragment length polymorphism (RFLP) has 
demonstrated considerable heterogeneity of EHV2 and initially suggested that 
EHV5 was homogenous (Browning & Studdert, 1987b; Browning & Studdert, 1989).  
Subsequent RFLP analysis of the EHV5 gB gene by Dunowska et al. (2000) has 
indicated considerable heterogeneity in EHV5. 
It is possible to make some generalisations based on the pathogenicity of EHV2 and 
EHV5 from the available reports, even though most of these reports have not 
differentiated the 2 viruses.   
(1) Consistent with gammaherpesvirus infections in other species, the clinical signs 
of disease associated with EHV2 and/or EHV5 in horses have almost invariably 
been associated with low grade infections and in no cases have there been 
substantiated reports of epizootics of severe disease associated with the equine 
gammaherpesviruses.  This is not to say they may not still be significant, particularly 
in those sections of the equine industry where diminished physical performance and 
lost training days are of major economic importance.   
(2) There has been a wide variety of clinical syndromes associated with “EHV2”, 
including pharyngitis and conjunctivitis (Blakeslee et al., 1975), keratoconjunctivitis 
(Collinson et al., 1994), severe ataxia and upper and lower respiratory disease 
(Borchers et al., 1997a; Borchers et al., 1998), immunosuppression in foals, 
conjunctivitis, general malaise, poor performance (Agius & Studdert, 1994), 
inappetence, lymphadenopathy of the head and neck and fever (Dunowska et al., 
2000)., respiratory disease (Blakeslee et al., 1975, Gleeson & Studdert, 1977), mild 
conjunctivitis, rhinitis and chronic follicular pharyngitis (Borchers et al., 1998; 
Browning & Studdert, 1987a), rhinitis, bronchiolitis, tracheitis, pneumonia, 
conjunctivitis, keratitis and pharyngitis including pharyngeal ulceration (Collinson 
et al., 1994), and pharyngeal ulceration and loss of racing performance (Browning 52   
et al., 1988b), and in pulmonary macrophages in association with chronic pulmonary 
disease (CPD) in adult horses (Schlocker et al., 1995).   
(3) It has been suggested that “EHV2” might be more important in younger animals, 
and an association of “EHV2” with severe respiratory disease in young foals has 
been reported by Fu et al. (1986) and Murray et al. (1996).  The most common 
clinical sign in foals in association with “EHV2” was pharyngitis (Fu et al., 1986; Palfi 
et al., 1978).  Experimental nasopharyngeal inoculation of foals with “EHV2” has 
induced chronic pharyngitis, with or without recurrent keratoconjunctivitis (Blakeslee 
et al., 1975; Gleeson & Coggins, 1985), characterised by lymphoid proliferation 
without overt clinical disease.   
(4) Most studies have demonstrated that the prevalence of “EHV2” infection is high, 
and it has been detected in both horses with respiratory disease and horses without 
respiratory disease (Dunowska et al., 1999).  “EHV2” was isolated from more than 
75% horses by Edington et al. (1994) and 90% of horses by Kemeny & Pearson 
(1970).  The prevalence of virus was high among horses with upper respiratory tract 
disease, abortion and severe ataxia (Borchers et al., 1997a) but no similar 
comparison was made in age-matched normal horses.   
(5) Attempts to reproduce disease with ”EHV2” have not provided convincing 
evidence that they are associated with respiratory disease (Palfi et al., 1978) and 
have resulted in only mild clinical signs of respiratory disease (Blakeslee et al., 
1975) and pharyngitis (Browning & Studdert, 1987a).  
(6) It is possible that EHV2 or EHV5 might have an indirect affect in producing 
disease.  “EHV2” might produce subclinical respiratory infection and predispose to 
secondary bacterial infection, thus indirectly causing a loss of performance (Burrell 
et al., 1996; Nordengrahn et al., 1996).  Nordengrahn et al. (1996) suggested that 
the EHV2 infections they investigated might have initiated a 2-phase respiratory 
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nasal discharge and slight increase in body temperature; a second phase 
associated with a serious respiratory disease, characterised by pneumonia, 
pulmonary abscesses, high fever and death several weeks later, possibly due to 
secondary bacterial infection with Rhodococcus equi.  It has also been suggested 
that EHV2 could play a role in the transactivation and possibly reactivation of latent 
EHV1 and EHV4 (Drummer et al., 1996; Borchers & Agius, 1997; Dunowska et al., 
1999).  
(7) It has been suggested that EHV2 might become latent within cells that are 
integral to the immune system and therefore may cause aspects of the immune 
function of these cells to be impaired (Murray et al., 1996).  Evidence of 
immunosuppression after both in vitro and in vivo infection with “EHV2” was 
reported by Fu et al. (1986).  It is interesting that there is a homologue of the gene 
encoding human immunosuppressive cytokine IL-10 in both EHV2 and EHV5.  This 
together with the ability of these viruses to infect lymphocytes, and the presence of 
genes encoding G-protein-coupled receptors (GPCR) might suppress the immune 
response and predispose horses towards secondary viral or bacterial infection 
(Burrell et al., 1996; Drummer et al., 1996; Dunowska et al., 2000). 
2.6.  Laboratory diagnosis of equine herpesvirus infection 
Methods used for the detection of EHV1, EHV2, EHV4 and EHV5 infection include: 
(1) cell culture for virus isolation from nasal swabs ( Palfi et al., 1978; Kydd et al., 
1994a,b), blood (Roeder & Scott, 1975; Welch et al., 1992; Borchers et al., 1997a; 
Dunowska et al., 1999) and other tissues (Dutta & Campbell, 1978; Carman et al., 
1997;  Edington et al., 1994); (2) serological or immunological tests (Yeargan et al., 
1985; Gilkerson et al., 1998; Mumford et al., 1998; Murray et al., 1996); (3) genetic-
based techniques such as RFLP, southern blotting and PCR assays (Ballagi-
Pordany et al., 1990;  O'Keefe et al., 1991; Sharma et al., 1992; Wagner et al., 54   
1992; Welch et al., 1992; Borchers & Slater, 1993; Kirisawa et al., 1993a; Lawrence 
et al., 1994; Osterrieder et al., 1994a; Reubel et al., 1995).  
2.6.1.  Cell culture  
Cell culture is vital to the laboratory diagnosis of viral infections (Mahy & Kangro, 
1996) and without it new types of virus would be difficult to detect.  Routine virus 
culture methods used for the isolation of EHV are both sensitive and robust, even 
though they are time consuming, and most researchers still use these methods as a 
“gold” standard to compare newer diagnostic methods.  Cytopathic agents have 
been confirmed as herpesviruses by electromicroscopic examination for typical 
icosahedral shaped virions, by immunofluorescent assay or enzyme linked 
immunosorbent assay (ELISA) with type-specific monoclonal antibodies or by PCR 
(Yeargan et al., 1985; Ballagi-Pordany et al., 1990; O'Keefe et al., 1991; Sharma 
et al., 1992; Wagner et al., 1992; Welch et al., 1992; Borchers & Slater, 1993; 
Kirisawa et al., 1993a; Lawrence et al., 1994; Osterrieder et al., 1994a; Reubel 
et al., 1995; Schlocker et al., 1995; Gilkerson et al., 1998a,b; Carvalho et al., 2000b; 
Varrasso et al., 2001).  The cross-reactivity between EHV1 and EHV4, and between 
EHV2 and EHV5 precludes the use of neutralisation tests. 
As herpesviruses can establish latency in lymphocytes or other tissues, a co-
cultivation or co-culture method has been used for reactivation of latent 
herpesviruses (Welch et al., 1992; Edington et al., 1994; Franchini et al., 1997).  
These authors demonstrated that co-cultivation with indicator cells was the most 
reliable method for detection of equine gammaherpesviruses, many of which could 
not be detected by PCR assays of DNA extracted from the same starting material 
used for the isolation virus by co-cultivation with indicator cells.  
EHV1 is capable of replicating not only in equine cells but also in mouse, monkey, 
rabbit, hamster and bovine cells, although EK or lung cells are preferred (Allen & 
Bryans, 1986; Crandell et al., 1988).  In contrast to EHV1, EHV4 has a more 55   
restricted cellular tropism and primary EK or lung cells are preferred, as the 
permissive cell lines are more restrictive and provide decreased virus yields.  Unlike 
EHV1, EHV4 is unable to replicate in RK13 cells and by culturing virus on primary 
equine cells and then transferring the isolated virus to RK13 cells the 2 viruses 
EHV1 and EHV4 can be distinguished (Lawrence et al., 1994).  Genomic changes 
can be produced during culture, and passage of EHV1 in heterologous RK13 cells 
resulted in the loss of a Bam HI site from 17 of 24 isolates (Allen et al., 1983).  
Crabb and Studdert (1995) suggested that homologous equine cells should be used 
for the in vitro cultivation of herpesvirus to minimise these changes. 
For routine isolation of virus, samples from the respiratory tract may include NS 
obtained by swabbing the nasopharynx, TW or BAL.  The diagnostic specimens are 
handled carefully to prevent inactivation of the virus.  Samples are placed in virus 
transport medium, then kept on ice or at 4°C and preferably not frozen.  For virus 
isolation from aborted fetuses, suspensions of lung, spleen or kidney are normally 
used (Crabb & Studdert, 1995).  Samples can be filtered through 0.45 µm 
membrane filter and then inoculated on to confluent cell cultures monolayer 
(Matsumura et al., 1992, Giles et al., 1993; Kydd et al., 1994; Crabb & Studdert, 
1995).  The alphaherpesviruses EHV1 and 4 produce a cytopathic effect in the 
inoculated cultures, often within 24 to 48 h p.i., that is characterised by rounding and 
clumping of cells, detachment of cells, and multinucleated syncytial cells.  The slow-
growing gammaherpesviruses EHV2 and EHV5, like EHV4, are also restricted to 
equine cells.  This is not unusual, as permissive infections by gammaherpesviruses 
are typically restricted to the cell type of the family or order of the natural host 
(Murphy et al., 1995).  CPE may not be evident until at least 3-5 days following 
inoculation and several passages of the primary isolate may be required before it is 
evident.   56   
Co-cultivation of either fixed tissue cells (Welch et al., 1992; Slater et al., 1994; Rizvi 
et al., 1997) or PBL (Siedek et al., 1999; van der Meulen et al., 2000) have been 
used in attempts to reactivate latent herpesviruses from cells.  Several methods of 
co-cultivation have been used. 
Fragments of the cranial nerves, nasal mucosa and lung have been adhered directly 
onto 25 cm
2 flasks and immediately overlaid with primary EK or RK13 cells which 
serve as detectors of reactivated virus.  For co-cultivation of PBL, suspensions of 
6X10
6 PBL from lymphoid tissues or PBL are overlayed onto monolayers of EK or 
RK13 cells in RPMI 1640 medium.  Such preparations are normally kept for 7-10 
days and passaged 3 times before being discarded.  Replication of the EHV can 
often be recognised by their characteristic CPE, detection of inclusion bodies or 
detection of viral particles by electron microscopy, immunological tests or molecular 
biological tests.  Using methods similar to this, EHV1 was isolated by co-cultivation 
from 60% of 40 horses examined at slaughter, and about one third of the positive 
horses harboured both alphaherpesviruses (Edington et al., 1985; Edington et al., 
1994).  EHV4 was isolated from buffy coat cells by these techniques (Matsumura 
et al., 1992). 
The use of interleukin-2 (IL2) and the mitogens phytohaemagglutinin (PHA) and 
pokeweed mitogen (PWM) can facilitate reactivation of virus in vitro, and blocking 
experiments with anti-IL-2 suggest that PWM and PHA act via IL-2 receptors (Smith 
et al., 1998).  IL-2, previously was known as T cell growth factor, is a lymphokine 
produced by activated T cells and is fundamental for the growth and differentiation 
of T and B cells during an active immune response; it can reactivate EHV and help 
maintain equine cell cultures (Smith et al., 1998).  Smith et al. (1998) demonstrated 
that IL-2 and equine chorionic gonadotrophin (eCG) initiated reactivation of EHV1 
from venous lymphocytes at a frequency of 1/10
-5.  Indirect immunofluorescence 
showed that > 80% of virus- positive leukocytes were CD5
+/CD8




-; co-cultivation demonstrated that the reactivated virus 
was infectious.  Virus was also reactivated in vitro from leukocytes of >70% of 
horses by PHA and PWM.  Transfer of supernatants showed that IL-2 and eCG 
acted indirectly by causing the release of other mediators from adherent cells; these 
mediators then reactivated EHV1 from T cells.  Blocking experiments with anti-IL-2 
showed that PWM and PHA acted via IL-2 but that eCG did not.   
EHV2 and 5, which are also latent in lymphocytes, can be reactivated or isolated 
using co-culture techniques.  Borchers et al. (1999a) isolated EHV5 from Przewalski 
wild horses by co-cultivation and found that 93% of the horses they tested were 
both EHV2 and EHV5 seropositive.  Franchini et al. (1997) suggested that co-
cultivation with indicator cells was the most reliable method for detection of the 
equine gammaherpesviruses because PCR failed to detect them in DNA extracted 
from the same material used for co-cultivation.  
2.6.2.  Immunological tests for detection of virus antigen and antibody 
There are 2 significant problems in the detection of type-specific antibody to the 
EHV.  First, the detection of type-specific antibody to EHV1 and EHV4 has in the 
past been confounded by the overall antigenic cross-reactivity between the 2 
viruses (Gibson et al., 1992a; Kydd et al., 1994).  A similar problem exists with the 
gammaherpesviruses EHV2 and EHV5: almost all EHV2 seropositive animals also 
have EHV5 antibody, which suggests a strong serological cross-reactivity between 
these 2 viruses, which may vary depending on the EHV2 and/or EHV5 strains 
(Borchers et al., 1999a).  Secondly, primary infection of foals often fails to stimulate 
a strong antibody response, and the antibody response in some individuals is slow 
to develop with peak titres not reached until weeks after infection (Mumford et al., 
1998).   
A number of serological tests have been used for the detection of antibody: virus 
neutralisation tests, immunofluorescent techniques, complement fixation tests, agar 58   
gel immunodiffusion tests and ELISA assays using recombinant protein antigens 
(Yeargan et al., 1985; Stokes et al., 1989; Guo, 1990; Whittaker et al., 1991; 
Matsumura et al., 1992; McLauchlan & Rixon, 1992; Sinclair & Mumford, 1992; 
Whittaker et al., 1992; Sinclair et al., 1993; Lewis et al., 1995; Tewari et al., 1995; 
Wellington et al., 1996; Stokes et al., 1997; Gilkerson et al., 1998a; Gilkerson et al., 
1999a; Gilkerson et al., 1999b; Gilkerson et al., 2000; van Maanen et al., 2000; 
Nordengrahn et al., 2001) and these are reviewed below. 
As in most virus infections, the IgM and IgG responses differ in duration.  Typically, 
in response to primary intranasal EHV1 infection, IgM levels increased before those 
of IgG neutralization and complement fixation antibody, peaked sooner and 
thereafter declined (Gibson et al., 1992a).  
Virus neutralisation tests 
Horses infected with the EHV produce virus neutralising antibody that may be 
detected by serum neutralisation tests.  However, 2 problems exist with the serum 
neutralisation test as a diagnostic assay.  First, as mentioned above, the antigenic 
cross-reactivity between the neutralising antibody induced by EHV1 and EHV4, and 
between EHV2 and EHV5, makes the interpretation of results difficult.  Second, the 
neutralising antibody response is limited, and EHV1 or EHV4 infection does not 
always stimulate 4-fold rise in neutralisation titres in the horse (Fitzpatrick & 
Studdert, 1984; Ellis et al., 1995; Singh et al., 1995; Burrell et al., 1996).  
Neutralisation assays are therefore not a suitable test for identifying recent infection 
in individual horses 
Immunofluorescence techniques 
This use of type-specific monoclonal antibodies for immunofluorescent techniques 
to detect viral antigen in cells infected by EHV1 and EHV4 has been described 
(Yeargan et al., 1985; Matsumura et al., 1992).  The technique was described as 59   
sensitive and ideal for rapid screening of virus-infected cultures (Beech, 1991b; 
Osterrieder et al., 1995).  The technique was also applied to the detection of EHV1 
infection primarily in CD5
+/CD8




- lymphocytes (Smith et al., 1998).  Indirect immunofluorescence was also 
used to detect EHV2 antigen in foamy macrophages in bronchial lavages of horses 
with chronic pulmonary disease (Schlocker et al., 1995). 
Enzyme-linked immunosorbent assay (ELISA) 
Using whole virus antigens for ELISA, antibody was detected in EHV1-infected 
horses.  Initial antibody, identified as belonging to the IgM class by double sandwich 
ELISA, was detected from 6 days p.i.  Peak IgM titres were observed between day 
10 and 18, declining to base levels by day 42 but total antibody levels continued to 
rise for the period of observation.  In contrast, virus neutralizing antibody was 
detectable in serum from day 14 but increased in titre and paralleled the total EHV1-
specific Ig levels detected by ELISA (Dutta et al., 1983; Chong & Duffus, 1992).  
One advantage of ELISA is the possibility of using recombinant virus protein 
antigens for the detection of antibody.  The N-terminal fragment comprising residues 
+1 to +50 (gB1-50) of EHV1 glycoprotein B was expressed as a glutathione S-
transferase fusion protein in Escherichia coli (Sinclair et al., 1993a).  The 
recombinant gB1-50 (rgB1-50) reacted (in immunoblots) with convalescent-phase 
sera from horses with natural EHV1 infections, although a specific cross-reaction 
was detected with EHV4, which was confirmed by inhibition ELISA.  Convalescent-
phase sera from horses with natural EHV1 or EHV4 infections possessed antibody 
titres against rgB1-50 ranging from 1:2,000 to 1:64,000, indicating the presence of 
an immunodominant antigenic site.  The study demonstrated the potential 
application of rgB1-50 as a diagnostic antigen and highlighted the glutathione S- 
transferase fusion system as a simple and effective method of producing purified 
milligram quantities of antigen.  60   
Recombinant proteins expressed using baculovirus vectors have also been used for 
the development of ELISA for the detection of EHV1 and EHV4 antibody.  
Baculovirus recombinant gD and gH both induced serum antibodies to EHV1 when 
measured by ELISA; the gD recombinant also produced a neutralizing antibody 
response in mice (Tewari et al., 1994).  Packiarajah et al. (1998) used baculovirus-
expressed glycoproteins of EHV1 gB, gC and gD to elicit very high levels of virus 
neutralising antibodies.  Western blotting demonstrated that the antibodies 
produced were not only specific for the baculovirus-expressed glycoproteins gB, gC 
and gD, but also highly specific for each EHV1 glycoprotein.  
A type-specific ELISA, which distinguished antibody to EHV4 and EHV1 thereby 
identified horses that have been infected with either or both of these antigenically-
related viruses, was first reported by Crabb et al. (1995).  The antigens used were 
fragments of the EHV4 and EHV1 glycoprotein G (gG) homologues expressed in 
E. coli as fusion proteins (Crabb & Studdert, 1993).  The expressed proteins 
comprised corresponding regions of the gG molecules that were highly divergent 
and encompassed strong, type-specific epitopes.  The ELISA was highly specific 
and is sufficiently sensitive to detect all horses previously infected with EHV4 and 
most previously infected with EHV1.  This assay has been widely used for the 
detection and differentiation of antibody to EHV1 and EHV4, including studies in 
Australia (Drummer et al., 1995; Gilkerson et al. 1998a; Gilkerson et al. 1998b; 
Gilkerson et al., 1999a; Gilkerson et al., 1999b; Gilkerson et al., 2000; Ruitenberg 
et al., 2001) and Japan (Yasunaga et al., 1998; Yasunaga et al., 2000). 
A sensitive and specific monoclonal antibody blocking ELISA was developed by van 
Maanen et al. (2000) and used successfully for the detection of antibodies directed 
against either EHV1 or EHV4.  It was reported to detect high antibody titres in SPF-
foals and conventional horses infected with either EHV1 or EHV4, increases in titre 61   
after vaccination with an EHV1 subunit vaccine, and after primary field infections in 
weaned foals.  . 
Recombinant protein antigens for ELISA for the detection of the antigenically cross-
reacting EHV2 and EHV5 antibody have not been reported.  A type-specific ELISA 
for the differentiation of EHV2 and EHV5 may well be possible, however, as Agius 
et al. (1994) showed that while EHV2 and EHV5 had similar protein profiles in 
western blots, bands in some positions were virus-specific; 6 glycoproteins, with 
distinct profiles, were identified for both EHV2 and EHV5.  
Complement fixation tests 
Although it is not a commonly used procedure in modern laboratories, complement-
fixing antibody can be detected soon after infection, but circulating levels decline 
rapidly, so that high level of CF antibody may be regarded as indicative of recent 
exposure (Tripod-Bottcher & Petzoldt, 1971; McGuire et al., 1974; Bryans, 1980; 
Gibson et al., 1992a). 
Agar gel immunodiffusion (AGID) 
AGID was considered a useful method for detecting herpesvirus antibody and has 
been utilised in a number of experimental studies (Purdy et al., 1977; Gutekunst 
et al., 1978; Holmes & Lunn, 1991).  
Western blotting  
Western blotting is used primarily to analyse the antibody response to individual 
glycoproteins or, by using specific antibodies, to detect individual glycoproteins.  
Western blotting detected a strong, type-specific epitope(s) on gG homologues of 
EHV1 and EHV4 (Pilling et al., 1994) and Western immunoblotting was useful to 
confirm that antibodies produced in response to EHV1 infection in mice were 
specific for each of the baculovirus-expressed glycoproteins gB, gC and gD 
(Packiarajah et al., 1998).  62   
Immunohistochemistry 
Immunohistochemical techniques are extremely useful for the detection of EHV 
antigens in formaldehyde-fixed tissue sections, particularly when combined with the 
use of monoclonal antibodies.  Such techniques were used by Kydd et al. (1994a,b) 
to demonstrate EHV1 viral antigens in respiratory tract-associated lymph nodes 12 
h after exposure of horses, and were also used to morphologically identify infected 
leucocytes as lymphocytes, monocytes, macrophages and plasma cells (Kydd et al., 
1994a,b).  Immunohistochemistry was also used by Rimstad & Evensen (1993) to 
examine the distribution of EHV1 in paraffin-embedded organ samples from aborted 
fetuses and foals.  Results obtained showed there was moderate to almost perfect 
agreement with results of PCR assays.  
2.6.3.  Genetic-based techniques for the detection of virus   
Sequence analysis and the confirmation that EHV1 and EHV4, and EHV2 and 5, 
are separate and distinct viruses and not minor variants (subtypes) was achieved by 
adoption of molecular biotechnology methods (reviewed above).  As a consequence 
of sequence analysis and the biotechnical revolution associated with sequencing, a 
range of newer techniques are now available for the detection of the EHV.  
Polymerase chain reaction (PCR) 
PCR, first reported in 1985 (Saiki et al., 1985) has revolutionised virological 
detection methods.  PCR involves amplifying target sequences of DNA or cDNA 
copies of RNA in vitro, and detecting the amplified material; the DNA is copied 
repeatedly until it is present in sufficient quantity to be detected (Mikel, 1994).  The 
use of the PCR for the identification of viral pathogens, such as the EHV, has a 
number of advantages over traditional methods of identification.  The technique can 
be highly specific and sensitive.  It can provide rapid results, within a day of 
submission of samples.  Viral pathogens may be present at low concentrations, 63   
possibly only 1 or 2 copies per sample, at a level which can not be detected by 
other laboratory techniques (Mikel, 1994). 
The PCR is based on the ability of DNA polymerase to make a new strand of DNA 
using the complementary strand as the template (Saiki et al., 1985; Mikel, 1994).  
Short DNA fragments (primers) are designed which bind to complementary regions 
of the target sequence.  Primers hybridise to opposite strands of the DNA template 
and are oriented so that DNA replication proceeds across the region between the 2 
primers, effectively doubling the amount of that DNA segment.   
Amplification is carried out in repeated cycles involving elevating the temperature to 
denature the double stranded sample DNA, then allowing extension of the primers 
with DNA replication enzymes to obtain a double-stranded product.  Thirty to 40 
consecutive cycles yield considerable quantities of PCR product, sufficient to detect 
by agarose gel electrophoresis after staining with ethidium bromide or other DNA-
binding dye.   
PCR assays need to be optimised not only with the DNA to be detected but also 
with a wide range of DNA from closely related viruses to confirm the specificity of 
the results (Mikel, 1994). 
PCR has been used as a tool in EHV research to identify virus, and to study the 
pathogenesis of the virus infection and latency (Borchers & Slater, 1993; Baxi et al., 
1996; Borchers et al., 1997a, b; Chesters et al., 1997; Franchini et al., 1997; 
Borchers et al., 1998; Borchers et al., 1999a, b; Buczynski et al., 1999) and the 
detection of LATs (Chesters et al., 1997; Borchers et al., 1999b). 
The presence of more than one type of EHV in individual horses is a common 
finding, and PCR assays have been particularly invaluable as a tool to detect or 
differentiate between the alphaherpesviruses EHV1 and EHV4, and the 
gammaherpesviruses EHV2 and EHV5 (Saiki et al., 1985; Kirisawa et al., 1993a; 64   
Lawrence et al., 1994; O'keefe et al., 1994; Carvalho et al., 2000b; Galosi et al., 
2001; Varrasso et al., 2001).  A number of PCR assays for detecting EHV1 (Ballagi-
Pordany et al., 1990; Osterrieder et al., 1994a; Welch et al., 1992), EHV4 (Borchers 
et al., 1997b), EHV2 (Reubel et al., 1995; Borchers & Agius, 1997; Rizvi et al., 
1997) and EHV5 (Reubel et al., 1995) have been described.  One-step (Kirisawa 
et al., 1993a; Lawrence et al., 1994; Carvalho et al., 2000b) and 2-step PCR assays 
for differentiating EHV1 and EHV4 (O'Keefe et al., 1991; Hardt et al., 1992; Sharma 
et al., 1992; Borchers & Slater, 1993; Rimstad & Hyllseth, 1994) have also been 
developed. 
Several primers and primer combinations have been reported.  Earlier reports, 
before the complete sequence of any of the EHV had been determined, tended to 
use a single set of primers to amplify a gene product which was then subjected to 
restriction enzyme digestion for specific identification of EHV1 or EHV4, and EHV2 
or EHV5 (Table 2.3).  Various primers used have been based on a variety of regions 
of the genome, the location depending on the degree of variability and hence 
specificity required (Table 2.3).   
Most researchers have concluded that PCR is slightly less sensitive than 
conventional virus isolation techniques for the detection of herpesviruses.  The 
possibility of simultaneous detection and differentiation of EHV1 and 4, and EHV2 
and 5 by PCR technology has, however, many advantages over traditional virus 
detection techniques.  The possibility of utilising degenerate primers to detect 
previously unidentified EHV, or a combination of primers in a multiplex PCR assay 
to simultaneously detect multiple herpesvirus in the same sample also offers an 
advantage, and so such multiplex PCR assays have been developed for the human 
herpesviruses (Markoulatos et al., 2001).  The possibility of utilising conventional 
PCR and RT-PCR, or detection of LATs, to differentiate the lytic and latent infection 
(Liolios et al., 2001) could be invaluable.  PCR assays based on the use of 65   
consensus (degenerate) primers have been used to detect previously unrecognised 
EHV in wild and zoo Equidae; amplicons with a high percentage of sequence 
identity to DNA polymerases of gammaherpesviruses were detected in a zebra and 
a wild ass (Ehlers et al., 1999). 
In situ hybridization (ISH) methods 
The key feature distinguishing ISH from PCR is that the sample DNA does not need 
to be extracted but is detected directly in the intact cell.  This makes it a particularly 
attractive assay for the pathologist.  This method is appropriate to determine the 
location of EHV in tissue or organs and is particularly appropriate to the detection of 
EHV1 in the equine fetus.  Unfortunately, ISH techniques are relatively insensitive, 
and usually negative in situations such as occult or latent infection by a virus where 
the number of target DNA sequences per cell (copy number) is low (Nuovo, 1992).  
ISH techniques allow specific nucleic acid sequences to be detected in 
morphologically preserved chromosomes, cells or tissue sections.  In combination 
with immunocytochemistry, the technique can relate microscopic topological 
information to gene activity at the DNA, mRNA, and protein level.  Depending on the 
probe used (labelled RNA or DNA), the technique can detect the complementary 
nucleic acid hybrid molecules (DNA:DNA, DNA:RNA or RNA:RNA) (Mikel, 1994).  
Consequently, ISH can be used to: (1) identify and localise viral infection; (2) map 
gene sequences to chromosomes; (3) identify sites of gene expression; (4) analyse 
the tissue distribution of transcription; and (5) follow changes in specific mRNA 
synthesis (Nuovo, 1992).  A misconception about ISH is that radiolabelled probes 
are necessary to maximise sensitivity.  Recent and dramatic advances in non-
isotopic labelling and detection systems have greatly enhanced the sensitivity of 
ISH using such common labels as biotin and digoxigenin (Nuovo, 1992) 
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Table 2.3.  Various reports of PCR assays used for the detection of EHV.  






Pordany et al. 
(1990) 
EHV1  Gp13 (gC)  +  Very good coincidence between PCR results and 
virus isolation for detection of EHV1 from aborted 
fetuses 
Baxi et al. 
(1996) 










gB  +  A nested PCR for the detection and differentiation of 
EHV1 and EHV4.  This assay was in the case of 
EHV1 100 times, and in the case of EHV4 1000 
times more sensitive than a standard PCR, and 
directly differentiated EHV1 and EHV4 further 
analytical techniques. 
Borchers 










+  EHV- 2 DNA detected by nested PCR based on the 
EcoRI-N genome fragment .  The products of the 
second round of the PCR reactions showed size 
polymorphism.  Sequencing of the products revealed 
that these size differences were due to repetition of 
a motif between 9-16 times depending on the 
isolate, suggesting that the nested PCR might be a 
useful tool for the differentiation of EHV-2 isolates. 
Borchers 
et al. (1997b) 
EHV4  gB  As described by 
Borchers & 
Slater (1993) 
Liquid nested-PCR to study the tropism of EHV4.  In 
4 animals, the trigeminal ganglia and in one case the 
lung were positive.  Direct in situ PCR 
 
Borchers. 















Agius et al. 
(1994)  
EHV4 DNA was amplified by PCR from PBL.  EHV2 
and EHV5 were isolated by co-cultivation and the 
identity of the virus isolates verified by PCR and 
restriction enzyme digestion.  
Borchers 
et al. (1999b) 





EHV4 DNA detected by PCR in the trigeminal 
ganglia.  An RT-PCR, detected EHV4-specific 
transcripts derived from genes 63 and 64 (HSV1 
homologues in trigeminal ganglia  
Carvalho 
et al. (2000a) 
EHV1   TK and gC    A PCR used for detection of DNA of latent EHV1 
strains from several  sources.  Three pairs of 
oligonucleotide primers spanning fragments of the 
thymidine kinase (TK) gene, and one primer pair 
spanning the glycoprotein C (gC) gene were used in 
specific amplifications.  Primers for and EHV4 PCR 
also described. 
Carvalho 




TK   +  A multiplex PCR developed for differentiation of 
strains and field isolates of EHV1 and EHV4.  
Specific primers were combined to amplify the 
thymidine kinase (TK) gene region of EHV1 and 
EHV4, which would yield fragments of different 
lengths for each virus in the same amplification 
reaction.  67   
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Chesters 




+  RT-PCR of gene 64, a putative LAT product of EHV1 
to demonstrate that EHV1 latency is established 
predominantly in CD5+/CD8+ leukocytes.antisense 
to and overlapping the 3’s end of EHV1 immediate–
early gene 64. 
VanDevanter 








+  A consensus primer PCR method which amplifies a 
region of herpesvirus DNA-directed DNA polymerase 
and which used degenerate primers in a nested 
format was developed.  Primers were designed to 
target sequences coding for highly conserved amino 
acid motifs covering a region of approximately 800 
bp.  The assay was applied to 22 species of 
herpesviruses (8 human and 14 animal viruses and 
including EHV2.  The data suggested that 
consensus primer PCR targeted to herpesvirus DNA 
polymerase may prove to be useful in the detection 
and identification of known herpesviruses in clinical 
samples and the initial characterization of new 
herpesvirus genomes. 











+   A PCR based on a combination of oligonucleotide 
primers selected using the octamer frequency 
disparity method with primers specific for EHV-5 
(described by other authors) recognised all of a 
series of gamma herpesvirus field isolates.  Their 
data suggested the most reliable method for 
detection of equine gamma herpesviruses is the co-
cultivation with indicator cells. 
Galosi et al 
2001 
EHV1  gC and gD  +  PCR diagnosis of aborted fetus 




Gp13 (gC)    PCR primers was located in the glycoprotein 13 
open reading frame and allowed the amplification of 
both EHV1 und EHV4.  By cleaving pattern analysis 
after Hinf I digestion EHV 1 could be distinguished 
from EHV 4. 




gB  +  Primers designed from aligned nucleotide 
sequences of gB genes of EHV1 and EHV4 to 
amplify specific regions for EHV1 or EHV4 or a 
common region of both viruses.  By using type 
specific primer mixture, amplified fragments were 
identified as EHV1 or EHV4 in a one-step reaction 
Lawrence 
et al. (1994) 
EHV1 and 
EHV4 




Primers designed to specifically amplify homologous 
regions of the gC and gene 76 genetic loci of EHV1 
and EHV4).  The resultant virus- specific products 
were discriminated based on size.  A strong 
correlation found between this PCR assay and virus 
isolation methods of EHV1 and EHV4 detection and 
discrimination. 
McCann et al. 
(1995) 
EHV1  gB  +  Variable sites within EcoR1-I and HaeIII (gB) 
fragments of EHV1 were used to develop PCR 
assays.  Both sites thought to provide the basis for 
the rapid DNA fingerprinting of EHV1 isolates. 




gp13 (gC)  +  DNA derived from EHV1 and EHV 4 infected cell 
cultures amplified by PCR using s pair of 
oligonucleotide primers.  Restriction fragment length 
polymorphisms of the products enabled the 2 virus 
types to be differentiated 




gp13 (gC)  Primers as 
described by 
O’Keefe et al. 
(1991).   
Detected virus in formaldehyde-fixed tissues of 
aborted foals. 68   
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Osterrieder 
et al. (1994a) 
EHV1 US4  Primer 
sequences not 
provided. 
Touch-down PCR differentiated field strains from the 
modified live vaccine strain RacH.   







+  Nested PCR for EHV2 and EHV5 using the 
nucleotide sequences from the glycoprotein B (gB) 
gene of EHV2 and the thymidine kinase (TK) gene of 
EHV5.  The simultaneous use of EHV2 specific and 
EHV5 specific primers in one nested amplification 
assay (multiplex PCR) was specific and sensitive.  
PCR was 10
3 times more sensitive than virus 
isolation for EHV2 and 10
6 for EHV5.  Considered a 
rapid and reliable method for the simultaneous 





EHV1      Paraffin-embedded organ samples were examined 
by PCR for EHV1 DNA.  Good correlation with 






gp13 (gC)  +  Two step PCR to detect EHV1 and 4, and restriction 
enzyme analysis of product to differentiate EHV1 
and 4. 
Rizvi  et al. 
(1997b) 
 ORF  64 
(tegument 
protein) 
+  PCR used to determine the distribution of EHV2 
DNA within neurological and lymphoid tissues from 
EHV-2 seropositive Welsh mountain ponies.   




TK, gH and 
gC   
+  PCR used to detect DNA of EHV1 and EHV4 within 
nasopharyngeal swab samples from horses.  
Slater et  
al. (1994a) 
EHV1  gB  As described by 
Borchers et al. 
(1993). 
PCR used to confirm the presence of virus DNA in 
ganglia and lymphoid tissues of EHV1-infected 
horses.  




gB  +  One step PCR to detect and differentiate EHV1 and 
EHV4. 
Varrasso 





  Single and semi-nested multiplex PCR for tissue of 
aborted fetus and nasal swabs 




gB  +  PCR and co-cultivation were used to identify the 
lymphoreticular system as the site of latency of 
EHV1.  Primers for PCR were designed from aligned 
nucleotide sequences of the gB genes to amplify the 
same region of both the EHV1 and EHV4 genomes.  
Subsequent restriction digests using specific 
enzymes distinguished the amplified fragments of 
EHV1 and EHV4. . 
Edington et al. 
(1994) 
EHV4    As described by 
Welch et al. 
(1992) 
PCR used to detect EHV4 in bronchial lymph nodes 
and trigeminal ganglia.  Results compared to 
conventional virus isolation techniques.  
Kershaw et al. 
(2001) 
EHV2    As described by 
Borchers et al . 
(1997a) 
A nested PCR on ocular swabs to determine the 
prevalence of EHV2.  Results compared to co-
cultivation of PBL of healthy and diseased horses 
but not on swabs. 













A consensus primer PCR approach was used to 
investigate the presence of herpesviruses in wild 
and zoo equids.  The PCR assay was based on 
degenerate primers targeting highly conserved 
regions of the DNA polymerase gene of 
herpesviruses, and modified by using a mixture of 
degenerate and deoxyinosine-substituted primers.  
Borchers 
et al.,(2002) 
EHV2      An EHV2-specific nested PCR used to determine the 
presence of virus in lung, nasal turbinates and 
neurological tissue of BALB/c mice were inoculated 
with EHV2. 
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ISH has been used in a number of situations to detect EHV.  Digoxigenin-labelled 
EHV1 BamHI fragments spanning almost the entire EHV1 genome were hybridised 
to RNA in tissue sections from latently EHV1-infected trigeminal ganglia of horses, 
and EHV1 RNA antisense to gene 63 (HSV1 homolog ICP0) was detected in a 
small number of neurons (Baxi et al., 1995).  Chesters et al. (1997) utilised ISH to 
locate EHV1 in CD5
+/CD8
+ leukocytes in bronchial lymph nodes and Schmidt et al. 
(1994) successfully used digoxigenin-labelled probes to examine tissue sections of 
equine fetuses aborted due to EHV1 infection. 
In the mouse model of EHV1 infection, digoxigenin-labeled ISH DNA or RNA probes 
detected early EHV1 DNA in bronchiolar and vascular endothelium in the lungs and 
in and around germinal centres in the spleens, and presumed “latent” virus one 
month later in the trigeminal ganglia, olfactory bulb and PBL (Baxi et al., 1996) 
Restriction fragment length polymorphism (RFLP) 
RFLP analysis is a DNA fingerprinting method that, to a limited extent, can 
distinguish between 2 viruses at the genomic level and recognise minor differences 
at the strain level that normally cannot be detected by antigenic assays.  It is based 
on the enzymatic digestion of the DNA to produce fragments which can be 
separated by electrophoresis.  Restriction enzymes recognise specific nucleotide 
sequences and cut the genome at that location.  The DNA fragments are 
immobilised on a nylon membrane (Southern blotting), and specific labelled DNA 
probes are used to reveal the bands. The number of fragments that can be 
analysed simultaneously, however, is dependent on the resolution of the detection 
system.  Typically 50-100 restriction fragments are amplified and detected on 
denaturing polyacrylamide gels.  In general, RFLP requires virus isolates but RFLP 
using PCR amplified products instead of native nucleic acid has recently been 
developed.  70   
RFLP analysis is rapid and less expensive than sequence analysis, but will miss 
many of the genetic differences that are revealed by sequencing (Vos et al., 1995).   
RFLP methods have been used to distinguish different EHV (Ballagi-Pordany et al., 
1990; Kirisawa et al., 1993b; McCann et al., 1995; Carvalho et al., 2000a) .  
Studdert and co-workers were able to utilise the technique to differentiate EHV1 and 
EHV4 (Studdert et al., 1981; Studdert, 1983).  The technique was also used to 
demonstrate that there were minor variations in the mobility of Bam HI fragments of 
EHV1 strains before and after vaccination of horses (Kirisawa et al., 1993b) and 
differences between EHV5 isolates from different horses have been reported 
(Dunowska et al., 2000). 
Southern blot, Northern blot and dot blot 
These 3 techniques have potential application for the detection of EHV in tissues.  
Comparison with PCR and RT-PCR for the detection of and determination of the 
genomic heterogeneity of EHV (Browning & Studdert, 1987b; Browning & Studdert, 
1989b; Kirisawa et al., 1993b; Collinson et al., 1994).  Morris & Field (1988) 
demonstrated the possibility of southern blot and dot blot for detecting virus DNA 
and to distinguish between subtypes of the EHV; the dot blot method was 
considered to have potential for the rapid detection of EHV1.  
2.7.  Immune response to equine herpesviruses 
The immune response to EHV is complex with humoral immunity neutralizing 
extracellular virus and contributing to inhibition of virus infectivity and replication 
(Murray et al., 1996).  Cell mediated immunity appears to be most important in 
surveillance against persistently infected cells and in preventing reactivation of 
latent EHV infection (Murray et al., 1996).  
In EHV1-infected specific pathogen-free horses, an ELISA was used successfully to 
detect antibody in serum from 6 days p.i.  Antibody titres continued to rise  71   
throughout the period of observation, and were slightly stimulated by re-inoculation.  
EHV antibody, identified as belonging to the IgM class by the double sandwich 
ELISA, was detected from 6 days p.i. and peak IgM titres were observed between 
day 10 and 18, declining to base levels by day 42.  Virus neutralising antibody was 
detectable in serum from day 14 and rises in titre were parallel to that of total ELISA 
antibody.   
Cellular immunity in EHV-1 infected SPF horses was examined by the antibody-
dependent cytotoxicity (ADCC) test and the specific lymphocyte transformation test.  
The ability of foal neutrophils to affect ADCC decreased significantly between 3 to 
10 days after inoculation. Peripheral blood leukocytes (PBL) displayed reactivity 
towards EHV-1 antigens from about day 14, with maximum stimulation indices being 
obtained 28-42 days p.i. (Chong & Duffus, 1992). 
The EHV1 glycoprotein gp14, the homologue of gB of HSV may be important for the 
expression of epitopes necessary for the induction of neutralizing antibodies 
(Osterrieder et al., 1994b; Munro et al., 1999).  Total serum antibody responses, as 
measured by ELISA, to EHV1 and EHV4 were significantly higher in horses that 
received the bivalent inactivated-virus vaccine, compared with that in horses that 
received monovalent vaccine.  This revealed that vaccination with modified-live 
EHV1 stimulated a cellular and antibody response that cross-reacted with EHV4 
(Ellis et al., 1995).  Vaccination induced a cytotoxic cellular immune response in 
young horses with maternal antibodies (Ellis et al., 1997). 
An in vitro T cell response mediated by both CD4
+ and CD8
+ T cells was detected 
both during the acute phase of infection and after challenge with a second dose of 
EHV1 at 2 months in lymphocyte populations taken from the spleens of mice (Alber 
et al., 1995; Fitzpatrick & Studdert, 1984).  The results gained from a mouse model 
indicate that important interactions occur at the level of T cell immunity between 72   
EHV1 and EHV4 which warrant further investigation in the natural host (Azmi & 
Field, 1993).   
Chemokines are likely to play a role in the regulation of immune functions in equine 
hosts during EHV infection and may affect viral replication and/or escape from 
immune responses (Camarda et al., 1999).    73
Chapter 3.  A nested multiplex PCR for the detection 
and differentiation of equine herpesvirus 1, 2, 4 and 5. 
 
Summary 
A nested multiplex PCR was developed for the detection of the four equine 
herpesviruses (EHV) that have been recovered from the respiratory tract of horses: 
the alphaherpesviruses EHV1 and EHV4, and the gammaherpesviruses EHV2 and 
EHV5.  There was good correlation between the multiplex PCR for the detection of 
EHV and the detection of virus by isolation in cell culture, although a combination of 
the 2 techniques provided greater sensitivity than either technique alone.  The 
nested multiplex PCR and cell culture detected up to 3 EHV in peripheral blood 
leukocytes (PBL) or nasal swabs (NS) from individual horses, and often the 
presence of 2 EHV types in the same cell cultures infected with these samples.  The 
multiplex PCR described appeared equally sensitive as specific PCR assays using 
a single set of primers for each individual virus but reduced labour and reagent 
costs.   
Introduction 
 
Various means of detecting EHV1, EHV2, EHV4 and EHV5 infections have been 
reported, including serological tests (Yeargan et al., 1985; Murray et al., 1996; 
Gilkerson et al., 1998a; Mumford et al., 1998), virus isolation from nasal swabs 
(Palfi et al., 1978; Kydd et al., 1994a,b), blood (Roeder and Scott, 1975; Borchers 
et al., 1997a,b; Dunowska et al., 1999) and other tissues (Dutta and Campbell 1978; 
Edington et al., 1994; Carman et al., 1997), and PCR assays (Ballagi-Pordany et al., 
1990; O'Keefe et al., 1991; Sharma et al., 1992; Wagner et al., 1992; Welch et al.,   74
1992; Borchers and Slater, 1993; Kirisawa et al., 1993a; Lawrence et al., 1994; 
Osterrieder et al., 1994; Reubel et al., 1995; Carvalho, 2000).   
A number of PCR assays for detection of EHV1 (Ballagi-Pordany et al., 1990; Welch 
et al., 1992; Osterrieder et al., 1994), EHV4 (Borchers et al., 1997b), EHV2 (Reubel 
et al., 1995; Borchers et al., 1997a; Rizvi et al., 1997b) and EHV5 (Reubel et al., 
1995) have been described.  The presence of more than one type of EHV in 
individual horses is a common finding, and one-step (Kirisawa et al., 1993a; 
Lawrence et al., 1994; Carvalho, 2000) and two-step (O'Keefe et al., 1991; Sharma 
et al., 1992; Borchers and Slater, 1993; Rimstad and Hyllseth, 1994) PCR assays 
for the detection and differentiation of EHV1 and 4, and EHV2 and EHV5 (Reubel 
et al., 1995) have been described. 
There are no reports describing multiplex PCR assays for the simultaneous 
detection of all 4 EHV associated with respiratory disease in the horse.  Such an 
assay would simplify the diagnostic process.  Multiplex PCR involves a combination 
of multiple primer pairs in the same amplification reaction with the objective of 
simultaneously producing different sized amplicons for each individual virus that 
might be present within a clinical sample.  The advantages of multiplex PCR 
methods include a reduced labour commitment and a reduction in the reagents 
required compared to a series of single analytical PCR assays (Edwards and Gibbs, 
1994).  In this report, a two-step multiplex nested PCR is described for detection 
and differentiation of EHV1, EHV2, EHV4 and EHV5 in cell cultures and clinical 
samples from horses. 
Material and Methods 
Reference virus strains  
Reference strains of the alphaherpesviruses EHV1 and EHV4 were obtained from 
Dr Trevor Ellis, Animal Health Laboratories, Agriculture WA.  Reference strains of   75
EHV2 (Strain 86/67) and EHV5 (Strain 2-141) were kindly provided by Professor MJ 
Studdert, Melbourne University.  These strains were cultured in primary equine 
kidney (EK) cells maintained in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco, Australia) supplemented with 2% fetal bovine serum (Gibco, Australia) at 
37°C in a 7% CO2-in-air atmosphere.   
Specimens from horses  
PBL and NS were collected from weanling foals, some of which showed signs of a 
mild acute respiratory disease.  Blood samples (20 ml) were collected in vacutainer 
tubes with EDTA, and NS were placed in 2 ml transport medium (DMEM with 2% 
FBS and antibiotics).  The blood and NS were kept on ice until processed further the 
same day. 
Peripheral blood samples were obtained from 14 horses in one stable at weekly 
intervals for 5 weeks.  These were obtained to assess the repeatability of the 
assays over this period, and to compare cell culture and direct multiplex PCR for the 
detection of virus in these samples. 
Isolation of virus in cell culture 
Isolation of virus from NS was by direct inoculation of 0.1 ml sample onto confluent 
primary EK cell cultures in 24-well trays.  Isolation of virus from PBL was attempted 
by co-culture of the cells with EK cells: PBL were separated by Ficoll-Paque
TM Plus 
(Amersham Pharmacia Biotech AB, Sweden) gradient centrifugation, and about 1 x 
10
5.6 PBL were added to each of 2 wells of confluent EK cells in 24-well trays, using 
medium supplemented with 20 IU/ml human recombinant interleukin-2 (Cetus 
Corporation, USA) as described by Smith et al. (1998).  Cultures were monitored 
daily and passaged at weekly intervals for a total of 4 passages.  DNA was 
extracted from the cell cultures, either after the detection of CPE or at the   76
conclusion of the fourth passage, and virus in the cultures was identified by nested 
multiplex PCR (described below).  
DNA extraction  
DNA was extracted from virus-infected cell cultures by the phenol-chloroform 
method described by Sambrook et al. (1989).  Briefly, cells were lysed in "lysis 
buffer" (10 mM Tris-HCl [pH 8.0], 0.1% [w/v] SDS, 20 mg/ml proteinase K [Sigma, 
USA]) at 56°C for 8-16 h until the suspension was clear.  The mixture was then 
added to an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1), mixed 
thoroughly by vortexing for 15 sec, and centrifuged (10,000 x g, 10 min).  The upper 
aqueous layer containing DNA was aspirated and the extraction procedure repeated 
several times (at least twice).  Once visible protein at the interface between the 2 
phases was eliminated, the aqueous layer was removed and added to one volume 
of chloroform to remove traces of phenol.  Following vortex mixing and 
centrifugation (10,000 x g, 10 min), the aqueous top phase was carefully removed 
and mixed with 0.1 volume of 3 M sodium acetate (pH 4.6) and 2 volumes of 100% 
ethanol.  The DNA was precipitated overnight at -20°C and collected by 
centrifugation (10,000 x g, 30 min, 4°C).  The pellet containing DNA was washed 
once with 70% (v/v) ethanol and dried under vacuum.  Resuspension of the DNA 
was typically performed by the addition of an appropriate volume of TE (10 mM Tris-
HCl, 1 mM EDTA; pH 8.0) and incubation at 4°C for at least 6 h before it was used.  
The extracted DNA was stored at -20°C. 
DNA was extracted from PBL and from cells pelleted by centrifugation from NS from 
horses, using a QIAmp Blood Mini Kit (Qiagen, Australia) and the protocol 
suggested by the manufacturer.  Briefly, the cell suspensions were combined with a 
chaotropic agent and proteinase K to disrupt cells and release the cell contents 
including DNA.  The lysate was then passed through a prepared silica column to   77
extract the nucleic acids from solution.  After elution with nuclease-free TE-buffered 
water, samples were stored at –80°C until needed.   
Nested multiplex PCR 
The primers used are shown in Table 3.1.  The first and second round nested 
primers for EHV2 and EHV5 were designed with Primer Design and Amplify 2.1 
programs (Bio-Rad Australia) using sequence data of a conserved region of the 
glycoprotein B (gB) gene derived from sequence data available in the Genbank 
database.  The first and second round nested PCR primers for EHV1 and EHV4 
were those previously described by Kirisawa et al. (1993).  All primers were 20 mers 
with G+C contents of less than or equal to 50%.  Primers were designed to ensure 
that the final reaction products could easily be differentiated on the basis of size 
from each other, with a predicted size of the PCR products of 188 bp for EHV1, 410 
bp for EHV5, 677 bp for EHV4 and 817 bp for EHV2. 
For first stage PCR amplification, 4 µl of the extracted DNA was added to a PCR 
mix using reagents supplied by PE Biosystem (Australia) with final concentration of 
1 mM MgCl2, 200 µM each dNTP, 1 µM each primer and 1 unit of Taq DNA 
polymerase made up to a 50 µl volume using PCR buffer.  Thermocycling conditions 
for both the first and second round reactions consisted of 1 cycle at 94°C for 5 min, 
followed by 30 cycles of denaturing at 94°C for 1 min, annealing at 60°C for 1 min 
and extension at 72 °C for 1 min, and a final extension step at 72°C for 7 min.  For 
the second round PCR, 2 µl of the first round amplification product was added to 
48 µl of another PCR mixture containing the second round primers (Table 3.1).  The 
final PCR reaction products were electrophoresed in 1.5% agarose containing 
10 µg/ml ethidium bromide and the reaction products were visualised under UV 
light.    78
 
Table 3.1.  Nucleotide sequence of primers and products used in the first and second rounds 
of the nested multiplex PCR. 
 





EHV2 EHV2L1  GATGGTCTCACCTCTAGCAT EHV2  gB 538-557  1111  First 
round 
primers   EHV2R1  CTGGTGTAACACAGGTCTTC    1627-1646   
 EHV5  EHV5L1  CCAACACAGAAGACAAGGAG EHV5  gB  345-364  1339 
   EHV5R1  CACGGTGATACAGTCAGAGA    1662-1681   
 EHV1/  FC2  CTTGTGAGATCTAACCGCAC  EHV1  gB  2427-2446  1118 
 EHV4     EHV4  gB  1737-1756  1175 
   RC  GGGTATAGAGCTTTCATGGG  EHV1  gB  3607-3588   
      EHV4  gB  2911-2892   
EHV2 EHV2L2  GGTCTCACCTCTAGCATAAC EHV2  gB 541-560  817 




EHV5 EHV5L1  CCAACACAGAAGACAAGGAG EHV5  gB 345-364  410 
   EHV5R2  AGTTGACCGTCGTTCTAGTG    733-752   
 EHV1/  FC3  ATACGATCACATCCAATCCC  EHV1  gB  2699-2718  188 
 EHV4     EHV4  gB  2003-2022  677 
   R1  GCGTTATAGCTATCACGTCC  EHV1  gB  2886-2867   
   R4  CCTGCATAATGACAGCAGTG  EHV4  gB  2679-2660   
 
The specificity of the PCR reaction products was confirmed by sequence analysis of 
the products obtained from the EHV-positive controls and field samples.  Size-
specific PCR products were purified and cloned into plasmid pCR2.1 (Invitrogen, 
Australia), and transformed into competent Top 10F E. coli (Invitrogen, Australia).  
Transformants were selected on LB/IPTG/X-gal plates.  Plasmid DNA was extracted 
and purified using a Wizard Plus SV Miniprep DNA purification system (Promega, 
Australia).  Sequencing was performed with an ABI 373A Automated DNA 
sequencer with fluorescent-labelled dideoxynucleotide chain terminators.  The 
sensitivity of the assay was determined by amplifying 10-fold serial dilutions of DNA 
from each of the four EHV.  Sensitivity and specificity were further examined by   79




Specificity and sensitivity of the multiplex PCR  
Typical results of the first round and second round PCR products obtained by the 
multiplex nested PCR using DNA extracted from infected cell cultures are shown in 
Figure 3.1.  The second round PCR primers amplified products of the predicted 
size: 188 bp for EHV1, 817 bp for EHV2, 677 bp for EHV4 and 410 bp for EHV5.  
No mispriming was observed. 
The species specificity of the PCR products was confirmed by sequencing.  The 
sequence of the EHV1 and EHV4 PCR products had >99% identity to the sequence 
of several strains of EHV1 and EHV4 available in the Genbank database.  The 
sequence of the EHV2 and EHV5 fragments had >98% identity to the sequence of 
EHV2 (Access No. EHV20824) and EHV5 (Access No.  AF050671) in the Genbank 
database, respectively.  
The sensitivity of the assay was determined by amplifying 10-fold serial dilutions of 
DNA from each of the four EHV.  As expected, the second round PCR reaction 
resulted in a marked increase in sensitivity of the reaction compared to first round 
reactions only, illustrated for EHV1 in Figure 3.2.  The multiplex PCR detected 0.1 fg 
of EHV1 and 1 fg EHV2, EHV4 and EHV5 (Figure 3.3).  
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Figure 3.1.  Multiplex PCR reaction products using control cell culture-derived DNA 
preparations of EHV1, EHV2, EHV4 and EHV5.  A, first round products; B, second round 
reaction products.  Lane 1, 100 bp ladder; lane 2, EHV2; lane 3, EHV4; lane 4, EHV5; lane 
5, EHV1; lane 6, mixture of EHV1, EHV2, EHV4 and EHV5. 
 
Various mixtures of the DNA of the 4 EHV were amplified by multiplex PCR and the 
expected PCR products amplified from the mixes were similar to those when single 
templates were used (Figure 3.4).   
Comparison of multiplex PCR and cell culture methods on the same samples 
from horses 
PBL and NS from 48 weanling foals in 3 stables were cultured in primary EK cells 
and the multiplex PCR was then used to identify EHV in the cell cultures.  Examples 
of the individual results obtained in 19 weanling foals are shown in Figure 3.5 and 






Figure 3.2.  Nested multiplex PCR reaction products obtained using various dilutions of 
EHV1 DNA as a template, illustrating the increased sensitivity obtained using a second 
round reaction.  A, first round reaction products; B, second round reaction products.  Lane 1, 
100 bp ladder; lane 2, negative control; lanes 3-14, serial 10-fold dilutions of EHV1 DNA 
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Figure 3.3.  Comparative sensitivity of the nested multiplex PCR for the detection of EHV2 
(A), EHV4 (B), EHV5 (C) and EHV1 (D).  Lane 1, 100 bp ladder; lanes 2-7, serial 10-fold 





Figure 3.4.  Different mixes of the EHV DNA templates amplified by two-step multiplex PCR 
to illustrate the apparent lack of competition between the various EHV DNA mixes.  Lane 1, 
100 bp ladder; lane 2, EHV2; lane 3, EHV4; lane 4, EHV5; lane 5, EHV1; lane 6, mixture of 
EHV2, EHV4, EHV5 and EHV1; lane 7, mix of EHV4 and EHV1; lane 8, mix of EHV2 and 
EHV4; lane 9, mix of EHV4 and EHV5; lane 10, mix of EHV2 and EHV1; lane 11, mix of 
EHV5 and EHV1; lane 12, mix of EHV2 and EHV5; lane 13, mix of EHV2, EHV4 and EHV1; 
lane 14, mix of EHV2, EHV5 and EHV1; lane 15, mix of EHV2, EHV4 and EHV5. 
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Figure 3. 5.  Example of two-step nested multiplex PCR results obtained using DNA 
extracted from equine PBL as a template.  Lanes 1, 7 and 20, 100 bp ladder; Lane 2, 
negative control; lanes 3-6, EHV2, EHV4, EHV5 and EHV1 positive controls, respectively; 
lanes 8-19, DNA extracted from PBL of 12 different horses; lane 13 is positive for both EHV2 
and EHV5; lanes 10, 15, 16 and 18 are negative, lanes 8, 9, 11, 12, 14, 17 and 19 are 
positive for EHV5. 
 
In co-cultured PBL samples, virus was detected by the development of CPE and 
identified by multiplex PCR in the co-cultured cells in 45 of 48 samples; EHV5 only 
in 38 samples, EHV2 only in 7, and co-infection with EHV5 and EHV2 in 7.  Direct 
multiplex PCR assays of PBL samples was less sensitive than culture in 
combination with the multiplex PCR, and detected EHV in only 31 samples: EHV5 
only in 22, co-infection of EHV2 and EHV5 in 1, and co-infection of EHV5 and EHV1 
in 8.  The EHV1 detected by direct PCR examination of DNA extracted from PBL 
was not detected by the co-culture techniques. 
In 32 of the 48 NS samples inoculated onto EK cell cultures, virus was detected by 
the development of CPE and identified by multiplex PCR: EHV5 only was detected 
in 19, EHV2 only in 8, EHV4 only in 2, and co-infection with EHV2 and EHV5 in 5 
samples.  Direct multiplex PCR was less sensitive than culture in combination with 
the multiplex PCR, and detected EHV in 28 samples only: EHV5 only in 20, EHV2 
only in 5, EHV4 only in 2, and EHV2 and EHV5 co-infection in one sample.   84
Table 3.2.  Comparison of multiplex PCR and virus isolation for the detection of EHV in PBL 
and nasal swabs in horses from 2 stables.  The results shown are characteristic of the 
results obtained in a total of 48 samples where culture and direct multiplex PCR assays 
were used to detect EHV.  The weanling horses sampled in Stable H2 had recently exhibited 
signs of a mild acute respiratory disease. 
 
PBL   Nasal  swabs  Stable 
sampled 
Horse 
Culture Direct  PCR    Culture Direct  PCR 
Stable H2  SS  -  -    EHV2  EHV2 
n = 19  BB  EHV5  -    EHV2  EHV2 
 N  EHV5  EHV1,  EHV5   EHV4  EHV4 
  TT  EHV5 -    EHV2 EHV2 
  MM  EHV5 -    EHV2 EHV2 
  CG  EHV5 -    EHV2 - 
  SB  EHV5 EHV5   EHV2 - 
 FS  EHV2,  EHV5  EHV5   EHV4 EHV4 
  Dr  EHV5 EHV5   EHV2 - 
 AO  EHV2,  EHV5  -    EHV2  EHV2 
 SG  EHV2,  EHV5  EHV5    EHV2, EHV5  EHV2, EHV5 
 LS  -  EHV1,  EHV5    EHV5  - 
 S  EHV2,  EHV5  EHV1,  EHV5   EHV5  EHV5 
 RM  EHV2,  EHV5  -    -  - 
  TL  EHV5 EHV1,  EHV5    EHV5 - 
  LK  EHV5 EHV5   EHV5 - 
 PC  EHV5  EHV5    -  - 
  SL  EHV5 EHV5   EHV5 - 
  R  EHV5 EHV5   EHV5 - 
Stable E  BA  EHV5  EHV5    -  EHV5 
n = 9  Z  EHV5  EHV5    EHV5  EHV5 
 MP  EHV5  EHV5    -  - 
  WB  EHV5 EHV5   EHV5 EHV5 
  BF  EHV5 EHV5   EHV5 EHV5 
 RR  EHV2,  EHV5  EHV5    EHV5  - 
  E  EHV5 EHV5   EHV5 EHV5 
  PS  EHV5 -    EHV5 EHV5 
 IS  EHV5  EHV2,  EHV5   EHV5  EHV5 
- denotes a negative PCR reaction. 
 
A comparison of co-culture in conjunction with multiplex PCR and direct PCR, for 
the detection of EHV in PBL, was made in 12 adult horses at weekly intervals over a 
5 week period; samples from the respiratory tract of these horses were not 
examined.  The results are show in Table 3.3.  Only EHV2 and EHV5 were detected 
in the PBL of these horses, and sometimes both were detected in the same    85
 
Table 3.3.  Comparison of cell culture combined with multiplex PCR and direct multiplex 
PCR for the detection of EHV in peripheral blood leukocytes in 12 horses sampled at weekly 
intervals. 
 
Horse  Day 1  Day 7  Day 14  Day 21  Day 28 
  CC   PCR  CC   PCR  CC   PCR  CC   PCR  CC  PCR 
1 EHV2 
EHV5  
EHV5 --  --  EHV5 EHV5 --  --  EHV5 -- 
2  EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 EHV2 EHV5 EHV5 EHV5 
3  EHV2   
EHV5 
EHV5 EHV5 --  EHV5 EHV5 --  --  EHV5 -- 
4  EHV2   
EHV5 
--  EHV5 EHV5 EHV5 --  EHV5 EHV5 --  -- 
5  EHV5 EHV5 EHV2     
EHV5 
EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 
6  --  EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 EHV5 -- 
7  EHV2  -- -- -- -- -- -- -- EHV5  EHV5 
8  EHV5 EHV5 --  EHV5 --  --  EHV5 EHV5 EHV5 EHV5 
9  -- -- EHV5  EHV5  -- -- EHV5  EHV5  EHV5  EHV5 
10  EHV2   
EHV5 
EHV5 --  --  EHV5 EHV5 --  EHV5 EHV5 EHV5 
11  EHV5  --  EHV2   
EHV5 
EHV5  EHV5  -- -- -- EHV5  EHV5 
12  -- -- EHV2     
EHV5 
EHV5  EHV2   
EHV5 
EHV5  --  --  EHV2   
EHV5 
EHV5 
13  EHV2   
EHV5 
EHV5 --  --  EHV5 EHV5 --  --  EHV5 EHV5 
14  -- -- EHV2     
EHV5 
EHV5  -- -- -- -- -- -- 
Total 
EHV2 
6 0 4 0 1 0 1 0 1 0 
Total 
EHV5 
9 8 9 9 10  8 5 6 12  9 
 
CC    denotes detection of virus by co-culture in conjunction with multiplex PCR detection of 
virus in the cell cultures. 
PCR  denotes direct multiplex PCR for detection of virus.   86
samples.  EHV5 was detected in the PBL of all 14 horses and similar EHV5 
detection rates were obtained by the 2 techniques used, co-culture and direct PCR 
examination, although EHV5 was not detected in all the horses on every sampling 
occasion and the same results were not always obtained by the 2 techniques.  
EHV2 was detected in 6 of the 14 horses on the first sampling, then the prevalence 
decreased in the successive 4 weeks to 4/14, 1/14, 1/14 and 1/14.  EHV2 was 
detected in the PBL only when co-culture was utilised for the detection of virus and 
it was not detected by direct PCR examination of PBL in any of the 14 horses in any 
of the sampling periods.  In only one horse (Number 12, Table 3.3) was EHV2 
detected in the same horse on more than one occasion.   
 
Discussion  
The nested multiplex PCR was optimised to the extent that it was able to detect 
0.1 fg of EHV1 DNA and 1 fg of EHV2, EHV4 and EHV5 DNA. The reason for the 
higher sensitivity obtained for EHV1 is not known but it was possibly at least partly 
attributable to the smaller size of the EHV1 amplicon.  The results also showed that 
re-amplifying the PCR product with a set of nested primers could increase the PCR 
sensitivity by approximately 1,000 to 10,000-fold, as previously reported by Kirisawa 
et al. (1993a).   
It was apparent, however, that the co-culture procedure used for the detection of 
EHV was generally more sensitive than the direct examination of samples using the 
multiplex PCR.  A similar greater sensitivity of culture compared to direct PCR was 
reported by others (Welch et al., 1992; Franchini et al., 1997).  This was particularly 
evident with the detection of EHV2 in PBL (Table 3.3), presumably due to a low 
genomic copy number present in the DNA extracted from PBL making it beyond the 
sensitivity of the multiplex PCR, and with sufficient replication of the EHV2 in co-
cultures during 4 cell culture passages to make it then detectable.  In nasal swabs,   87
however, co-culture in conjunction with multiplex PCR and direct multiplex PCR 
methods detected EHV2 at a similar rate (Table 3.2).  This discrepancy suggests 
the EHV2 detected in PBL may have been latent virus present at a low copy number 
per cell, and reactivated by co-culture.   
The detection of EHV1 was an exception to the observation that replication of virus 
in cell cultures enhanced the detection rate compared to direct PCR assays.  EHV1 
was detected in 8 of 48 PBL samples by the multiplex PCR but was not detected in 
PBL-EK co-cultures; in all 8 cases the EHV1 was detected by PCR in association 
with EHV5 which, with one exception, was detected in the co-cultured cells.  It is 
possible that EHV5 replicated at a greater rate than EHV1, maybe at the expense of 
EHV1, during the 4 passages before the cultures were tested and under the 
conditions used. 
It was also apparent that direct multiplex PCR and  co-culture (in combination with 
the multiplex PCR for the detection of virus in the co-cultures), in many cases 
resulted in the detection of different EHV.  There are a number of possible 
explanations for this.  First, replication of virus in the cultures would have provided a 
higher EHV genomic copy number, which would have contributed to the greater 
sensitivity.  If latent virus was present and reactivated during co-culture, this would 
have increased the genomic copy number significantly to perhaps detectable levels, 
while the copy number present in the original sample may have been very low and 
sometimes below levels detectable by the PCR.  Second, differences in the viruses 
detected by culture and by direct multiplex PCR were possibly at least partly 
associated with competitive replication of one EHV type compared to another in the 
cultures.  Third, it was likely that the sensitivity of the co-culture procedures used for 
the detection of virus in PBL was at least partly due to the use of IL-2 in the cell 
culture medium, which can assist in the reactivation of latent EHV (Smith et al., 
1998); previous results from our laboratory demonstrated a higher detection rate of   88
EHV in PBL co-cultured in the presence of IL-2 (Little, 1998).  Fourth, the use of 
PCR to identify cytopathic viruses present in cell cultures would have contributed to 
the apparent sensitivity of the cell culture procedure, and it would certainly have 
contributed to the detection of multiple types of virus in the cultures, some of which 
may have been missed if conventional serological techniques had been used for the 
identification of viruses in the cultures.   
The choice of what procedure to use for the detection of EHV in equine tissues 
needs to be weighed against the possibly greater sensitivity but certainly increased 
labour costs and time required for the detection of virus by co-culture, versus the 
possibly decreased sensitivity but reduced reagent and labour costs associated with 
PCR techniques.  However, regardless of whether PCR is used for the direct 
detection of virus in tissues, it was apparent that the multiplex PCR described here 
could be used for the identification of viruses in cell cultures and that its use 
contributed significantly to the virus detection rate that was obtained.  In cell 
cultures, only the second round reaction was used, which appeared adequate to 
detect virus, presumably due to replication of the virus resulting in a higher number 
of genome copies compared to what was present in the original tissue sample.  A 
significant advantage of PCR for the identification of virus in cell cultures was that it 
sometimes detected 2 viruses in the same cell co-culture.  It is significant that it was 
possible to sometimes detect the presence of up to 3 EHV in the same sample of 
PBL when a combination of co-culture and direct PCR was used.  These multiple 
virus infections may have been missed if conventional diagnostic techniques had 
been used only.  The possible detection of multiple virus types in the same sample 
when PCR assays are used is a significant advantage of this technology.   
In conclusion, a multiplex nested PCR was developed that was able to detect 
various combinations of EHV1, EHV2, EHV4 and EHV5 from horses.  The method 
was sensitive and reduced labour and reagent costs compared to previously   89
described PCR assays.  The assay was capable of detecting individual EHV and co-
infections directly in clinical samples and also in cell cultures, and was considered a 
useful tool for future studies of the epidemiology and pathogenesis of EHV 
infections.     90
Chapter 4.  The prevalence of equine 
herpesviruses in clinically normal horses. 
 
Summary 
To provide data on the prevalence of viruses in normal horses, prior to an 
epidemiological study of the contribution of equine herpesviruses (EHV) to 
respiratory disease in horses (reported in Chapters 5 and 6), nasal swabs (NS) 
and peripheral blood leukocytes (PBL) were obtained from 282 clinical normal 
horses and examined for EHV by a combination of virus isolation in cell culture 
using co-culture techniques or direct inoculation of virus onto primary equine 
kidney cells, and by a multiplex PCR.   
The results clearly demonstrated the widespread occurrence of EHV in the 
clinically healthy horses.  The rate of detection of different types of EHV varied, 
as did the prevalence in young and adult horses.  In young horses <2 years of 
age the most common EHV detected was EHV5, detected in 83.2% of 131 of 
these horses (55.8% of PBL and 51.9% of NS samples).  In adult horses >2 
years of age, EHV5 was detected in a lower percentage of horses, in 40% of 
horses when both PBL and NS were examined, in the PBL of 28.3% and NS of 
6.7%.  In contrast to the high prevalence of EHV5, the equine herpesviruses 
EHV1, EHV2 and EHV4 were detected in the PBL or NS of only 4.6%, 6.1% and 
0.8% respectively of horses <2 years of age.  In horses >2 years of age, only 
EHV5 was detected in NS but EHV1, EHV2 and EHV4 was detected in the PBL 
of 24/127 (18.9%), 7.1% (9/127) and 0.6% (1/127) horses, respectively.    
Multiple types of EHV were detected at a low frequency in PBL samples and at a 
lesser frequency in NS from the horses sampled.  The most frequent mixed 
infection was EHV1 in association with EHV5, detected in PBL of 3.8% of horses 
<2 years of age and 7.1% of horses >2 years of age.   91
Introduction 
The 4 types of EHV recognised as having a possible association with respiratory 
disease are EHV1, EHV2, EHV4 and EHV5 (Chapter 2).  
The role of the alphaherpesviruses EHV1 and EHV4 in respiratory disease is 
well recognised (Duxbury & Oxer, 1968; McChesney, 1975; Sherman et al., 
1977; Coggins, 1979; Reif, 1979; Sherman et al., 1979; Studdert et al., 1984; 
Allen & Bryans, 1986; Colahan et al., 1992; Carman et al., 1997; Murray et al., 
1998), although there is minimal epidemiological data on the occurrence of 
respiratory infection by EHV1 and recent sero-epidemiological investigations 
have suggested that a large proportion of horses are asymptomatically infected 
with EHV1 at a very early stage of life (Gilkerson et al., 1999a).  Little is known 
of the prevalence and possible reactivation of latent EHV1 in later life. 
There is minimal information on the pathogenicity of the gammaherpesviruses 
EHV2 and EHV5, principally because they have only recently been defined into 
2 distinct types (Browning & Studdert, 1987b; Agius et al., 1992).  Early reports 
that EHV2 was extremely wide-spread, with infection rates based on isolation of 
virus from the nasal cavity and buffy coat cells approaching or exceeding 80% in 
normal horses (Kemeny & Pearson, 1970) and horses with respiratory 
symptoms (Turner & Studdert, 1970; Studdert, 1971; Roeder & Scott, 1975; 
Blakeslee et al., 1975; Palfi et al., 1978; Fu et al., 1986) may not be correct as 
the “EHV2” reported may have been EHV2 or EHV5.  More recent data have 
suggested a lower prevalence of EHV2 and a higher prevalence of EHV5 in 
clinically healthy horses (Dunowska et al., 1999; Dunowska et al., 2000).   
Prior to investigating the occurrence of EHV in horses with respiratory disease, it 
was considered essential to have background data on the prevalence of these 
viruses in clinically normal horses, and to determine if the prevalence changed 
with age.  An investigation of the occurrence of EHV in normal horses was 
therefore undertaken and the results are reported in this Chapter.  Serological 
techniques were considered inadequate for these investigations; while methods   92
do exist for the detection and differentiation of antibody to EHV1 and EHV4 
(Crabb et al., 1995; Drummer et al., 1995; Dutta et al., 1983; Gilkerson et al., 
1998a,b; 1999b; van Maanen et al., 2000), techniques for differentiation of the 
antigenically-related EHV2 and EHV5 have not been reported.  It was expected 
that the use of the multiplex PCR for the differentiation of EHV1, EHV2, EHV4 
and EHV5 reported in Chapter 3 would provide a sensitive method for the 
detection and differentiation of these viruses, especially EHV2 and EHV5, and 
provide new insights into the prevalence of these viruses in horses.   
Materials and methods 
Animals and tissues collected   
One hundred and forty nine horses less than 2 years of age from 18 properties 
were sampled (Groups 1 to 18, Table 4.1).  Forty seven of these horses (Groups 
1 to 7; Table 4.1) were sampled twice at intervals of up to 9 months; these 
clinically normal horses were sampled twice in the expectation that they might 
develop clinical signs of respiratory disease and the samples would provide data 
on changes in the virus population associated with the onset of disease.  In 
Groups 1-4 the repeat samples were obtained from both PBL and NS, in Groups 
5-7 only NS were sampled.     93
Table 4.1.  Horses less than 2 years of age examined by multiplex PCR for EHV. 




Group 1 Property A  2  10 Thoroughbred colts sampled initially at 7 – 10 months of 
age and re-sampled again after an interval of 6 months 
Group 2  Property A  2  9 Thoroughbred fillies sampled as weanlings (7 – 10 months 
of age) and re-sampled after an interval of 4 weeks   
Group 3  Property B   2  9 Thoroughbred weanlings (7 - 10 months of age) re-
sampled 10 weeks later 
Group 4 Property A  2  6 Thoroughbred weanlings re-sampled 10 months later 
Group 5 Property C  2  5 Thoroughbred weanlings re-sampled 9 months later 
Group 6 Property D  2  4 Thoroughbred weanlings re-sampled 9 months later 
Group 7 Property E  2  4 Thoroughbred weanlings re-sampled 8 months later 
Group 8 Property A  1  5 Thoroughbred yearlings , history of respiratory disease 5 
months previously 
Group 9 Property F  1  11 Standardbred yearlings  
Group 10 Property G  1  10 Thoroughbred weanlings 
Group 11 Property H  1  10 Mixed weanlings and yearlings of mixed breeding 
Group 12 Property I  1  12 Thoroughbred weanlings (7 - 10 months of age)  
Group 13 Property J  1  12 Thoroughbred weanlings. 
Group 14 Property K  1  11 Standardbred weanlings  
Group 15 Property L  1  10 Thoroughbred weanlings 
Group 16 Property M  1  7 Thoroughbred weanlings 
Group 17 Property N  1  4 Thoroughbred weanlings 
Group 18 Property P  1  10 Thoroughbred yearlings  
 
One hundred and twenty seven adult Standardbred and Thoroughbred horses (2 
years of age or greater) of mixed breeding were sampled once only; PBL and 
NS were obtained from 45 of these horses, and PBL only were obtained from 
the remainder.  Eighty two were horses presented to the Murdoch University 
Veterinary Hospital for non-respiratory conditions, with no evidence of 
respiratory disease at the time of presentation or any history of respiratory 
disease during the 6 months prior to presentation.  Forty five of the horses were 
from 5 small Thoroughbred and Standardbred stables in the outer Perth 
metropolitan area. 
Samples were collected and numbered randomly so that the identity of each 
individual sample was not known until the analyses were completed.   94
Processing of samples  
Nasal swabs were obtained from individual horses and placed in transport 
medium (Dulbecco’s modified Eagle’s medium [DMEM] with 2% fetal bovine 
serum [FBS], supplemented with penicillin and streptomycin).  Blood (20 ml) was 
collected by jugular venipuncture into EDTA vacuum tubes and PBL were 
separated from blood by Ficoll-Paque
TM Plus (Amersham Pharmacia Biotech 
AB, Sweden) gradient centrifugation as previously described in Chapter 3.  The 
samples were kept on ice or at 4°C after collection and were processed within 3 
h of collection. 
Detection of virus in NS and PBL samples by direct PCR 
examination   
DNA was extracted from both the PBL and NS using a QIAmp Blood Mini Kit 
(Qiagen) and the protocols described by the manufacturer.  Viral DNA was 
detected by a nested multiplex PCR assay described in Chapter 3.  Positive 
control DNA of each EHV type (as described in Chapter 3), extracted from virus-
infected cell cultures by the phenol-chloroform method (Sambrook et al, 1989), 
was included in each PCR.  Negative controls consisted of H2O processed in 
parallel with the NS and PBL tissues.   95
Detection of virus in samples by combination of cell culture and PCR 
Virus isolation from NS and PBL was attempted by cell culture as previously described 
in Chapter 3.  Briefly, isolation of virus from NS was by direct inoculation sample onto 
confluent primary EK cell cultures and isolation of virus from PBL was by co-culture of 
the cells with primary EK cells.  Cultures were monitored daily and passaged at weekly 
intervals for a total of 4 passages.  DNA was extracted from the cell cultures either after 
the detection of a cytopathic effect (CPE) or at the conclusion of the fourth passage, and 




The results shown in Table 4.2 to 4.6 represent a combination of both direct 
multiplex PCR examination of DNA extracted from NS and PBL, and multiplex 
PCR examination of DNA extracted from cell cultures inoculated with the NS 
and PBL.   
The results of examination of NS and PBL from horses <2 years of age are 
shown in Tables 4.2 and 4.3, and summarised in Table 4.5.  Results of repeated 
examination of 4 groups (Groups 1-4) of these horses <2 years of age are 
shown in Table 4.2. 
The results of examination of NS and PBL from horses >2 years of age are 
shown in Table 4.4 and summarised in Table 4.6. 
In horses <2 years of age, at least one type of EHV was detected in 105/131 
(80.1%) of horses when both NS and PBL were examined, in the PBL of 79/131 
(60.3%) of horses, and in NS of 72/154 (50%) of horses (Tables 4.2 and 4.3).  In 
horses >2 years of age, at least one type of EHV was detected in the PBL of 
85/154 (55.2%) of horses and in the NS of 3/45 (6.7%) of horses (Table 4.4).   96
EHV1 was detected in the PBL of 6/131 (4.6%) of the clinically normal horses <2 
years of age (Table 4.5) but at a higher rate (24/127; 18.9%) in PBL horses >2 
years of age.  EHV1 was not detected in the NS of any of 209 horses examined 
(Table 4.6). 
EHV2 was detected less frequently than EHV1.  It was detected in PBL of 3.8% 
of horses <2 years of age, and in 7.1% of horses >2 years of age.  It was 
detected in NS of a low 2.6% of horses <2 years of age and was not detected in 
NS of horses >2 years of age. 
EHV4 was detected in only one of the horses <2 years of age and one horse > 2 
years of age, in the NS and PBL respectively. 
EHV5 was the most common virus detected.  In horses <2 years of age it was 
detected in either the PBL or NS of 83.2% of horses when both tissues were 
examined, in the PBL of 55.8% of horses and in the NS of 51.9%.  In horses >2 
years of age, the prevalence of EHV5 was less than in horses <2 years of age; it 
was detected in either the PBL or NS of 40% of these horses when both 
samples were examined, in the PBL of 28.3% and in the NS of 6.7%.  
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Table 4.2.  Equine herpesviruses detected in PBL and NS samples from clinically normal 
weanling horses (groups 1–7 shown in Table 1) sampled twice.  Shaded areas indicate 
that no samples were obtained and tested. 
PBL NS   
Group 
 
Horse  1st sampling  2nd sampling  1st sampling  2nd sampling
1 1  EHV5 -- -- EHV5 
 2  EHV5  EHV5  EHV5  EHV5 
 3  EHV5+EHV1  --  EHV5  EHV5 
 4  EHV5  EHV5  --  EHV5 
 5  EHV5  EHV5  --  EHV5 
 6  EHV5  EHV5  EHV5  EHV5 
 7  EHV5  EHV5  EHV5  EHV5 
 8  EHV5  --  EHV5  EHV5 
 9  EHV5  --  EHV5  EHV5 
 10  EHV5 EHV5 EHV5  EHV5 
2   1  EHV5 EHV5 -- EHV5 + EHV2
  2  EHV5 + EHV1  EHV5 + EHV1  EHV5  EHV5 
  3  EHV5 + EHV1  EHV5 + EHV1  EHV5  EHV5 
 4  EHV5  EHV5  EHV5  -- 
  5  --  EHV5 + EHV1  EHV5  -- 
 6  EHV5  EHV5  EHV5  EHV5 
 7  EHV5+EHV1  EHV5  --  EHV5 
   8  EHV5  EHV5  EHV5  EHV5 
 9  EHV5 EHV5 EHV5  EHV5 
3   1  EHV5 EHV5 -- EHV5 
 2  EHV5  EHV5  --  EHV5 
 3  EHV5  EHV5  EHV2  -- 
 4  EHV5  EHV5  EHV5  EHV5 
 5  EHV5  EHV5  EHV5  EHV5 
 6  EHV5  EHV5  --  -- 
 7  EHV5  EHV5  --  EHV5 
 8  --  --  EHV5  EHV5 
 9  --  EHV5 + EHV2  EHV5  EHV5 
4   1  -- EHV5 -- EHV5 
 2  --  --  --  EHV5 
 3  --  --  EHV5  EHV5 
  4  EHV5 + EHV1  EHV5  --  EHV5 
 5  EHV5  EHV5  --  -- 
 6  EHV5  --  EHV5  -- 
5   1  -- EHV5 
 2     EHV5  EHV5 
 3     EHV5  EHV5 
 4     --  EHV5 
 5     EHV5  EHV5 
6 1  -- EHV5 
 2     EHV5  EHV5 
 3     --  EHV5 
 4     EHV5  EHV5 
7 1  EHV5 -- 
 2     --  EHV5 
 3     --  EHV5 
 4     EHV5  EHV5 
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Table 4.3.  Equine herpesviruses detected in PBL and NS samples from clinically normal 
weanling horses (groups 8–19 shown in Table 4.1) sampled once only.  Shaded areas 
indicate where no samples were obtained. 
 
Sample   Sample 
Group   Horse 
PBL NS   
Group Horse 
PBL NS 
8   51  -  -    13  104  EHV5  EHV5 
 52  -  -      105  EHV2  EHV2 
 53  -  EHV5      106  -  - 
 54  -  -      107  EHV5  - 
 55  -  EHV5      108  EHV5  EHV5 
 56  -  EHV5      109  -  EHV5 
  57  EHV5 + EHV1  -      110  EHV5  - 
 58  EHV5  -      111  -  EHV5 
 59  EHV5  EHV5      112  EHV5  - 
 60  EHV5  EHV5      113  -  - 
9 61  EHV1  -      114  -  EHV5 
 62  EHV5  EHV5      115  -  - 
 63  -  EHV5    14  116  EHV5  EHV5 
  64  -  EHV2 + EHV5     117  -  - 
  65  -  EHV2 + EHV5     118  -  - 
 66  -  -      119  EHV5  - 
 67  EHV5  -      120  -  - 
 68  -  EHV5      121  -  EHV5 
 69  -  EHV5      122  -  EHV5 
 70  -  EHV5      123  -  EHV5 
 71  EHV5  -      124  -  - 
10 72  EHV5  -     125  -  EHV5 
  73  EHV5  -      126  EHV2 + EHV5  EHV5 
 74  EHV5  -    15  139  -  - 
 75  EHV5  EHV5      140  EHV5  EHV5 
 76  EHV5  -      141  -  - 
 77  EHV5  -      142  EHV5  EHV5 
 78  EHV5  -      143  -  EHV5 
 79  EHV5  -      144  EHV2  - 
 80  EHV5  -      145  -  EHV5 
 81  EHV5  -      146  EHV5  - 
11 82  -  -     147  EHV5  EHV5 
 83  -  -      148  -  EHV5 
 84  -  EHV5    16  155  EHV5  - 
 85  -  EHV5      156  EHV5  EHV5 
 86  EHV5  -      157  EHV5  EHV5 
 87  -  EHV5      158  EHV5  EHV5 
 88  EHV5  -      159  -  EHV5 
  89  EHV5  EHV5 + EHV4     160  EHV5  EHV5 
 90  EHV5  -      161  EHV5  EHV5 
 91  -  -    17  227  EHV5  EHV5 
12 92  EHV2  -     228  EHV5  - 
 93  EHV5  EHV5      230  EHV5  - 
 94  EHV5  -      232  EHV5  EHV5 
 95  EHV5  EHV5    18  297   EHV5 
 96  EHV5  -      298   - 
 97  -  EHV5      299   EHV5 
 98  EHV5  EHV5      300   - 
 99  -  EHV5      301   EHV5 
 100  EHV5  EHV5     302   EHV5 
 101  -  EHV5     303   - 
 102  EHV2  -      304   - 
 103  -  -      305   EHV5 
           306   EHV5   99
Table 4.4.  Equine herpesviruses detected in PBL and NS samples from horses >2 
years of age presented to Murdoch University Veterinary Hospital or sampled at their 
stables and where there was no history of recent respiratory disease.  Horses were 
sampled once only.  Shaded areas indicate no samples were obtained. 
 
Horse PBL  Nasal 
swab    Horse  PBL  Nasal swab 
CL001 --      F  --   
CL003 --      G  EHV5   
CL005 EHV5     H  EHV5   
CL007  EHV5 + EHV2      I  --   
CL009 EHV2     J  --   
CL011 --      K  EHV5   
CL014 EHV2     L  --   
CL019 EHV2     M  EHV5   
CL020 --      N  --   
CL024 EHV5     O  --   
CL025 EHV1     P  --   
CL026 EHV1     Q  EHV5   
CL029 --      R   --   
CL030 EHV5     S   --   
CLO36 EHV2      T  --   
CLO38 EHV5      U  --   
CLO40  EHV5 + EHV2      1 N 3--23--99  EHV5  -- 
CL048 --      2 N 3--23--99  --  -- 
CL051 --      3 N 3--23--99  EHV5  -- 
CL058 EHV1     4 N 3--23--99  --  -- 
CL060/L --      5 N 3--23--99  --  -- 
CL061/L EHV1      6 N 3--23--99  EHV5 + EHV1  EHV5 
CL062/L EHV5      7 N 3--23--99  --  -- 
CL063/L --      8 N 3--23--99  EHV5 + EHV1  EHV5 
CL064/L  EHV5 + EHV1      9 N 3--23--99  EHV5  -- 
CL065 --      10 N 3--23--99  EHV5 + EHV1  -- 
CL066 --      11 C 3--31--99  EHV5  -- 
CL067 --      12 C 3--31--99  --  -- 
CL068 --      13 C 3--31--99  --  -- 
CL071 EHV4     14 C 3--31--99  EHV5  -- 
CL071/L --      15 C 3--31--99  --  -- 
CL073/L --      16 C 3--31--99  EHV5 + EHV1  -- 
CL074/L --      17 C 3--31--99  EHV1  -- 
CL075/L --      18 C 3--31--99  --  -- 
CL076/L --      19 C 3--31--99  --  -- 
CL077/L --      20 C 3--31--99  EHV5  -- 
CL078/L EHV2      21 K 4--1--99  --  -- 
CL079/L  EHV2 + EHV1      22 K 4--1--99  EHV5  -- 
CL080/L EHV1      23 K 4--1--99  --  -- 
CL081/L --      24 K 4--1--99  EHV5  -- 
CL082/L --      25 K 4--1--99  --  -- 
CL083/L EHV5      26 K 4--1--99  --  -- 
CL085/L --      27 K 4--1--99  --  -- 
CL086/L EHV5      28 K 4--1--99  EHV5  -- 
CYM --      29 K 4--1--99  --  -- 
DRM --      30 K 4--1--99  EHV5  -- 
RJ --      31 K 4--1--99  --  -- 
SIS --      42 O 4--20--99  --  -- 
BLK --      43 O 4--20--99  --  -- 
CLO65/L --      44 O 4--20--99  --  -- 
CLO66/L EHV1      45 O 4--20--99  --  -- 
CLO67/L EHV1      46 O 4--20--99  EHV1  -- 
CLO68/L EHV1      47 O 4--20--99  EHV5 + EHV1  EHV5 
CLO69/L EHV1      48 O 4--20--99  EHV5 + EHV1  -- 
CLO70/L EHV1      49 O 4--20--99  EHV5 + EHV1  -- 
CLO74 --      50 O 4--20--99  --   
CLO87/L --      51 O 4--20--99  --  -- 
CLO88/L --      52 M 4--23--99  EHV1  -- 
CLO89/L --      53 M 4--23--99  EHV5 + EHV1  -- 
CLO90/L EHV5      54 M 4--23--99  EHV1  -- 
BILLY EHV2     55 M 4--23--99  --  -- 
A --          
B   --           
C EHV5           
D   EHV5           
E --          
   100
Table 4.5.  Summary of the prevalence of EHV DNA in horses <2 years of age from data 
shown in Tables 4.2 and 4.3.  Where horses were sampled twice, only the results of the 
first sampling are included.  Shaded areas indicate no samples were obtained. 
 
Virus  Prevalence of virus     Detected in combination with other EHV infection 



























































































Table 4.6.  Summary of the prevalence of EHV DNA in NS and PBL of horses >2 years 
of age from data shown in Table 4.4.   
 
Virus  Prevalence of virus     Detected in combination with other EHV infection 

























































































* Results provided only where both NS and PBL were examined from the same horse. 
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Repeat sampling of the same horses <2 years of age, albeit at a prolonged 
interval of 5 weeks to 9 months (Groups 1-4, Table 4.1), showed a general 
persistence of EHV5 in both the NS and PBL in the re-sampled horses.  EHV1 
was detected in PBL and likewise it was detected in the PBL of the same horses 
when they were sampled a second time (Group 2, Table 4.2).  EHV2 was 
detected in the NS of one horse (Groups 3, Table 4.2) and was detected in the 
PBL of one of the same group of horses at the second sampling. 
Mixed EHV infections were detected, particularly in the PBL but also 
occasionally in NS:  The most common mixed infection was EHV5 in 
combination with EHV1, particularly in PBL, and occasional mixed infections of 
EHV5 and EHV2 (Tables 4.5 and 4.6). 
Discussion 
 
Genomic analysis and differentiation of EHV2 into two EHV types, EHV2 and 
EHV5 (Agius et al., 1992; Browning & Studdert, 1987b; Browning & Studdert, 
1989b) and subsequent sequence analysis of EHV2 (Telford et al., 1995) and 
the reports of the use of PCR to differentiate the two types (Reubel et al., 1995), 
was critical to the development of the multiplex PCR reported in Chapter 3 and 
its use in this current Chapter to differentiate these two viruses during this 
survey of normal horses.  Prior to the differentiation of these two viruses, reports 
of the detection of “EHV2” in horses (Kemeny & Pearson, 1970; Turner & 
Studdert, 1970; Fu et al., 1986) could have referred to either EHV2 or EHV5 or a 
mixture of both.  Only in more recent reports has there been any discrimination 
between EHV2 and EHV5 (Borchers et al., 1999; Dunowska et al., 1999; 
Dunowska et al., 2000). 
In this current study of clinically normal horses there was a marked difference 
between the prevalence of EHV2 and EHV5.  EHV2 was present in a low   102
percentage only of the normal horses examined while EHV5 was common in 
both NS and PBL.  EHV5 was the virus detected most commonly, present in 
either the PBL or NS of 83.2% of horses <2 years of age.  In horses >2 years of 
age the prevalence of EHV5 was less than horses <2 years of age although it 
was still common and was detected in either the PBL or NS of 40% of horses.  
The prevalence of EHV5 we detected was higher than has been reported by 
others (Reubel et al., 1995; Dunowska et al., 1999) possibly due to a 
combination of co-culture and PCR techniques used.  
The high prevalence of EHV5 in these normal horses suggests it is unlikely to 
have a direct role in respiratory disease in the horse.  The low prevalence of 
EHV2, however, suggests it might have some role and that it is important in any 
investigation of the prevalence and pathogenicity of the equine 
gammaherpesviruses that EHV2 and EHV5 be distinguished. 
The significance of the high prevalence rate of viruses and especially EHV5 in 
the PBL and NS of many of these clinically healthy horses is difficult to interpret.  
Latency is a well recognised phenomenon in EHV infections, and the techniques 
used do not differentiate latent and lytic virus infection.  It is therefore unknown if 
the virus DNA detected represents active virus replication or perhaps replication 
of virus in a low percentage of cells.  
EHV1 has been reactivated from CD5
+/CD8
+ T lymphocytes in peripheral blood 
(Smith et al., 1998) and EHV2 from macrophages (Dutta & Campbell, 1978; 
Schlocker et al., 1995) by co-culture.  EHV4 has been shown to establish 
latency in lymph nodes of the respiratory tract and in PBL (Welch et al., 1992; 
Edington et al., 1994) which is consistent with the detection of EHV4 in one 
sample of PBL in this current study.  EHV2 has been showed to be latent in B 
lymphocytes (Drummer et al., 1996) and EHV2 DNA has been detected in both 
PBL and the nervous system (Rizvi et al., 1997).  The site of latency of EHV5   103
has not been reported but the high prevalence rate of EHV5 DNA and the ability 
to reactivate EHV5 from PBL suggests this is a primary site of latency of EHV5.  
What is unknown is whether the high prevalence of EHV5 in the NS of many 
groups of horses indicates a continuous turnover of virus in the nasal epithelium, 
the detection of latent virus in the nasal epithelium, or perhaps virus detected in 
PBL contaminating the NS. 
The frequency of EHV1 and EHV4, and also EHV2, was much lower than the 
frequency of EHV5.  As the horses examined were clinically normal at the time 
of sampling, and it is recognised that EHV1 and EHV4 (Sherman et al., 1977; 
Mumford & Edington, 1980; Studdert et al., 1981; Allen & Bryans, 1986; Fu et 
al., 1987; Studdert 1996; Mumford et al., 1998; Murray et al., 1998; Ruiz et al., 
1998; Carvalho et al., 2000b; Galosi et al., 2001; Schroer et al., 2000), and 
arguably “EHV2” (Blakeslee et al., 1975; Gleeson & Studdert, 1977;  Browning & 
Studdert, 1987a; Agius & Studdert, 1994; Collinson et al., 1994; Borchers et al., 
1997a; Borchers et al., 1998; ; Dunowska et al., 2000) are potential pathogens, 
it is assumed that in a majority of cases these other viruses detected were latent 
infections.  In some cases a combination of different EHV types in both the nasal 
epithelia and PBL of the clinically normal horses, indicating that, as in humans, 
latent infection with  a variety of EHV types is possible in the same animal. 
In conclusion, the results provide clear evidence that caution must be used 
when interpreting the isolation and/or detection by PCR of any of the EHV in 
blood or nasal epithelia of horses with respiratory disease.  There was a high 
prevalence of EHV5 DNA and virus in NS and PBL of most clinical healthy 
horses but it is not known if this represented continued lytic infection of cells in 
these tissues or latent virus infection.  In contrast, the other gammaherpesvirus 
was detected in only a low percentage of clinically normal horses, suggesting 
that, if a high prevalence of EHV2 was detected in association with respiratory   104
disease, this might indicate an aetiological role for EHV2 in the disease.  A low 
prevalence of EHV1 and EHV4 was also detected, presumably due to detection 
of latent virus.   105
Chapter 5.  The association of equine 
herpesviruses with respiratory disease and poor 
performance in adult horses in Western Australia 
 
Summary 
To determine the association between equine herpesvirus (EHV) infection and 
respiratory disease and/or poor performance in adult horses in Western 
Australia, a prospective clinical study was conducted whereby respiratory tract 
samples from 98 adult horses presented for evaluation of respiratory disease 
and/or poor performance, and peripheral blood leucocytes (PBL) from 65 of 
these horses, were examined for EHV 1, 4, 2 and 5 by a multiplex PCR.  EHV 
was identified in respiratory tract samples from 49 (50%) of the 98 horses and in 
PBL of 31 of 65 (48%) of these horses.  The relative incidence of factors 
identified in the history, signalment, physical and laboratory evaluation of horses 
in the study population was compared between horses from which EHV was 
identified in respiratory samples and horses negative for EHV.  The presence of 
EHV in respiratory tract samples was associated with an acute onset of disease, 
pyrexia and clinical signs of systemic illness, such as depression and/or 
anorexia but haematological and cytological assays were not useful indicators of 
EHV-infected horses.  Cytological examination of tracheal wash (TW) and 
bronchoalveolar lavage (BAL) samples revealed an overall incidence of lower 
airway disease (LAD) of 62% in the study population.  It was concluded that 
EHV and LAD were important causes of respiratory disease in the study 
population, and that haematological and cytological data were a poor indicator of 
EHV infection.     106
Introduction  
Respiratory disease has been identified as an important cause of wastage in the 
Australian horse racing industry (Bailey et al., 1997; Jeffcott et al., 1982).  
Affected horses commonly present with nasal discharge, coughing, poor 
performance and, less often, a range of other symptoms.  These varied clinical 
signs are often interpreted by owners and trainers as indicative of viral infection.  
The results of cytologic evaluation of respiratory tract samples or haematological 
changes may be regarded as supportive of this diagnosis.  However, the 
contribution of viral infection in such syndromes is often not determined and 
studies of racing populations in England have suggested that viral infection is an 
uncommon cause of respiratory disease in performance horses (Burrell, 1985; 
Burrell et al., 1994; Burrell et al., 1996). 
Four EHV have been identified in the respiratory tract of horses.  The 
alphaherpesviruses EHV1 and EHV4 are widely regarded as important 
respiratory pathogens, but the clinical importance of infections with the 
gammaherpesvirus EHV2 and EHV5 is poorly understood (Browning & Agius, 
1996; Dunowska et al., 1999).  Other viruses have also been associated with 
respiratory disease in the horse, but their role and significance is poorly defined.  
Three equine rhinovirus serotypes have been reported but only one serotype, 
now designated Equine rhinitis A virus, has been reported in Australia (Studdert 
& Gleeson, 1978).  Serological surveys have demonstrated a rhinovirus infection 
rate of 48% in Australian horses, suggesting a high prevalence of subclinical 
infections (Li et al., 1997).  In other countries, studies have reported a higher 
seroprevalence (up to 86% in some groups of horses), but seroconversion was 
infrequently associated with clinical disease (Rose et al., 1974). More recent 
findings have suggested that rhinoviruses, due to difficulties associated with   107
their isolation, may be underestimated causes of equine respiratory disease in 
Australia (Li et al., 1997).  
For optimal management of respiratory disease in horses it is necessary that the 
contribution of viral agents be documented.  The impact of other conditions, 
such as LAD, bacterial infections and exercise induced pulmonary haemorrhage 
(EIPH), which may occur subsequent to viral infection or which may be 
misdiagnosed as viral infection, should also be considered.  A multiplex PCR 
(Chapter 3) was utilised to identify EHV in respiratory tract and peripheral blood 
samples collected from horses presented for evaluation of respiratory disease 
and/or poor performance.  The study aimed to determine the incidence of EHV 
infection in these horses and to evaluate parameters, identified during physical 
and laboratory evaluation of affected horses, useful for the correct diagnosis of 
equine herpesvirus infection.  The hypothesis examined was that EHV are a 
significant cause of respiratory disease in horses.  
Materials and methods 
Horses sampled 
Ninety-eight adult horses were presented to Murdoch University Veterinary 
Hospital between August 1997 and June 1999 for evaluation of respiratory 
disease and/or poor performance.  In many instances, owners and trainers 
believed their horses to be suffering viral respiratory tract infections.  Eighty-nine 
were racehorses (Standardbreds, n=45 or Thoroughbreds, n=44), aged between 
2 and 7 years, the remainder were performance or show horses (one 
Thoroughbred, one Arab, one Warmblood, one Pony, 2 Quarterhorses and 3 
Miniature Horses) aged between 1 and 13 years.  
A detailed history was obtained for each horse and a thorough physical 
examination, including endoscopic inspection of the upper respiratory tract, was   108
performed. Vaccination against EHV was not reported within the 12 months prior 
to presentation for any horse in the study population.  Horses presented for poor 
performance were included only if physical examination was suggestive of 
respiratory disease and excluded other problems, such as lameness or cardiac 
disease. Information recorded at the time of recruitment into the study 
population included the type and character of nasal discharge, presence of 
coughing, enlargement of retropharyngeal and/or sublingual lymph nodes, effect 
on general health and performance and the presence of similarly affected in 
contact horses.  The degree of PLH was assessed and graded during 
endoscopic examination, according to criteria described previously (Baker, 
1987; McKane et al., 1995).  The amount of tracheal exudate was also 
subjectively graded: grade 0, no exudate evident within the trachea; grade 1, 
occasional fleck of mucus present on ventral surface of trachea; grade 2, thin or 
discontinuous white-grey mucus layer on ventral surface of trachea; grade 3, 
continuous layer of white-grey mucus layer on ventral surface of trachea, 
tracheal wash sample difficult to aspirate; grade 4, thick layer of grey-brown 
mucus on ventral surface of trachea, tracheal wash sample difficult to aspirate. 
Sample collection 
Blood was collected by jugular venipuncture into vacuum tubes containing 
EDTA for virus isolation (n=65) and routine haematology (n=98) (Vacutainer, 
Becton Dickinson, Rutherford, New Jersey).  Nasal swabs (NS) were collected 
from all horses and stored in transport medium consisting of Dulbecco's 
modified Eagle's medium (DMEM; Gibco, Australia), with 2% FCS (Gibco, 
Australia) and antibiotics.  Endoscopic TW samples were obtained by 
instillation and aspiration of 20–30 ml of sterile 0.9% saline into the distal 
trachea.  BAL samples were collected as previously described (Raidal et al., 
1995).  Aliquots of TW and BAL fluid were submitted for routine laboratory   109
analysis, as described below.  Remaining tracheal wash and BAL fluid was 
used for virus  detection.  
Laboratory analysis 
Total white cell and differential white cell counts were determined as part of a 
routine haematological evaluation of horses included in the study population.  
Gross and cytologic characteristics of TW samples were assessed and graded 
as previously described (Mair et al., 1987).  TW samples were submitted for 
bacteriologic culture if gross characteristics and/or cytology were suggestive of 
bacterial infection (purulent sample with greater than 75% neutrophils and/or 
bacteria evident on microscopic evaluation of the sample).  Cytological 
examinations were conducted of BAL samples stained using Wright-Giemsa and 
Perl’s stain on direct smears or Cytospin preparations.  Individual laboratory 
results (peripheral blood neutrophil:lymphocyte ratio, tracheal wash mucus and 
cytology grade, BAL lymphocyte:pulmonary alveolar macrophage count and the 
percentage of neutrophils, mast cells and eosinophils) and cytologic diagnosis 
were compared for horses from which EHV was isolated relative to those from 
which virus was not identified.  Based on laboratory findings and criteria used by 
others in publications on equine airway cytology (Derksen et al., 1989; Fogarty, 
1990; Sweeney et al., 1992; Freeman et al., 1993; McGorum & Dixon, 1994; 
McKane et al., 1995; Freeman & Roszel, 1997), a cytologic diagnosis was made 
for each horse in the study population using the criteria outlined below: 
(1) Consistent with viral respiratory disease.  Predominance of epithelial cells, 
often in sheets or deciliated, or the presence of changes characteristic of 
ciliocytophthoria (McGorum & Dixon, 1994) in tracheal wash samples; an 
increased proportion of lymphocytes in BAL samples (percentage of BAL-
derived lymphocytes greater than the percentage of pulmonary alveolar 
macrophages).   110
(2) Lower airway disease (LAD).  Increased cellularity (particularly increased 
non-degenerate neutrophils) and mucus content in tracheal wash; BAL with 
greater than 10% neutrophils, greater than 2% eosinophils or greater than 2% 
mast cells. 
(3) Bacterial infection or secondary infection.  Tracheal wash with increased 
cellularity and mucus content and with greater than 75% neutrophils, often 
degenerate, and with bacteria evident on cytologic evaluation and/or culture of 
sample. 
(4) Exercise induced pulmonary haemorrhage (EIPH).  Greater than 50% of 
pulmonary alveolar macrophages containing haemosiderin pigment determined 
by Perl's staining. 
(5) Normal.  No evidence of cytologic change on evaluation of tracheal wash 
and BAL samples.  
Virus detection 
Detection of virus in PBL, NS, TW and BAL fluids was attempted.  All samples 
for virus detection were kept at 4
oC and processed within 3 h of collection.  
The identification of EHV1, 4, 2 or 5 in PBL, NS, TW and BAL samples was 
performed using a multiplex PCR technique described in Chapter 3. 
Statistical analysis 
The relative incidence of factors identified in the signalment, history, physical 
and laboratory evaluation of horses from which EHV was identified in respiratory 
tract samples was compared with that of horses from which EHV could not be 
identified.  Analyses were completed by comparison of all horses from which 
EHV was identified and by subdividing EHV-positive horses to separately 
assess the incidence of each factor amongst horses from which 
alphaherpesviruses EHV1 and/or EHV4, and gammaherpesviruses EHV2 or   111
EHV 5, were identified.  Comparisons were performed using chi-square analysis 
with Yates correction.  The Fisher exact test was used if there were fewer than 5 
observations for any factor.  The age of affected horses was compared using the 
Mann-Whitney rank sum test.  Significance was assumed when P<0.05.  
Results 
Virus isolation from respiratory tract samples 
EHV was detected in 49 horses (50%) in the study population (Table 5.1).  The 
alphaherpesviruses EHV1 and EHV4 were identified in 13 and 11 horses, 
respectively, and 2 horses had both EHV1 and EHV4 identified in respiratory 
tract samples.  The gammaherpesviruses EHV2 and/or EHV5 were identified in 
nasal swabs collected from 25 horses (EHV2, n=7, 7.1%; EHV5, n=16, 16.3%; 
EHV2 and EHV5, n=2, 2.0%); these viruses were not recovered from tracheal 
wash or BAL samples and were isolated concurrently with alphaherpesviruses 
only twice.  The prevalence of EHV2 (9 of 98 horses, 9.2%) in NS was 
significantly higher than the 0% detected in clinically normal adult horses 
(reported in Chapter 4; P<0.001 determined by χ
2 analysis).  The prevalence of 
EHV2 in PBL was also higher in horses with respiratory disease (10 of 65, 
15.4%) than in the adult control group, although this difference was not 
significantly different (P=0.117).  There was no consistent correlation between 
the detection of EHV in PBL and in the respiratory tract, sometimes they were 
detected in the PBL and respiratory tract of the same horses, sometimes only in 
PBL and not the respiratory tract, sometimes in the respiratory tract and not PBL 
(Table 5.2). 
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Table 5.1.  Viruses detected in respiratory tract samples of horses presented for evaluation 
of respiratory disease and/or poor performance (n=98).   
 




PBL NS  TW  BAL 
1 SB  2  M  VIR  EHV5  EHV5  --  -- 
2 SB  2  M  VIR  --  EHV5  --  -- 
3  SB  2  M  NAD  EHV 2 + EHV5  EHV5  --  EHV1 
4 TB  4  F  NAD  EHV2  EHV5  --  EHV1 
5 SB  3  F  NAD  --  EHV5  --  -- 
6 SB  4  F  NAD  EHV2  EHV2  --  -- 
7 SB  6  M  BACT  EHV2  EHV2  --  -- 
8 TB  12  F  NAD  --  EHV2  --  -- 
9 SB  3  F  NAD  EHV2  --  --  -- 
10 SB  3  F  LAD  EHV5  EHV2  --  -- 
11 SB  2  M  VIR  EHV5  EHV5  --  -- 
12 SB  3  F  LAD  NE  --  --  -- 
13 TB  3  MC  LAD  NE  EHV2  --  -- 
14 SB  3  MC  NAD  --  --  --  -- 
15 Arab  1  M  NAD  --  --  --  -- 
16 TB  3  M  LAD  NE  EHV2  --  -- 
17 TB  5  F  LAD  --  --  --  -- 
18 TB  3  MC  LAD  EHV1  EHV4  --  -- 
19 SB  4  F  NAD  NE  --  --  -- 
20 SB  4  M  EIPH  --  --  --  -- 
21 SB  4  MC  LAD  EHV1  EHV2  --  -- 
22  SB  5  M  EIPH  EHV1 + EHV5  --  --  -- 
23 TB  3  MC  NAD  --  --  --  -- 
24 SB  7  MC  LAD  EHV5  --  --  -- 
25 QH  13  MC  LAD  --  EHV1  --  -- 
26 TB  3  MC  LAD  --  --  --  -- 
27 TB  3  F  LAD  --  EHV5  --  -- 
28 TB  2  M  NAD  --  --  --  -- 
29  Friesian  8  MC  LAD  EHV1 + EHV2  --   --  -- 
30 SB  6  MC  EIPH  --  --  --  -- 
31 SB  4  MC  NAD  EHV1  --  --  -- 
32 SB  4  M  LAD  EHV2  EHV1  --  -- 
33 QH  5  MC  NAD  NE  --  --  -- 
34  SB  5  M  EIPH  EHV2 + EHV5  EHV5  --  -- 
35 TB  4  F  EIPH  NE  --  --  -- 
36 TB  2  F  BACT  EHV5  --  --  -- 
37 SB  2  F  BACT  NE  --  --  -- 
38 SB  4  MC  LAD  EHV2  EHV5  --  -- 
39
A  TB  4  MC  BACT  NE  --  --  EHV4 
40
A  TB  3  MC  BACT  NE  --  EHV1  -- 
41 SB  3  F  LAD  --  --  EHV4  -- 
42 SB  4  MC  LAD  NE  EHV5  --  -- 
43 Pony  1  M  BACT  EHV4  EHV5  --  -- 
44 TB  6  MC  EIPH  NE  --  --  -- 
45 SB  5  MC  LAD  NE    --  EHV1  -- 
46  TB  2  F  LAD  NE  EHV1  --  EHV1 + EHV4 
47
B  TB  2  F  LAD  NE  EHV4  EHV4  EHV4 
48
B  TB  2  M  LAD  NE  EHV4  EHV4  EHV4 
49
B  TB  2  M  LAD  NE  EHV4  EHV4  EHV4 
50 SB  4  MC  EIPH  EHV4  --  --  -- 
51 SB  6  MC  NAD  NE  --  --  EHV4 
52 SB  4  F  LAD  NE  --  --  EHV4 
53  TB  4  MC  LAD  NE  EHV4  --  EHV1 + EHV4 
54 TB  2  MC  LAD  EHV4  EHV1  --  -- 
55 SB  3  F  BACT  NE  --  --  -- 
56 TB  5  MC  EIPH  NE  --  --  --   113
 
Table 5.1 (continued). 
 
 
57 SB  2  M  NAD  NE  --  --  -- 
58 TB  3  F  LAD  NE  --  --  -- 
59 SB  3  F  NAD  NE  EHV1  --  -- 
60 SB  5  MC  LAD  NE  --  --  -- 
61 SB  4  MC  LAD  NE  EHV1  --  -- 
62 TB  3  F  LAD  NE  EHV1  --  -- 
63 TB  2  MC  BACT  NE  --  --  -- 
64 SB  3  F  LAD  NE  --  --  -- 
65 TB  2  M  BACT  NE  --  --  -- 
66 TB  3  F  LAD  --  EHV1  --    -- 
67 SB  3  MC  BACT  --  --  --  -- 
68 TB  7  MC  LAD  NE  --  --  -- 
69  SB  5  MC  LAD  EHV1 + EHV4  EHV1  --  -- 
70
C  TB  2  MC  LAD  --  --  --  EHV4 
71
C  TB  2  MC  BACT  --  --  EHV1  -- 
72
C  TB  2  M  LAD  --  EHV4  EHV4  -- 
73
C  TB  2  MC  BACT  --  EHV4  EHV4  EHV4 
74 Min  2  M  NAD  --  --  --  NE 
75 Min  2  F  NAD  --  --  --  NE 
76 SB  2  F  LAD  --  --  --  -- 
77 Min  1  F  LAD  --  --  --  NE 
78 SB  2  F  LAD  --  EHV5  --  -- 
79 SB  4  M  LAD  EHV5  EHV5  --  -- 
80
D  TB  2  F  LAD  EHV5  EHV2 + EHV5  --  -- 
81
D  TB  2  M  LAD  EHV2  EHV5  --  -- 
82
 D  TB  2  MC  LAD  --  --  --  -- 
83
D  TB  2  F  LAD  --  EHV5  --  -- 
84 TB  2  MC  LAD  EHV5  EHV5  --  -- 
85 TB  3  MC  LAD  NE  --  --  -- 
86 SB  5  F  LAD  --  --  --  -- 
87 TB  6  MC  BACT  --  --  --  -- 
88  TB  4  MC  NAD  EHV5  EHV2 + EHV5  --  -- 
89 TB  4  MC  NAD  --  --  --  -- 
90 SB  2  F  BACT  --  --  --  -- 
91 SB  2  MC  LAD  --  --  --  -- 
92 TB  7  MC  LAD  NE  --  --  -- 
93 SB  5  MC  LAD  --  --  --  -- 
94
E  TB  2  F  NAD  EHV1  --  --  -- 
95
E  TB  2  F  LAD  EHV1  --  --  -- 
96
E  TB  2  F  NAD  --  --  --  -- 
97
E  TB  2  F  NAD  EHV1  --  --  -- 
98  SB  3  MC  LAD  EHV1 + EHV5  --  --  -- 
 
Cytologic diagnosis indicated as VIR (consistent with viral infection), LAD (lower airway disease), BACT 
(bacterial infection or superinfection), NAD (normal).  
NS denotes nasal swab, TW denotes tracheal wash, BAL denotes bronchoalveolar lavage. 
NE denotes not examined. 
Shaded areas indicate the stable of origin 
A, B, C, D when multiple affected horses were sampled at the same 
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Table 5.2.  Comparison of the results of EHV detection in PBL and respiratory tract of 





EHV identified in PBL  EHV identified in samples from 
respiratory tract 
1 EHV5  EHV5 
3  EHV2 + EHV5  EHV5 + EHV1 
4  EHV2  EHV5 + EHV1 
6 EHV2  EHV2 
7 EHV2  EHV2 
9 EHV2  - 
10 EHV5 EHV2 
11 EHV5 EHV5 
18 EHV1 EHV4 
21 EHV1 EHV2 
22  EHV1 + EHV5  - 
24 EHV5  - 
29  EHV1 + EHV2  - 
31 EHV1  - 
32 EHV2 EHV1 
34  EHV2 + EHV5  EHV5 
36 EHV5  - 
38 EHV2 EHV5 
43 EHV4 EHV5 
50 EHV4  - 
54 EHV4 EHV1 
69  EHV1 + EHV4  EHV1 
79 EHV5 EHV5 
80  EHV5  EHV2 + EHV5 
81 EHV2 EHV5 
84 EHV5 EHV5 
88  EHV5  EHV2 + EHV5 
94
E  EHV1 - 
95
E EHV1  - 
97
E EHV1  - 
98  EHV1 + EHV5  - 
 
1 Horse numbers correspond to those used in Table 5.1. 




Five instances of apparent “outbreaks” of viral respiratory disease were 
investigated during the course of these studies (multiple horses from the same   115
stable presented for evaluation); EHV4 was isolated from multiple sites and from 
multiple horses in 2 of these apparent outbreaks (Stable A and Stable B shown 
in Table 5.1).  EHV1 (and not EHV4) was isolated from one horse in Stable B.  
In a third outbreak (Stable C shown in Table 5.1), EHV1 was isolated from one 
horse and EHV4 from the other.  In the fourth outbreak (Stable D), only the 
gammaherpesviruses EHV5 and/or EHV2 were detected, and they were 
detected in NS from 3 of the 4 horses sampled.  Although EHV was not 
identified in respiratory tract samples from any of the 4 horses sampled in the 
fifth “outbreak” (Stable E), EHV1 was identified in PBL from 3 of these horses.  
One or more types of EHV was detected in 13 BAL samples, 9 tracheal washes 
and 40 NS.  Virus was evident in NS only from 38 horses.  Samples from the 
lower respiratory tract, obtained by TW and BAL, were important for the 
detection of alphaherpesviruses; from 9 horses, EHV1 or EHV4 were identified 
only in these samples and in each of these horses, the clinical presentation was 
consistent with acute viral disease.  
The months in which each EHV-positive sample was detected and the month of 
presentation for all horses in the study population are shown in Figure 5.1.  
Horses were recruited into the study population over 23 months from August 
1997 to July 1999.  The number of isolates in July is therefore reduced because 
samples were obtained during this month in 1998 only.  Disease associated with 
the isolation of EHV from respiratory tract samples demonstrated a bimodal 
distribution, with virus most commonly identified in late summer-autumn 
(February-April) and spring (September-November).  There were few or no 
viruses isolated during the colder winter months.  The total number of cases 

































































































Figure 5.1.  Graphic representation of the prevalence of EHV (detected in all samples 
from respiratory tract and PBL) in horses presented for evaluation of respiratory disease 
and/or poor performance during the 12-month period of the survey. 
 
despite ongoing attempts to recruit horses into the study population by 




A summary of the data is shown in Table 5.3.  Horses for which EHV was 
evident in respiratory tract samples tended to be young, but this did not 
differentiate them from the remainder of the study population.  The median age 
of horses with EHV1 or EHV4 (3 years) or with EHV2 (4 years) identified in 
respiratory tract samples was not significantly different to that of virus negative 
horses (3 years).  The number of horses ≤3 or ≥4 years was not significantly 
different between groups.  Commonly, affected horses had a history of acute   117
disease (clinical signs evident for less than 7 days prior to presentation), 
compared to a more protracted or recurrent problem in horses from which EHV 
was not identified.  The relative incidence of this finding (65% for horses from 
which EHV1 or EHV4 were identified and 67% for horses from which EHV2 was 
identified) was significantly greater than that for horses which were EHV-
negative (22%, P<0.001 for both groups).  The presence of other, in contact, 
horses with similar clinical signs was not significantly different for horses from 
which EHV was identified compared to horses from which EHV was not 
detected.  Clinical findings that were more common in horses from which EHV1 
and EHV4 or EHV2 was identified included pyrexia (either at the time of 
examination or in the history relayed by the owner) (P=0.015 and P=0.056, 
respectively) and mild systemic illness (P=0.082 and P=0.041, respectively).  
Systemic signs most commonly reported included depression, lethargy and 
anorexia.  Physical findings that were not useful for the identification of horses 
from which EHV could be identified included retropharyngeal or submandibular 
lymphadenopathy, pharyngeal lymphoid hyperplasia, tracheal exudate, and the 
presence of coughing or nasal discharge.  
Performance was not assessed for 20 horses spelling at the time of presentation 
or which were show horses.  Owners or trainers of 35 (85%) of 41 horses with 
EHV in respiratory tract samples assessed performance as reduced.  This 
incidence was higher than that reported for 39 horses from which EHV could not 
be identified in respiratory tract samples (64%) and the difference approached 
significance (P=0.053).  Significant differences were not apparent when horses 
with EHV1/EHV4 or EHV2 were analysed separately.   118
Table 5.3.  Factors evaluated as potential predictors of viral infection in EHV-positive 
and EHV-negative horses. 
 






History/signalment      
Median age (range) (years)  3 (1- 13)  3 (1 – 8)  0.649  
History of acute disease  34/49 (69%)  11/49 (22%)  <0.001 
In-contact affected horses  30/49 (61%)  24/49 (49%)  0.310 
Pyrexia (>38.5oC)  18/49 (37%)  7/49 (14%  0.020 
Systemic illness  24/49 (49%)  10/49 (20%  0.006 
Poor performance
1   35/41 (85%)  25/39 (64%  0.053 













Physical examination      
Abnormal auscultation  19/49 (39%)  24/49 (49%)  0.419 





































Haematology and cytology      
Peripheral blood 
neutrophil:lymphocyte ratio < 1 
7/49 (14%)  8/49 (16%)  1.00 
Tracheal wash 










Lymphocytes > pulmonary 
alveolar macrophages
4 
Neutrophils > 10% 







































1    Not applicable for 20 horses 
2    Not recorded for 2 horses in the virus-positive group 
3    Not recorded for 1 horse in each group 
4    BAL samples not obtained for 3 horses in each group 
MW Comparison by Mann-Whitney rank sum test 
f      Comparison by Fisher exact test 
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Horses with EHV5 identified in respiratory tract samples were more likely than 
EHV-negative horses to have a history of acute disease (P<0.001), systemic 
illness (P=0.016) and poor performance (P=0.022).  The incidence of other 
factors evaluated was not significantly different to that observed for horses 
where EHV was not identified. 
Haematology and cytology of respiratory tract samples 
The laboratory findings were not markedly different in EHV-infected and non-
infected horses (Table 5.3).  Of 26 horses where EHV1 or EHV4 was identified 
in respiratory tract samples, 4 (15%) had a reversed neutrophil to lymphocyte 
ratio (fewer neutrophils than lymphocytes on differential count).  This finding was 
also recorded for 3 (21%) horses with EHV5 infection and 8 (16%) horses in 
which EHV was not detected in respiratory tract samples.  A reversed 
neutrophil:lymphocyte ratio was not evident in EHV2-positive horses.  No horse 
in any group had an absolute leukopenia, neutropenia or neutrophilia.  
Cytological findings in tracheal washes were not significantly different in horses 
from which any of the EHV were detected, compared to horses in which EHV 
was not detected.  Changes such as loss of epithelial cells, deciliation and 
ciliocytophthoria, suggested to be indicative of viral infection, were not observed 
in any samples examined.  There was no association between the detection of 
EHV and the relative proportions of pulmonary alveolar macrophages and BAL-
derived lymphocytes in BAL fluid (P=1.00). 
In total, 29 horses (59%) from which EHV was detected in respiratory samples 
had cytologic evidence of LAD (EHV1 or EHV4, 16 of 26; EHV2, 5 of 9 and 
EHV5, 8 of 14).  Four horses with acute EHV4 disease were represented for 
further examination when clinical signs failed to resolve; all had cytologic 
evidence of LAD at the time of re-examination.  In a number of other horses, 
clinical signs, particularly coughing and exercise intolerance, persisted until   120
specific treatment for LAD was instituted (Dr S Raidal. Personal 
communication), suggesting that respiratory tract inflammation was a significant 
component of the clinical syndrome exhibited by many horses with EHV1 or 
EHV4 associated respiratory disease.  The overall incidence of cytologic 
changes consistent with LAD in the total study population was 62% (n=61) and 
the incidence of this condition for EHV-positive horses was not significantly 
different to that evident for horses from which EHV could not be identified.  
Bacterial infection or superinfection was evident in samples from 14 horses in 
the study population (14%) and was not significantly more common in any 
group.  Species isolated included Actinobacillus equuli (3 horses), Pasteurella 
sp. (2 horses, in mixed culture with α- and/or β-haemolytic Streptococcus sp.), 
β-haemolytic Streptococcus sp. (3 horses, including S. equi from 1 horse), α-
haemolytic Streptococcus sp. (1 horse), Staphylococcus intermedius (1 horse), 
Bordetella sp. (1 horse), and mixed Gram-negative organisms (1 horse).  
Significant bacterial growth was not evident in cultures from 2 horses with 
cytology consistent with bacterial infection. 
Cytologic evidence of EIPH was observed in BAL samples from 17 horses in the 
study population (17%).  Most performance horses had small numbers of 
haemosiderophages in BAL samples.  There was no significant difference in the 
incidence of EIPH for horses from which EHV could be identified in respiratory 
tract samples than was evident for horses which were EHV-negative. 
Detection of virus in PBL 
Virus detection was attempted in PBL from 65 horses in the study population 
with respiratory disease and/or poor performance.  EHV was detected in PBL 
from 31 (48%) of the 65 horses.  EHV2 and EHV5 were detected singly or in 
association with another virus from 21 horses: EHV2 10 times and EHV5 13 
times (both viruses were detected concurrently on 2 occasions).  EHV1 was   121
identified in 10 horses, including 3 (of 4) horses presented from a single stable 
with clinical signs consistent with acute viral disease (Stable E).  EHV4 was 
present in 4 samples.  EHV was identified in respiratory samples from 20 horses 
which also had EHV in PBL (31%).  The same virus was present in both PBL 
and respiratory tract samples from 11 horses (Table 5.2).  
Discussion 
In the current study, NS were the most useful samples for recovery of EHV from 
the respiratory tract, although EHV1 or EHV4 were detected only from TW or 
BAL samples in 9 horses in the study population.  Gammaherpesviruses were 
not detected in TW or BAL samples in the current study, in contrast to previous 
reports describing the presence of EHV2 antigen in pulmonary alveolar 
macrophages (Schlocker et al., 1995) and the recovery of EHV2 from lavaged 
macrophages (Edington et al., 1994).  
EHV infection appeared to be an important contributor to respiratory disease in 
this study population.  EHV was identified in respiratory tract samples from 49 
horses (50%) and the alphaherpesviruses, EHV1 and/or EHV4, were detected in 
26 horses (26%).  These rates are higher than reported in other studies and 
higher than reported in normal horses > 2 years of age in the current study 
(Chapter 4).  In one study in the UK (Sharma et al., 1992), virus was detected by 
PCR in NS from 12% of horses with suspected EHV1 or EHV4 induced 
respiratory or neurologic disease and in-contact horses.  Another study in the 
UK failed to detect acute viral disease in a population of 26 racehorses in 
training over a 14 month period (Burrell, 1985) and was unable to associate 
serological evidence of EHV infection with pyrexia (Burrell et al., 1994, Burrell et 
al., 1996; Crabb & Studdert, 1995).  
Five outbreaks of acute respiratory disease were investigated in the present 
study.  EHV4 and/or EHV1 were an apparent cause of the outbreaks in only 3 of   122
the 5 stables evaluated.  In these 3 stables (Stables A, B and C shown in Table 
5.1), EHV4 was detected, twice in conjunction with EHV1, in samples from the 
respiratory tracts.  The clinical presentation of the horses from which EHV4 
and/or EHV1 were identified in respiratory samples was similar to that described 
following natural or experimental infection with EHV1 or EHV4 (Studdert et al., 
1970; Studdert, 1974; Wilks & Studdert, 1976; Edington et al., 1985; Gibson et 
al., 1992b).  Respiratory disease associated with EHV1 or EHV4 infection was 
clinically indistinguishable, as has been previously reported (Crabb & Studdert, 
1995). 
In one of the respiratory disease outbreaks investigated (Stable D, Table 5.1), 
only gammaherpesviruses, including EHV2, were detected.  The contribution of 
these viruses to respiratory disease in horses is uncertain.  EHV2 has been 
previously associated with respiratory disease (Jolly et al., 1986; Schlocker et 
al., 1995; Murray et al., 1996), lower airway inflammation (Schlocker et al., 
1995) and poor performance (Rose et al., 1974; Jensenwaren et al., 1998), but it 
has also been isolated from large numbers of asymptomatic horses.  However, 
the interpretation of these earlier studies is difficult because EHV2 and EHV5 
were only recognised as distinct viral entities in 1987 (Browning & Studdert, 
1987b).  
Horses with respiratory disease in the fifth stable evaluated (Stable E) 
demonstrated clinical signs consistent with EHV infection.  EHV was not 
detected in respiratory tract samples although EHV1 was evident in PBL from 3 
of 4 affected horses.  As EHV1 was detected in PBL of only 10% of horses in 
the sampled population, the results suggested that this outbreak was due to 
EHV1.  Cell-associated viraemia has been reported following EHV1 infection 
(Gleeson & Coggins, 1985; Gibson et al., 1992) and EHV1 has been isolated for 
a more protracted period following experimental infection from buffy coat cells   123
than from nasal samples (Edington et al., 1985; Gibson et al., 1992; Welch et 
al., 1992).  It is therefore possible that horses in Stable E may have suffered 
disease caused by EHV1 infection but that virus was no longer being shed from 
the nasal mucosa when samples were collected.  The possibility that other 
viruses, such as equine rhinovirus (Li et al., 1997), which would not have been 
detected by methods employed in these studies, may have contributed to the 
disease syndrome evidenced by horses in Stables D and E cannot be excluded.  
The clinical significance of the site from which virus is recovered is uncertain.  
Kydd et al. (1994a; 1994b) reported infectious virus and viral antigen in 
respiratory epithelium and stromal leucocytes at all levels of the respiratory tract 
within 24 h of experimental infection with EHV1.  Virus was recovered from 
nasal samples of horses for up to 14 days following experimental EHV1 infection 
(Gibson et al., 1992), but the duration of virus shedding in lower respiratory tract 
secretions has not been determined.  It is possible that virus identified in 
respiratory tract samples in the current study was associated with latent viral 
infection and not active virus replication.  Latency is  a hallmark of herpesvirus 
infections and sites of latency have been described for EHV1 (Scott et al., 1983; 
Welch et al., 1992; Edington et al., 1994; Slater et al., 1994; Smith et al., 1998), 
EHV4 (Welch et al., 1992; Edington et al., 1994; Borchers et al., 1999) and 
EHV2 (Edington et al., 1994; Drummer et al., 1996).  
The ability to differentiate active and latent infection is important for the 
management and treatment of virus-infected horses.  Latency-associated 
transcripts have been identified for EHV1 and EHV4 (Baxi et al., 1995; Chesters 
et al., 1997; Borchers et al., 1999) and the use of such techniques to determine 
the prevalence of latency and factors initiating re-activation would seem to be 
important in future epidemiological investigations of EHV infections.  It is 
possible that stressors such as transportation, racing or training may reactivate   124
latent infection (Turner et al., 1970) and contribute to respiratory disease in 
racing animals.  
There appeared to be a seasonal distribution in the virus detection rates during 
the current study, as virus isolation rates were highest during late summer-
autumn and spring. Allowing that horses were sampled during July on only one 
occasion, EHV was not identified in any respiratory tract samples between May 
and July, suggesting that EHV shedding and possibly respiratory disease is less 
common during these months. This is similar to a previous report (Gilkerson et 
al., 1994), where EHV4 was isolated from foals only during the months of 
January to March and calendar month was a more important risk factor for virus 
shedding than age or weaning status, but contrasts findings in Japan 
(Matsumura et al., 1992), where clinical cases of EHV4 infection were observed 
year round and EHV1 infections occurred only during the colder winter months. 
The overall number of cases presented for inclusion in the current study and the 
frequency of LAD had a similar distribution to that evident for horses with EHV 
identified in respiratory samples. The seasonal distribution of cases of 
respiratory disease is supported by analysis of cases of respiratory disease 
presented to Murdoch University Veterinary Teaching Hospital between 1995 
and 1999, as fewer horses presented for evaluation of respiratory disease in the 
winter months than in the spring/summer months. Seasonal factors, such as 
pollen or dust exposure, and/or management factors, such as yearlings being 
broken in March-April and 2-year-old horses commencing training in August-
September, may be important determinants of the incidence of respiratory 
disease.  
A number of factors identified in the history or evident on physical examination 
proved useful for the identification of horses from which EHV1, EHV4 or EHV2 
could be identified in respiratory tract samples.  The presence of an acute onset   125
of illness, pyrexia and signs of systemic illness (particularly inappetance, 
depression or lethargy) were more commonly identified for horses positive for 
EHV than for horses from which EHV could not be identified.  Other clinical 
observations reported in horses with EHV infection, such as coughing, nasal 
discharge, lymphadenopathy, PLH and tracheal exudates (Studdert et al., 1970; 
Studdert, 1974; Gibson et al., 1992) were observed with equal frequency in both 
EHV-infected and non-infected populations of horses in the current study, and 
probably reflect the non-specific nature of these responses. There was a trend 
for the isolation of EHV in respiratory samples to be more commonly associated 
with poor performance, although the difference between groups was not 
significant, except for horses from which EHV5 was identified.  Given the 
prevalence of EHV5 amongst healthy adult horses (Chapter 4), it is surprising 
that EHV5 was associated with acute disease, systemic illness and poor 
performance in the current study.  Wider epidemiological studies maybe 
required to clarify the contribution (if any) of this agent to respiratory disease and 
poor performance in horses.  
Haematological and cytological evaluations of respiratory tract samples were of 
no value for the identification of EHV-infected horses.  Reversed peripheral 
blood neutrophil to lymphocyte ratios have been reported associated with 
experimental EHV (Lunn et al., 1992; Gibson et al., 1992a,b), but were not 
observed more frequently in horses from which EHV was identified compared to 
those which were EHV-negative.  Changes such as reactive PBL were detected 
infrequently.  Similarly, cytological changes, such as sheets of epithelial cells, 
deciliation of epithelial cells, ciliocytophthoria (Freeman et al., 1993) or 
increased relative BAL neutrophils (McGorum & Dixon, 1994), were not 
observed more often in respiratory tract samples where EHV was identified than 
was the case for samples which were EHV-negative.  Increased numbers of   126
BAL lymphocytes, relative to pulmonary alveolar macrophage numbers, could 
not be correlated with the subsequent isolation of virus from respiratory tract 
samples.  
The high incidence of LAD observed in the current study has been reported 
previously (Burrell, 1985; Schlocker et al., 1995; Christley et al., 2001).  In the 
current study, specific treatment for LAD was required for the resolution of 
clinical signs of respiratory disease in some horses that were positive for EHV, 
suggesting that post-viral bronchitis contributed to the clinical syndrome 
exhibited by these individuals or that LAD was a clinical problem prior to and 
during EHV-associated disease.  An involvement of EHV in the development 
inflammatory respiratory conditions has been suggested (Schlocker et al., 1995), 
but this could not be confirmed due to the high prevalence of LAD in both EHV-
infected and EHV-negative horses.  The prevalence of LAD in the overall study 
population, however, suggests this condition is of paramount importance as a 
cause of respiratory disease and/or poor performance in Western Australia.  
In contrast to the findings of other studies (Wood et al., 1993; Burrell et al., 
1994; Burrell et al., 1996), bacterial infection or superinfection was relatively 
uncommon in the horses examined in the current study.  The administration of 
antibiotics by owners, trainers or referring veterinarians prior to presentation was 
common in horses included in the study population and probably accounts for 
this finding.  Viral infection has been suggested to predispose horses to bacterial 
infection, and LAD may do the same because increased mucopurulent 
respiratory secretions, which are the hallmark of LAD (Burrell, 1985; Christley et 
al., 2001), are associated with altered mucus rheology and are detrimental to 
mucociliary clearance (Dulfano & Adler, 1975).  Impaired clearance is 
associated with the multiplication of opportunistic oropharyngeal bacteria, 
particularly Streptococcus species and members of the genus Pasteurella, in   127
tracheal aspirate samples (Raidal et al., 1995, 1996).  These species of bacteria 
were isolated most commonly in the current study and have previously been 
associated with lower airway inflammation in performance horses (Wood et al., 
1993; Burrell et al., 1994, 1996).  A causative role for these bacteria in the 
development of respiratory disease would seem unlikely in the current study 
population because antibiotic treatment was associated with incomplete or 
transient resolution of clinical signs.  
EHV was detected in PBL from 33 horses (49%), a proportion similar to that 
detected in healthy horses (Chapter 4).  It is unknown, however, whether the 
virus detected from PBL was a lytic or latent viral infection.  It has been reported 
that EHV1 will establish latency within T-lymphocytes (Scott et al., 1983; Kydd et 
al., 1994b; Smith et al., 1998), EHV2 may become latent within B-lymphocytes 
(Drummer et al., 1996) and EHV4 has also been recovered from PBL ( Welch et 
al., 1992; Edington et al., 1994) but methods to discriminate active viral 
replication from latent infection were not available in the current study.  
The prevalence of the gammaherpesviruses EHV2 and EHV5 in PBL of horses 
(36%) was similar to that reported in New Zealand (Dunowska et al., 1999), but 
less than that reported based on serological data (Kemeny & Pearson, 1970; 
McGuire et al., 1974; Roeder & Scott, 1975; Borchers et al., 1997).  Virus was 
concurrently isolated from the respiratory tracts of 18 horses from which EHV 
was isolated from PBL; in 12 of these horses the same virus was isolated from 
both PBL and respiratory samples.  While it has been suggested that latent 
EHV1 and EHV4 can be recovered only when EHV2 is present (Welch et al., 
1992; Edington et al., 1994), this did not appear to be the case in the current 
study.  EHV4 was isolated infrequently from PBL, consistent with the 
observation that EHV4 viraemia is not a dominant feature of EHV4 pathogenesis   128
(Edington et al., 1994) and that EHV4 is latent primarily within trigeminal ganglia 
(Borchers et al., 1999b).  
In conclusion, the results indicate EHV is an important cause of respiratory 
disease and poor performance in horses in Western Australia.  Interpretation of 
the results of the various methods used for the detection of virus is difficult, 
however, and it is particularly important that techniques for discrimination of 
latent and active virus infection and to further define the contribution of latent 
virus to the manifestation of clinical disease.  An acute onset of clinical disease, 
pyrexia and systemic signs, such as depression and inappetance, were good 
indicators of EHV infection.  Other clinical signs commonly interpreted by 
owners and trainers as indicative of viral infection were not useful for the 
identification of EHV-infected horses.  Haematological and other laboratory 
evaluations of respiratory tract samples were not helpful in discriminating EHV 
infected horses.  Cytology of airway samples was useful for the diagnosis of 
other respiratory diseases, particularly LAD, which was commonly observed 
both in EHV-positive horses and horses from which EHV was not identified.  
Specific treatment of LAD was required for resolution of clinical signs for many 
horses within the current study population.  These findings suggest that LAD is a 
significant cause of respiratory disease and poor performance in horses in 
southern Western Australia.   129
Chapter 6.  Evidence for the association of EHV2 
with respiratory disease in young horses 
 
Summary 
The occurrence of equine herpesvirus (EHV) in nasal swab (NS) and peripheral 
blood leucocyte (PBL) of 109 weaned or unweaned foals on 6 Thoroughbred 
breeding establishments was determined by multiplex PCR; from 2 of the 
properties where respiratory disease was detected, serial samples were also 
obtained and provided data on the occurrence of EHV in association with 
respiratory disease.   EHV5 was detected in NS and/or PBL at a high prevalence 
rate (84 of 104) healthy foals and yearling horses; its occurrence was not 
associated with clinical signs of respiratory disease.  In contrast, EHV2 was 
detected more commonly in NS and/or PBL from foals with respiratory disease 
(24/29, 83%) than in similar samples from healthy horses (8/90, 9%).  
Experimental infection of 8 horses with EHV2 was attempted and induced 
clinical signs of respiratory disease, but less severe than observed in the 
naturally-infected horses observed during the epidemiological studies.  The 
results suggested that EHV2 (but not EHV5) was associated with mild upper 
respiratory tract infection in young horses. 
Introduction 
Equine herpesviruses are commonly detected in the respiratory tract of horses, 
sometimes but not always associated with respiratory disease.  EHV1 is 
associated with respiratory disease, abortion and, on occasions with neurologic 
disease.  EHV4 is a common cause of respiratory disease.  The role of the 
gammaherpesviruses EHV2 and EHV5 as pathogens is less clear; these two   130
EHV types have been identified from healthy horses, as well as from horses with 
respiratory disease (reviewed by Browning & Agius, 1996).  
Interpretation of the older literature concerning the association of EHV2 with 
disease is difficult due to changes in classification of this virus.  It was only as 
recently as 1992 that viruses recognised as EHV2 were distinguished into two 
genetically distinguishable virus types: EHV2 and EHV5 (Browning & Studdert, 
1987b; Agius et al., 1992; Telford et al., 1993).  Results of virus isolation and 
antibody studies completed prior to this time may have therefore been due to 
infection with EHV2, with EHV5, or a mixture of both viruses.  To identify reports 
that refer to EHV2 and that do not differentiate EHV2 and EHV5, the EHV2 
referred will be identified as “EHV2” (consistent with the terminology utilised in 
Chapter 2). 
“EHV2” has been isolated from a variety of sites, including the respiratory tract 
(Fu et al., 1986; Turner & Studdert, 1970; Rose et al., 1974; Wilks & Studdert, 
1974), the genital and digestive tracts and ocular conjunctiva (Studdert, 1971; 
Browning & Studdert, 1988; Collinson et al., 1994), buffy coat cells from 
peripheral blood (Kemeny & Pearson, 1970; Wilks & Studdert, 1974; Roeder & 
Scott, 1975; Fu et al., 1986) and equine tissue used for primary cell culture 
(Hsiung et al., 1969). 
“EHV2” infection has been reported as common, almost ubiquitous in the horse 
population in several countries, based on isolation rates of virus from the 
respiratory tract and circulating leukocytes of horses (reviewed by Browning & 
Agius, 1996).  “EHV2” has been associated with pharyngitis and conjunctivitis 
(Blakeslee et al., 1975; McAllister & Blakeslee, 1977; Thein, 1978; Collinson 
et al., 1994), upper and lower respiratory tract disease (Palfi et al., 1978; Jolly 
et al., 1986; Borchers et al., 1997a, 1998; Murray et al., 1996), poor 
performance (Rose et al., 1974; Jensen-Waern et al., 1998), chronic pulmonary   131
disease (Schlocker et al., 1995) and severe pneumonia (Fu et al., 1986; Lakritz 
et al., 1993).   
Some have suggested that “EHV2” infection may predispose to infection by 
other viruses or bacteria (Palfi et al., 1978; Belak et al., 1980; Nordengrahn 
et al., 1996; Purewal et al., 1998), possibly by suppression of equine peripheral 
blood lymphocyte function (Allen & Blakeslee, 1980).   
The use of serological tests for determining the role of EHV2 as a cause of 
disease has been of minimal value.  A high prevalence of complement-fixing 
and/or serum neutralising antibodies directed against EHV2 has been reported 
in a number of studies (McGuire et al., 1974; Rose et al., 1974; Jolly et al., 
1986) but the prevalence of anti-“EHV2” antibody is not significantly different in 
healthy horses and those suffering respiratory disease.  Antibody levels also do 
not change significantly during the course of experimental or natural infections 
(Wilks & Studdert, 1976; Telford et al., 1993) although in these reports it would 
not have been possible to differentiate antibody to EHV2 and EHV5. 
“EHV2” was isolated in cell culture with equal frequency from sick and healthy 
horses (Turner & Studdert, 1970; Wilks & Studdert, 1974), but it is important to 
recognise that when these observations were made that EHV2 and EHV5 had 
not been differentiated.  
In Chapter 4, it was reported that EHV5 could be detected in a high proportion of 
PBL and NS samples from normal horses and that the other gammaherpesvirus 
EHV2 could be detected in the PBL or NS of only a low proportion of horses.  In 
this Chapter (Chapter 6), the detection of EHV2 in a high proportion of some 
weanling and unweaned Thoroughbred foals on a number of properties in 
association with respiratory disease is described.  To further examine the 
pathogenicity of EHV2, 8 yearling horses of mixed breed were experimentally 
infected with EHV2 and peripheral blood and nasal swab samples were serially   132
evaluated for the presence of EHV.  Results were compared with those obtained 
from 3 control horses not infected with EHV2.  
Materials and Methods 
Foals sampled from Thoroughbred breeding farms 
Foals were sampled from 7 Thoroughbred breeding farms, Properties A-G, as 
part of ongoing studies on the contribution of EHV infection to respiratory 
disease in horses.  Details of the foals sampled are summarised in Table 6.1. 
Sampling procedure 
For detection of EHV in PBL by PCR, blood was collected by jugular 
venipuncture into vacutainer tubes containing EDTA and stored on ice until 
processed further on the day of collection, normally within 3 h.  NS were placed 
into transport medium as described in Chapter 3, stored on ice until DNA was 
extracted for PCR, usually within 3 h.  For serum, blood was collected into plain 
vacutainer tubes and the serum was harvested the following day and stored 
frozen at -20°C until used for detection of neutralising antibody.   
Detection of virus by PCR 
DNA was extracted from PBL and from cells pelleted by centrifugation from NS 
using a QIAmp Blood Mini Kit (Qiagen, Australia).  DNA was extracted from 
virus-infected cell cultures by the phenol-chloroform method described by 
Sambrook et al. (1989).  Details of the multiplex PCR used for the detection of 
EHV1, EHV2, EHV4 and EHV5 were described in Chapter 3. 
Experimental infection of horses with EHV2  
EHV2 virus used for experimental infection of the horses was detected in one of 
the Group 1 colts from Property A.  The virus was cultured in primary equine   133
kidney (EK) cells maintained in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco, 
Table 6.1.  Description of groups of foals examined to determine the prevalence of EHV 
in NS and PBL of normal foals.  Foals which developed respiratory disease subsequent 
to the initial sampling were re-sampled. 
 
Group  Property   History  
1  A  10 colts sampled as weanlings (7-10 months of age) when they 
were clinically normal, then sampled 4 weeks later, 1-2 weeks 
after the development of mild respiratory disease characterised by 
an initial serous nasal discharge which in most cases progressed 
to a mucoid or mucopurulent nasal discharge, coughing, and less 
commonly, retropharyngeal and submandibular lymphadenopathy.  
A third sample was obtained 5 months after the original sampling. 
2  A  10 fillies maintained in isolation from but sampled at the same 
times as the colts in Group 1, and which remained asymptomatic 
throughout the study period. 
3  A  7 unweaned foals (2-4 months of age) with clinical signs of mild 
respiratory disease similar to that exhibited by Group I colts and 
sampled when the third sample was collected from Group I; 
affected foals were re-sampled on a second occasion 8 weeks 
later. 
4  B  9 weanlings (7-10 months of age) sampled on two occasions 10 
weeks apart; respiratory disease was not identified in these foals 
at either sampling time or in the period between visits. 
5  C  12 weaned colts (7-10 months of age) with clinical signs of mild 
respiratory disease characterised by serous or mucoid nasal 
discharge; sampled once only. 
6  C  7 fillies housed separately to but sampled at the same time as the 
colts in Group 5; showed no evidence of respiratory disease. 
7  Property A  10 unweaned foals (6-10 months of age), sampled once.  No 
history of disease reported at time of sampling. 
8  Property D  10 healthy weaned foals (6-10 months of age), sampled once.  No 
history of disease reported at time of sampling. 
9  Property E  12 healthy weaned foals (6-10 months of age), sampled once.  No 
history of disease reported at time of sampling. 
10  Property F  12 healthy weaned foals (6-10 months of age), sampled once.  No 
history of disease reported at time of sampling. 
11  Property G  10 healthy weaned foals (6-10 months of age), sampled once.  No 
history of disease reported at time of sampling. 
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Australia) supplemented with 2% fetal bovine serum (Gibco, Australia) at 37°C 
in 7% CO2-in-air atmosphere.  A stock preparation of virus for inoculation of 
horses was prepared; the titre of this inoculum was 10
7.3 or 10
6.38  tissue culture 
infectious doses per ml (TCID50/ml), measured by a standard microtitre method; 
50% endpoints were estimated by the method of Reed and Muench (1938). 
Fourteen mixed breed yearling geldings and fillies were purchased and were 
randomly assigned to 4 groups.  All horses underwent routine physical 
examination and samples were collected for haematology, serology and virus 
detection by PCR prior to inclusion in the study.  Experimental horses were 
randomly assigned to experimental groups and maintained in isolation from 
other horses on pasture, with supplementary feeding provided.  Personnel 
handling horses wore gowns and gloves, which were changed between each 
group of horses, to prevent iatrogenic spread of natural or experimental 
respiratory viral infection.  Horses were observed daily and samples (NS and 
peripheral blood) were collected in weeks 1, 2, 4 and 5 for virus detection by 
PCR, before being experimentally infected with EHV2.  EHV4 and/or EHV2 were 
identified in samples collected in week 2 from two horses in Group 4, so this 
group was removed from the study group. 
The remaining 3 groups of horses were infected as shown in Table 6.2; 2 groups 
(Groups 1 and 2) were administered EHV2 and the remaining group (Group 3) 
were used as controls and administered uninfected cell culture material.  All 
horses were monitored by daily physical examination for clinical signs of 
respiratory disease.  Blood samples and NS were collected twice weekly for 
haematology, serology and virus identification by PCR.  
All horses were sedated with xylazine hydrochloride (100 mg/ml) at a dose rate 
of 0.7 – 1.1 mg/kg prior to infection as preliminary experiments (not reported) 
indicated sedation reduced the likelihood of forcible expulsion of the inoculum 
after it was administered.   
 
Table 6.2.  Protocol for the experimental infection of horses with EHV2.  
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Group  Virus dose and method of administration 
Group 1 (n=4)  Administered EHV2 (10
6.38 TCID50/ml): 5 ml intravenously, 5 ml by 
nasal spray and 10 ml into tracheal lumen via a nasotracheal 
catheter 
Group 2 (n=4)  Administered EHV2 (10
7.38 TCID50/ml): 20 ml into tracheal lumen via 
percutaneous intratracheal injection 
Group 3(n=3)  Administered virus-free EK cell suspension: 5 ml intravenously, 4 ml 




Tests for neutralising antibody in serum of experimentally infected horses 
Serum virus neutralization (VN) tests were used to determine the serum 
antibody titres against EHV2 and EHV5 by standard methods.  Briefly, serial 2-
fold dilutions of serum were mixed with EHV2 or EHV5 to provide a final 150 
TCID50 of virus, and then incubated at 37°C for 1 h.  Each dilution was then 
added to 2 wells of a microtitre plate containing confluent monolayers of primary 
EK cells.  After incubation for 7 days at 37°C in a 7% CO2-in-air atmosphere, the 
antibody titres were determined as the reciprocal of the highest dilution of serum 
causing 50% or greater inhibition of CPE compared to control cultures 
inoculated with virus only.   
Results 
Detection of EHV in foals in breeding establishments  
On Property A, 3 groups of foals were examined, and viruses identified in NS 
and PBL by a combination of virus isolation and multiplex PCR for colts (Group 
1), fillies (Group 2) and unweaned foals (Group 3) from property A are shown in 
Table 6.3.     136
Table 6.3: Virus isolation results from 27 weanling Thoroughbred foals on Property A, 
some of which were sampled prior to the onset of respiratory disease.  Respiratory 
disease developed in Group 1 (colts) between the first and second sampling.  
Respiratory disease was not evident in Group 2 foals (fillies), which were 
accommodated separately and in isolation from Group 1.  In Group 3, there was 
evidence of respiratory disease just prior to week 28 when samples were obtained from 
3 of these foals.  The results shown are a composite of PCR and virus isolation attempts 
in cell culture, from nasals swabs and PBL. 
 
Horse First  sample 
Week 1 
















(4 weeks after second 
respiratory disease 










Group 1:  colts 
1  - EHV5  EHV2 --  EHV5 --     
2  EHV5 EHV5  EHV2 EHV5  EHV5 EHV5     




EHV5 --     
4  --  EHV5  EHV2 EHV5  EHV5 EHV5     
5  --  EHV5  EHV2 EHV5  EHV5 EHV5     
6  EHV5 EHV5  EHV2 EHV5  EHV5 EHV5     
7  EHV5 EHV5  EHV2 EHV5  EHV5 EHV5     
8 EHV5  EHV5  EHV4  EHV2
EHV5 
EHV5 --     
9 EHV5  EHV5  EHV2  EHV5 EHV5  --     
10 EHV5  EHV5  EHV2  EHV2
EHV5 
EHV5 EHV5     
Group 2: fillies 




       





       






       
14 EHV5  EHV5  -- EHV2
EHV5 
       
15 EHV5 -- -- EHV1
EHV5 
       
16 EHV5  EHV5  EHV5  EHV5         
17 --  EHV1 
EHV5 
-- EHV5         
18 EHV5  EHV5  EHV5  EHV5         
19 EHV5  EHV5  EHV5  EHV5         
20 EHV5  EHV5  EHV5  EHV5         
Group 3: unweaned foals 
21         --  --  --  EHV2 
22         --  EHV2  EHV2  EHV2 
23         EHV2     
EHV4 
EHV2 EHV2  EHV2 
24             EHV2  EHV2 
25             -  EHV2 
26             EHV2 
EHV5 
EHV5 





Shaded cells indicate where no samples were taken and examined.  
– indicates negative results.   137
In the first sampling of foals in Groups 1 and 2, when respiratory disease was 
not evident in any of the foals, EHV5 was detected in all foals, in either the NS 
or PBL, and in many cases, both samples (Table 6.3).  EHV1 was detected in 
PBL of one colt (Group 1) and 3 fillies (Group 2) and EHV2 was detected in one 
filly (Group 2) only. 
Colts in Group 1 developed clinical signs of respiratory disease approximately 2 
weeks after they were first sampled.  Clinical signs consisted of an initial serous 
nasal discharge which in most cases progressed to mucoid or mucopurulent 
discharge.  Coughing was observed in most foals.  Mild retropharyngeal and/or 
submandibular lymphadenopathy was evident in some foals.  Body temperature 
was monitored intermittently at the discretion of farm staff and pyrexia was not 
observed.  Appetite and weight gain were not affected by the illness, which 
resolved spontaneously over 4–6 weeks.   
The fillies in Group 2 remained clinically normal. 
At the time of the second sampling, 1-2 weeks after the onset of clinical signs in 
the Group 1 colts, the prevalence of EHV2 was considerably higher in the Group 
1 colts than in the first sampling; on this occasion it was detected in 9 of the 10 
colts (in NS of 8 of the 10 colts and in PBL of 2 of the 10 colts).  In contrast, in 
the Group 2 fillies that did not develop disease, EHV2 was detected in only one 
of the 10 fillies.  However, EHV4 was also detected in NS from 2 of 10 colts and 
not in the fillies.  The prevalence of EHV1 remained unchanged; it was detected 
in the same colt (Horse 3) in Group 1 as in the first sampling, and again from 3 
fillies in Group 2, but not the same fillies in which it was detected the first time 
(Table 6.3).  The prevalence of EHV5 in the NS of the colts was decreased at 
the second sampling occasion, concurrent with the increase in the prevalence of 
EHV2 in these same samples, but the prevalence of EHV5 in PBL remained 
similar in the 2 groups at the 2 sampling times.    138
At the time of the third sampling, 5 months after the initial disease outbreak 
when respiratory disease was no longer evident, EHV2 was not detected in the 
colts in Group 1 and EHV5 was again detected in NS from all foals and PBL of 6 
of the 10 colts.  
At the time of this third sampling, a separate group of unweaned foals (Group 3) 
resident on the same property were exhibiting similar clinical signs to those 
previously observed in the foals in Group 1.  Three of the affected foals were 
sampled, and EHV2 was detected in NS samples of one of the 3 foals (in 
conjunction with EHV4) and in PBL of 2 foals.  When this group of foals were re-
examined 4 weeks later, when all foals were clinically normal, EHV2 was 
detected in all 7 foals tested (in the NS of 5 including the same 2 foals that were 
initially EHV2-positive, and in the PBL of 6 foals).  EHV4 was not detected in the 
second sampling (Table 6.3). 
Group 4, Thoroughbred weanlings resident on Property B, were sampled twice 
at 6-week intervals and the results are shown in Table 6.4.  Respiratory disease 
was not identified in these foals at either sampling time or in the period between 
visits.  EHV5 was detected in PBL and/or NS of all 9 foals on at least one 
occasion.  EHV2 was detected in the NS collected from one foal at the first 
sampling time and in PBL, concurrently with EHV5, of one different foal at the 
second sampling.  
Virus isolation results from 2 groups of weanlings (Groups 5 and 6) resident on 
property C are presented in Table 6.5.  The colts (Group 5) had exhibited signs 
of a mild respiratory disease in the 2-4 weeks preceding sampling.  EHV2 was 
detected in the NS sample of one colt, in conjunction with EHV5, and in PBL of 8 
of the 12 colts.  EVH5 was detected in NS samples from 10 of the 12 colts.  In 
contrast, in   139
Table 6.4.  Virus isolation results from 9 weanling Thoroughbred foals (Group 4, 
Property B) sampled twice at a 6-week interval.  Respiratory disease was not evident at 
either sampling time or in the period between sampling.   
 
Horse  First sample  Second sample 
  Nasal swab  PBL  Nasal swab  EHV5 
28/21 -- EHV5 -- EHV5 
29/22 -- EHV5  EHV5  EHV5 
30/23  EHV2  EHV5 - EHV5 
31/24 EHV5 EHV5 EHV5 EHV5 
32/25 EHV5 EHV5 EHV5 EHV2  
EHV5 
33/26 - EHV5  EHV5  EHV5 
34/27 - EHV5  EHV5  EHV5 
35/28 EHV5  -  EHV5 EHV5 
36/29 EHV5  -  EHV5 EHV5 
 
the fillies which had not shown any signs of respiratory disease, EHV2 was not 
detected but EHV5 was detected in all 7 fillies in this group.   
PCR results of NS and PBL collected from a further 54 healthy weanling foals 
(groups 7 to 11, Table 6.1) from 5 different properties including a group from 
Property A, are given in Table 6.6.  Respiratory disease had not been reported 
in any of these horses at or preceding the time of sampling, and there were no 
reports of respiratory disease in these foals in the 3 month period following 
sampling.  EHV2 was evident in PBL from only 3 of the 54 foals, concurrently in 
the NS of one of these foals.  EHV5 was identified in 34 of the foals, in PBL of 
21 foals and in NS of 20 foals.  EHV4 was identified once in a NS sample and 
EHV1 was identified in PBL from one horse.  
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Table 6.5.  Virus isolation results from 12 weanling Thoroughbred colts with respiratory 
disease (Group 5) on Property C.  Results from 7 Thoroughbred fillies (Group 6) resident 
on the same property but housed separately to the colts and not showing respiratory 
disease are also shown.   
Horse  Nasal swab  PBL 
Group 5 (Colts with respiratory disease) 
127  EHV5  -- 
128  -- 
EHV2 
EHV5 
129  EHV5  EHV2 
130  EHV5 
EHV2 
EHV5 
131  EHV5 
EHV2 
EHV5 
132  EHV5  EHV5 








135  EHV5  EHV5 
136  EHV5  EHV5 
137  EHV5  EHV5 
138  --  EHV2 
Group 6 (Fillies with no respiratory disease) 
155  --  EHV5 
156  EHV5  EHV5 
157  EHV5  EHV5 
158  EHV5  EHV5 
159  EHV5  -- 
160  EHV5  EHV5 
161  EHV5  EHV5 
 
Experimental infection of horses with EHV2 
Status of horses in 5 week period prior to infection with EHV2  
Rectal temperatures were within the normal range in all horses, and 
haematology results were all within normal limits in all horses, for the duration of 
the 5 week period prior to infection with EHV2.  
EHV5 was detected in NS and PBL collected from each horse at least once prior 
to experimental infection and was intermittently detected in samples from all 
horses throughout the study (Table 6.7).   141
Table 6.6.  Virus isolation results from healthy weanling Thoroughbred foals on 5 
different properties where there was no recent history of respiratory disease.   
 
Horse NS  PBL 
Group 7 (Property A) 
51 -  - 
52 -  - 
53 EHV5  - 
54 -  - 
55 EHV5  - 
56 EHV5  - 
57 --  EHV1 
EHV5  
58 --  EHV5 
25 EHV5  EHV5 
60 EHV5  EHV5 
Group 8 (Property D) 
72 -  - 
73 -  - 
74 EHV4  - 
75 -  EHV5 
76 EHV5  - 
77 -  EHV5 
78 -  - 
79 -  - 
80 -  - 
81 -  - 
Group 9 (Property E) 
92 -  EHV2 
93 EHV5  EHV5 
94 -  EHV5 
95 EHV5  EHV5 
96 -  EHV5 
97 EHV5  - 
98 EHV5  EHV5 
99 EHV5  - 
100 EHV5  EHV5 
101 EHV5  - 
102 -  EHV2 
103 -  - 
Group 10 (Property F  ) 
104 EHV5  EHV5 
105  EHV2 EHV2 
106 -  - 
107 -  EHV5 
108 EHV5  EHV5 
109 EHV5  - 
110 -  EHV5 
111 EHV5  - 
112 -  EHV5 
113 -  - 
114 EHV5  - 
115 -  - 
Group 11 (Property G ) 
139 -  - 
140 EHV5  EHV5 
141 -  - 
142 EHV5  EHV5 
143 EHV5  - 
144 -  EHV2 
145 EHV5  - 
146 -  EHV5 
147 EHV5  EHV5 
148 EHV5  - 
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All horses were seropositive to EHV2/EHV5 prior to experimental infection; 
neutralising antibody titres ranged between 1:2 and 1:8 and did not alter 
following experimental infection (data not shown).   
In Group 4, the horses exhibited serous or mucoid nasal discharge in Week 2, 
concomitant with the detection of EHV4 in nasal swab samples of 2 horses.  
EHV4 was not detected in samples collected during week 4, but was again 
detected (with EHV5) in the nasal swab from one horse in week 5.  EHV2 was 
also identified in NS and/or PBL; this horse had serous or mucoid nasal and/or 
ocular discharge at this time.  Horses in Group 4 were removed from the 
experimental study group. 
 
Table 6.7.  Initial screening by PCR of NS and PBL for evidence of pre-existing EHV 
infection of 14 horses purchased and intended for an experimental EHV2 infection.  
Over a 5 week period, EHV5 was detected in all horses, and EHV4 and/or EHV2 in 2 
horses in Group 4 and this group was removed from the study group and not used in the 
EHV2 infection study.  
 
Week 1    Week 2    Week 4    Week 5  Group Horse 
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Status of horses after infection with EHV2 
In Group 1, serous or mucoid nasal discharge was first observed for each horse 
2-5 days after infection.  Clinical signs persisted for 5-8 days (Figure 6.1).  One 
horse was inappetant 12 days following infection and one horse had an elevated 
rectal temperature (39.4
oC) on day 13 post-infection.  EHV2 was detected in NS 
from all four horses on day 3 following infection and was still present in NS from 
2 horses on day 7 post-infection, but was not detected in PBL at any time Table 
6.8).  Antibody levels did not vary significantly post-inoculation of EHV2 (data 
not shown).  There was no significant change in absolute or relative numbers of 
peripheral blood leukocytes associated with EHV2 infection (data not shown). 
In Group 2, EHV2 was detected in peripheral blood samples from 2 horses 3 
days following the infection with EHV2, and was detected in NS from the 
remaining 2 horses 7 days after infection (Table 6.8).  All horses demonstrated 
serous and/or mucoid nasal discharge between 9 and 18 days following 
infection (Figure 6.1).  Rectal temperatures remained within normal levels 
(Figure 6.1).  Antibody levels did not vary significantly post-inoculation of EHV2 
(data not shown).  There was no significant change in absolute or relative 
numbers of peripheral blood leukocytes associated with EHV2 infection (data 
not shown).  
In the control group, a very mild nasal discharge was sometimes detected 
(Figure 6.1) but this is not unusual and was considered within normal limits; it 
occurred mainly in one horse and much milder than that detected in the EHV2-
infected groups; EHV2 was not recovered from horses in this control group 
(Table 6.8). 
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Figure 6.1.  Rectal temperatures, clinical observations and virological findings for each 
horse in 2 groups of horses (Groups 1 and 2) infected with EHV2 and control group 
(Group 3).  There results for each horse are colour coded, so that the results in 
individual horses can be compared.  Although the EHV2-infected horses did develop 
transient mild clinical signs of respiratory disease and EHV2 was transiently detected in 
some of the horses during these periods, there were no significant concurrent changes 
in rectal temperature during these periods. 
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Table 6.8.  Direct PCR results of NS and PBL samples from horses experimentally infected with 
EHV2.  
 
Days post infection 
0 3  7 10  14 
 
Horse 
PBL NS PBL NS PBL  NS  PBL NS PBL NS 
Group 1.  Inoculated with EHV2 (10
6.38 TCID50/ml): 5 ml intravenously, 5 ml by nasal spray and 10 
ml into tracheal lumen via a nasotracheal catheter 
5  EHV5 EHV5  EHV5 EHV2 -- EHV5  EHV5    EHV5  -- -- 
6  -- --  -- EHV2  -- --  -- EHV5  -- -- 
13  EHV5 EHV5  EHV5 EHV2 --  EHV2  EHV5 EHV5  EHV5 EHV5 
14  EHV5 EHV5  EHV5 EHV2 --  EHV2  EHV5 EHV5  EHV5 EHV5 
Group 2.  Inoculated with EHV2 (10
7.38 TCID50/ml): 20 ml into tracheal lumen via percutaneous 
intratracheal injection 
1 EHV5    --  EHV2  EHV5 EHV5 EHV5  EHV5 EHV5  --  EHV5 
10 EHV5  EHV5  EHV2  EHV5 --  --  EHV5 EHV5  EHV5 EHV5 




EHV5 --  EHV5 EHV5 
12 EHV5  EHV5  EHV5   EHV5  EHV2 
EHV5 
EHV5 EHV5  EHV5 EHV5 
Group 3.  Controls inoculated with EK cell suspension: 5 ml intravenous, 10 ml intratracheal, 5 
ml intranasal 
3  EHV5 EHV5  EHV5  EHV5 EHV5 EHV5  EHV5 EHV5  EHV5 EHV5 
7  -- --  EHV5  EHV5 EHV5 --  EHV5 EHV5  EHV5 EHV5 
8  EHV5 EHV5  EHV5  EHV5 EHV5 EHV5  EHV5 EHV5  --  EHV5 
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Discussion 
As “EHV2” has only recently been separated into 2 genetically distinct virus 
types, EHV2 and EHV5, earlier reports of the association of these viruses with 
respiratory or other disease conditions in horses (Kemeny & Pearson, 1970; 
Turner & Studdert, 1970; Studdert, 1971; Rose et al., 1974; Wilks & Studdert, 
1974; Roeder & Scott, 1975; Fu et al., 1986; Browning & Studdert, 1988; 
Collinson et al., 1994) failed to determine the specific virus involved.  This may 
have also contributed to the confusion regarding their role in disease and 
differentiation of their role in normal and diseased horses.  In Chapter 4 it was 
demonstrated, for example, that EHV5 was common in normal horses, 
suggesting that a high prevalence of EHV2 in horses with disease might be 
indicative of a cause and effect relationship between EHV2 and the disease.  
Prior to the recognition of the distinction between EHV2 and EHV5, the detection 
of EHV5 would have been considered to indicate the presence of “EHV2” only 
and the results would not have reflected a differential detection rate in normal 
and diseased horses.  The results reported in this Chapter, therefore, are novel 
and shed new light on the association of the individual gammaherpesviruses 
with disease. 
Another novel aspect of this study was that serial sampling enabled comparison 
of the EHV status of horses prior to and after the occurrence of disease, and 
samples from horses with respiratory disease that could be compared with 
concurrent samples from similar groups on the same property without 
respiratory disease.  In a larger breeding establishment, the occurrence of 
disease in one cohort but not in another cohort on the same property suggests 
the importance of running horses in small groups to limit the spread of 
respiratory disease in large breeding establishments.   147
In all of the groups of foals examined, from all properties included in the study 
reported in this Chapter, EHV5 was detected at a high prevalence rate in NS 
and/or PBL, and there was no apparent reason to associate this virus with 
respiratory disease.  The prevalence rate of EHV5 in disease-affected foals was 
similar to that in normal horses.  Pooled results from all foals that had no recent 
history of respiratory disease showed that EHV5 was detected in NS and/or PBL 
of 81% of healthy foals (84/104).  This prevalence is in agreement with the 
results reported in Chapter 4, where it was reported to be present in 83.2% of 
131 (55.8% of PBL and 51.9% of NS samples) of young horses <2 years of age, 
and in 40% of adult horses >2 years of age when both PBL and NS were 
examined, in the PBL of 28.3% and NS of 6.7%. 
While the high prevalence rate of EHV5 detected is similar to that reported in 
other groups of young and adult horses in Chapters 3 and 4 it is at variance with 
the results reported by Nordengrahn et al. (2002).  These authors reported a 
high prevalence rate of EHV2 in PBL of adult horses of 68% (26 of 38) in 
Sweden and 71% (15 of 21) in the United Kingdom, and that it was present in 
PBL of all 27 foals examined and 93% of nasal specimens in these foals.  
Although they did not examine all samples for EHV5, they were unable to detect 
EHV5 in PBL of the 40 adult horses or 10 foals from Sweden, detected it in only 
4 (15%) of 27 Hungarian foals but were able to detect it in the PBL of 2 of 4 and 
NS of 3 of 4 foals examined in the United Kingdom.  The results reported by 
Nordengrahn et al. (2002) suggest it would be unlikely that EHV2 was a 
pathogen and that it was more likely that EHV5 would be a pathogen (based on 
its low detection rate in normal horses).  This discrepancy in the apparent 
prevalence rates of EHV2 and EHV5 reported by Nordengrahn et al. (2002) and 
that detected in the current study cannot be explained.  They did report,   148
however, that their EHV5 PCR was 10 times less sensitive than their EHV2 
PCR.    
A higher prevalence rate of EHV2 than EHV5 was also detected by Borchers 
et al. (1999a) in the PBL of Przewalski’s wild horses in 4 German zoos; they 
detected EHV2 and EHV5 DNA in PBL of 7 and one of 40 horses, respectively.  
Dunowska et al. (2000) also reported a high prevalence of EHV2 in 18 foals in 
New Zealand, and detected EHV2 DNA in 155 of 157 PBL samples and 40 of 
172 NS from 18 foals, but an apparently higher prevalence rate of EHV5 was 
detected in either PBL, nasal swabs, or both, of 15 of the 18 foals on 32 
occasions over a several-week period.  Reubel et al. (1995) also differentiated 
EHV2 and EHV5 in PCR assays applied to studies of the epidemiology of EHV2 
and EHV5 infections of racehorses and breeding mares in Victoria and New 
South Wales, Australia.  PBL from 31% of horses were positive for EHV2, 16% 
positive for EHV5, 8% positive for both viruses and 63% negative for both 
viruses. 
In contrast to EHV5, a low prevalence rate of EHV2 was detected in normal 
horses (Chapter 4) and this was true also in the normal foals included in this 
current study.  There was, however, a high prevalence of EHV2 from NS and/or 
PBL in groups of weanling foals with active or a recent history of respiratory 
disease.  In the weanling colts in Group 1 that were sampled prior to the onset of 
respiratory disease, EHV2 was detected in 9 of 10 of the foals immediately after 
the onset of respiratory disease but was not detected prior to the onset of 
disease, and neither was it detected in the same foals 5 months after the 
outbreak of respiratory disease.  This finding was in marked contrast to the 
results obtained from samples collected from a cohort of 10 fillies (Group 2) that 
did not develop respiratory disease and in which EHV2 was detected in the PBL 
of 3 and in the NS of only one foal; these fillies were resident on the same   149
property but accommodated separately and did not exhibit signs of respiratory 
disease.  This seems to be the first report where EHV2 and EHV5 have been 
differentiated and where EHV2 has been associated with the onset of respiratory 
disease.   
A high prevalence of EHV2 was also detected in another group (Group 3, Table 
6.3) of foals resident on the same property as Groups 1 and 2, which were 
sampled during and immediately after the onset of respiratory disease.  A high 
prevalence of EHV2 was also associated with respiratory disease in another 
group of foals (Group 5) resident on a separate property, where the foals were 
segregated according to sex, and EHV2 was detected in the NS of one of the 12 
foals and in the PBL of 8 of the 12 colts but EHV2 was not detected in a 
separate cohort of 7 fillies (Group 6) resident on the same property that did not 
develop respiratory disease.  
The source of the EHV2 in the affected foals is unknown.  The properties on 
which the foals were sampled were all small breeding establishments, there was 
not a large movement of horses into and out of the properties, and so an 
external source of the virus was probably unlikely, although not impossible.  A 
more likely source of the infection is reactivation of a previously existing latent 
infection.  The site of latency of EHV2 has been suggested as the trigeminal 
ganglia (Rizvi et al., 1997) and B lymphocytes (Drummer et al., 1994), and 
certainly in the current studies it was detectable in PBL.  It is interesting, 
however, that in the Group 1 foals that were affected with respiratory disease 
that EHV2 was detected in PBL only at about the time of respiratory tract 
infection and continued persistence of EHV2 in PBL could not be demonstrated 
5 months after the original occurrence of disease.   
Whether there was a direct cause and effect relationship between EHV2 and the 
occurrence of respiratory disease in the 3 groups of foals with respiratory   150
disease is unknown.  Certainly there was an association and a much higher 
prevalence rate of EHV2 in these horses than in the group of age-matched foals 
in the same region in the same year.  Overall, EHV2 was infrequently detected 
in healthy foals without respiratory symptoms (4 of 109, 3.6%) and frequently 
detected (26 of 35, 74.2%) in foals in the sample groups that had clinical 
respiratory signs.  However, EHV2 was not the only virus detected in the 
affected foals: EHV1 and EHV4 were occasionally detected, and EHV5 was 
commonly detected.  An examination for other viruses such as rhinoviruses and 
adenoviruses was not made. 
EHV4 may have played some role in the respiratory disease detected in the 
sample group.  It was, however, only detected in NS samples from 2 of 10 
horses in Group 1 and one of 3 foals in Group 3, associated with respiratory 
disease.  Infection with EHV2 has been suggested as predisposing to secondary 
bacterial (Jolly et al., 1986; Murray et al., 1996) and viral infection (Purewal 
et al., 1992).  It has been suggested that “EHV2” infection can predispose to 
superinfection by EHV4 by immunosuppression (Allen & Blakeslee, 1980; 
Browning & Studdert, 1988; Murray et al., 1996).  Evidence of 
immunosuppression after both in vitro and in vivo infection with “EHV2” was also 
reported by Fu et al. (1986); it has also been reported to occur during EHV1 
infection (Hannant et al., 1999) and is observed among other herpesvirus 
infections (Rinaldo, 1990).   
A possible association between EHV2 and EHV4 is supported by a previous 
report that EHV2 may act as a trans-activating factor, which may either trigger or 
upregulate EHV1 and EHV4 expression from a latent state (Edington et al., 
1994; Purewal et al., 1998; Welch et al., 1992; Camarda et al., 1999, Purewal 
et al., 1992).  EHV2 has been found to encode ORFs with significant homology 
to cellular immunomodulatory proteins, similarly to other gammaherpesviruses.    151
These include an IL-10 homolog (E7) that may be involved in the suppression of 
antiviral immune functions and three ORFs encoding putative G protein-coupled 
receptors that potentially interact with cellular chemokines (Purewal et al., 1992; 
Telford et al., 1995; Camarda 1999).  Chemokines are likely to play a role in the 
regulation of immune functions in equine hosts during EHV2 infection and, via 
interaction with E1, may affect viral replication and/or escape from immune 
responses (Camarda et al., 1999). 
EHV1 was present at a low prevalence rate in the PBL of one colt (Group 1), 3 
fillies (Group 2) and one other foal in Group 7, all resident on Property A, but not 
evident in NS from any of the foals examined; it was not detected in respiratory 
samples or at increased prevalence rates from foals during or after the onset of 
respiratory disease, suggesting that this virus type had no role in the disease 
outbreaks reported.  The low prevalence rate of EHV1 is consistent with the low 
prevalence rates reported in Chapter 4, where EHV1 was detected in the PBL or 
NS of only 4.6% of horses <2 years of age, and was detected in the PBL but not 
NS of 24/127 (18.9%) of horses.   
An interesting observation, the significance of which is not understood, is that in 
the Group 1 colts (Table 6.3) it was not possible to detect EHV5 in the NS, or at 
least there was a much lower prevalence of EHV5, immediately following 
respiratory disease when a high prevalence of EHV2 was detected.  Prior to and 
following the respiratory disease outbreak, EHV5 was detected in most of the 
same foals.  A similar observation was made in the horses infected 
experimentally with EHV2, those in Groups 1 and 2 (Table 6.3), when it was not 
possible to detect EHV5 in many of the samples from which EHV2 were 
detected.  Other than repeating the multiplex PCR analyses to confirm the 
result, further investigation of why this occurred was not made.  Maybe the 
replication of EHV2 reduced the replication of EHV5 in the nasal epithelium.    152
Maybe EHV5 was still present but in the presence of a (perhaps) high level of 
EHV2, there was a competitive interaction in the PCR assay; competitive 
interaction in the multiplex PCR assay used needs to be explored further by 
conducting a series of experiments in which the level of DNA template of the two 
gammaherpesviruses is varied.   
The animal experiments were conducted to determine the pathogenicity of 
EHV2 were complicated by the lack of EHV-free horses in which to conduct the 
experiments.  Perhaps the major problem was the common occurrence of EHV5 
in normal horses.  To overcome the possible problem of competitive interaction 
between EHV5 and EHV2, initially it was planned to infect all experimental 
horses with EHV5 prior to infection with EHV2 but it was determined during the 
pre-infection monitoring of the horses that all but one (horse 6 in Group 1, Table 
6.3) were already infected with EHV5, and so this was not considered 
necessary.  The experiment therefore actually examined the effect of EHV2 on a 
pre-existing EHV5 infection.  The horses all had a pre-existing low level of 
EHV2/EHV5 neutralising antibody, presumed to be due to EHV5, but the 
possibility that the foals had undergone previous infection with EHV2 could not 
be discounted.  In preliminary experiments (not described in this thesis) a high 
dose of EHV2 was used intranasally in a preliminary attempt to infect horses 
without success, perhaps as this route of infection was associated with a strong 
coughing reaction, and consequent expulsion of most of the inoculum; the EHV2 
was consequently administered by sedation of horses and direct intratracheal 
inoculation of the inoculum in the experiments reported in this thesis.  
Mild clinical signs of respiratory disease were produced by intratracheal and 
intravenous inoculation of cell-culture replicated EHV2, and EHV2 was 
recovered from the experimentally infected horses with mild signs of disease.  In 
effect, Koch’s postulates were fulfilled.  The signs of respiratory disease that   153
occurred in the horses experimentally infected with EHV2 were mild; under field 
conditions these could perhaps be exacerbated by concurrent infection with 
other viruses such as EHV4.  EHV4 was detected in foals in Groups 1 and 3 on 
Property A, from where the isolate used for the experimental infections had been 
obtained, suggesting the possibility of an association between EHV2 and EHV4 
in the production of respiratory disease at least in that cohort of horses.   
EHV2 infection might predispose to superinfection by EHV4, perhaps by an 
immunosuppressive action.  Immunosuppression by “EHV2” has been 
suggested (Allen & Blakeslee, 1980; Browning & Studdert, 1988; Murray et al., 
1996) and some evidence of immunosuppression after both in vitro and in vivo 
infection with “EHV2” was reported by Fu et al. (1986), which has been 
suggested to predispose to secondary bacterial (Jolly et al., 1986; Murray et al., 
1996) or viral infection (Purewal et al., 1992).  Immunosuppression is commonly 
observed with other herpesvirus infections (Rinaldo, 1990), including EHV1 
(Hannant et al., 1999).     154
 
Chapter 7.  General discussion 
Respiratory disease is a well recognised cause of wastage in the Standardbred and 
Thoroughbred horse industries (Jeffcott et al., 1982; Bailey et al., 1997), and 
thought to contribute to reduced performance.  Viruses, and particularly 
herpesviruses, are frequently suspected as causes by clinicians and trainers but 
there is little hard evidence of the frequency of equine herpesvirus (EHV) infections 
and if indeed EHV are particularly important as causes of respiratory disease.   
When this study was commenced there was minimal information on the potential 
role of equine alphaherpesviruses EHV1 and EHV4, and gammaherpesviruses 
EHV2 and EHV5 in equine respiratory disease of both Thoroughbred and 
Standardbred horses in Western Australia.  While it may be expected that the 
situation in Western Australia is essentially similar to that in the rest of Australia, 
there are distinct climatic differences and some management practices that differ in 
Western Australia and most other regions of Australia.  Most horse properties in 
Western Australia are small, and there are very few large establishments similar to 
those studied by Gilkerson et al. (1998a,b, 1999a,b) in the Hunter Valley.  The 
studies reported in this thesis were designed to examine the distribution and 
frequency of virus infections in the normal horse population, and then to determine 
the frequency with which EHV were associated with respiratory disease in Western 
Australia.  The studies relied heavily on the good will of horse owners, stables and 
breeding establishments and often the samples were obtained at times that were 
suitable to the owners and stables, not always the optimal times for the 
epidemiological studies.   155
There have been very few recent reports of the distribution or epidemiology of the 
EHV in horse populations in Australia.  A comprehensive and detailed study of the 
epidemiology of EHV1 in foals in the Hunter Valley region was reported by 
Gilkerson et al. (1998a,b, 1999a,b); these reports concentrated on the 
alphaherpesviruses and particularly EHV1 and did not consider the role of EHV2 or 
EHV5.  They were studies relying extensively on the use of serological techniques 
for the detection of infection, whereas this current study relied on virus isolation or 
detection of virus by PCR technology.  The New South Wales studies were 
conducted primarily in foals in large breeding establishments with considerable 
traffic of horses into and out of the farms.  We wondered if the situation reported by 
Gilkerson et al. (1998a,b, 1999a,b) would be the same in Western Australia, where 
the breeding establishments were smaller, where there was minimal movement of 
mares into and out of the farms and the farms were essentially closed herds.  We 
wondered if, perhaps, infection might not occur at a later age in such foals, perhaps 
not until the foals started to be dispersed, and if this might not totally change the 
epidemiological pattern of EHV infections, and could affect comparative virological 
results in different regions.  A study to determine if this is true would require a 
sequential study of groups of foals from birth and while this type of investigation was 
not included in the current study, such a sequential study has been initiated in 
Western Australia by others in this laboratory (Pizzirani, A., Personal 
communication). 
Poor performance and respiratory disease were the two “syndromes” which we 
attempted to associate with herpesvirus infections.  Identification of these 
syndromes was an immediate problem.  Respiratory disease can be and was 
determined subjectively by clinical examination, and it can be associated with 
definable clinical parameters such as coughing or other clinico-pathological 
parameters.  In contrast, poor performance is much more difficult to define.  By   156
necessity, reliance on the subjective opinion of owners and trainers regarding poor 
performance was required and the necessity to rely on such subjective data 
obviously leads to the possibility of error.  The horses included in the study 
populations, especially those in Chapter 5, were those where there was clear 
clinical evidence of respiratory disease, and in some of which poor performance had 
been noted by the owners; the study was primarily, therefore, a study of the 
association of herpesviruses with respiratory disease. 
While the research reported in this thesis concentrated on the role of herpesviruses 
as a cause of respiratory disease and poor performance, additional examinations for 
bacterial pathogens was made when these were suspected (Chapter 5), but an 
obvious criticism of the methodology used in the study was that it did not consider 
the possible involvement of other viral pathogens such as erboviruses (rhinoviruses) 
and adenoviruses.  Erbovirus infections have been reported to be common in the 
Australian horse population: equine rhinovirus type 1 (Erbovirus type 1) is a 
potentially important cause of acute febrile respiratory disease in horses in 
Australia, perhaps underestimated due to failure in many instances to isolate virus 
by conventional cell culture methods (Li et al., 1997).  Sero-epidemiological data 
has also indicated that Erbovirus type 2 infections of horses may be common in 
Australia (Huang et al., 2001).  When this thesis study was commenced an attempt 
was made to obtain sequence data for the design of primers and to obtain positive 
control templates for the Erboviruses but this was difficult at that time, and a 
decision was therefore made to concentrate on the potential role of 4 types of EHV, 
and especially the gammaherpesviruses types 2 and 5 on which there was almost 
no epidemiological data in Australia. 
The research reported in this thesis had a number of novel features: first, it utilized 
PCR technology that enabled the simultaneous detection of all 4 EHV types;    157
second, it provided an extensive study of the distribution of EHV in the normal horse 
population, and therefore a basis on which to assess the importance of viruses 
recovered from diseased horses; third, it provided new data on the distribution and 
probable role of the two gammaherpesviruses in respiratory disease.   
Prior to undertaking the epidemiological studies reported in Chapters 4, 5 and 6, a 
multiplex PCR assay was developed that enabled the simultaneous detection of all 
four EHV known or suspected to be associated with respiratory disease (Chapter 3).  
This PCR was able to detect individual EHV and various combinations of EHV1, 
EHV2, EHV4 and EHV5 in clinical samples and also in cell cultures.  The method 
reduced labour and reagent costs compared to previously described PCR assays 
for detection and differentiation of the alphaherpesviruses EHV1 and EHV4 (Ballagi-
Pordany et al., 1990; Wagner et al., 1992; Borchers & Slater, 1993, Kirisawa et al., 
1993a, Rimstad & Evensen, 1993; Lawrence et al., 1994; O'Keefe et al., 1994, 
Osterrieder et al., 1994; Osterrieder et al., 1994; Slater et al., 1994; McCann et al., 
1995; Baxi et al., 1996; Carvalho et al., 2000a,b; Galosi et al., 2001; Schroer et al., 
2000; Varrasso et al., 2001), and the gammaherpesviruses EHV2 and EHV5 
(Reubel et al., 1995; Borchers et al., 1997; Rizvi et al., 1997b; VanDevanter et al., 
1996; Borchers et al., 1998, 1999a, 2002; Dunowska et al., 2000, Kershaw et al., 
2001; Dynon et al., 2001).  The multiplex procedure enabled the processing of a 
larger number of samples than would have been possible using conventional 
technology.  Importantly it enabled detection and differentiation of the poorly studied 
gammaherpesviruses EHV2 and EHV5.  The multiplex PCR developed was novel 
and it appeared to be the first time that such a PCR for the detection of the 4 EHV 
types associated with the equine respiratory tract has been reported.  
Cell culture inoculation of samples or co-culture procedures have been considered 
the gold standard technique for the detection of EHV (Dutta & Campbell, 1978; 
Gleeson & Coggins, 1980, Sabine et al., 1983; Crabb et al., 1992; Edington et al.,   158
1994; Schlocker et al., 1995; Borchers et al., 1997, Drummer et al., 1996; Franchini 
et al., 1997; Smith et al., 1998; Borchers et al., 1999a, Siedek et al., 1999, van der 
Meulen et al., 2000; Henning et al., 2000; Kershaw et al., 2001).  The incorporation 
of IL-2 in the co-culture medium, as described by Smith et al. (1998) is regarded as 
a sensitive method for the detection of EHV; it is believed that IL-2 promotes the 
reactivation and replication of latent EHV in peripheral blood mononuclear cells and 
helps maintain the co-cultured cells (Smith et al., 1998).  The rates are higher than 
previously obtained in this laboratory (Little, 1998) when peripheral blood leukocytes 
(PBL) were co-cultured in the absence of IL-2.  In the current study there was a 
good correlation between the multiplex PCR results and the detection of virus by 
isolation in cell culture (Chapter 3) but obviously a greater detection rate occurred 
when direct multiplex PCR of tissues was combined with cell culture procedures, 
whether it be by direct inoculation of respiratory tract samples onto primary equine 
kidney (EK) cells or co-culture of PBL with EK cells.  These results are essentially 
similar to the results reported by others who found co-culture a generally more 
sensitive assay when used in combination with PCR than the use of PCR alone, 
when sampling PBL (Franchini et al., 1997) and nasal swabs (NS) (Welch et al., 
1992).  A distinct advantage of PCR was that it enabled the detection of multiple 
serotypes of virus and up to 3 different EHV were detected in some respiratory tract 
samples (Chapters 4 and 5). 
The tissues selected for determination of EHV infections in horses were primarily 
NS and PBL.  This was because these were easily obtainable tissues; the collection 
of NS did not require the use of bronchoscopes and could be easily undertaken in 
the field.  A comparison of the viruses detected in NS with those that could be 
detected in bronchoalveolar lavages and tracheal washes (Chapter 5) indicted that 
NS provided the greatest chance of detecting EHV if only a single sample was 
obtained.     159
The studies reported in Chapter 5 provided clear evidence that EHV infection 
contributed to respiratory disease in the adult horse population studied.  EHV1 
and/or EHV4 were detected in 26 horses (26%) with respiratory disease and/or poor 
performance, rates higher than reported in other studies (Sharma et al., 1992; 
Burrell, 1985; Burrell et al., 1994; Burrell et al., 1996; Crabb & Studdert, 1995) and 
EHV4 and/or EHV1 were an apparent cause of small outbreaks of respiratory 
disease in 3 stables.  The clinical presentation of the horses from which EHV4 
and/or EHV1 were identified in respiratory samples was similar to that described 
following natural or experimental infection with EHV1 or EHV4 (Studdert et al., 
1970; Studdert, 1974; Wilks & Studdert, 1976; Edington et al., 1985; Gibson et al., 
1992a,b).  Respiratory diseases associated with EHV1 or EHV4 infection were 
clinically indistinguishable, as has been previously reported (Crabb & Studdert, 
1995). 
There was a seasonal distribution of cases of respiratory disease.  This was evident 
from an analysis of cases of respiratory disease presented to Murdoch University 
Veterinary Teaching Hospital between 1995 and 1999; fewer horses were 
presented for evaluation of respiratory disease in the winter months and than in the 
spring/summer months (Chapter 5).  There also, however, appeared to be a 
seasonal distribution in the virus detection rates (Chapter 5); the study (Chapter 5) 
suggested that calendar month was a more important risk factor for virus shedding 
than age or weaning status.  This observation was similar to a previous report by 
Gilkerson et al. (1994) but contrasts with findings in Japan (Matsumura et al., 1992).  
Seasonal factors could be pollen or dust levels, which in Western Australia increase 
markedly during summer months, and/or management factors such as yearlings 
being broken in March/April and two year old horses commencing training in 
August/September.   160
The studies reported in Chapter 6 demonstrated that EHV2 was an aetiological 
agent of respiratory disease in weanling foals.  While EHV2 has been suggested as 
a cause of disease by many authors (reviewed in Chapter 2) these reports all 
described “EHV2” prior to the classification of the gammaherpesviruses into 2 types, 
and it seemed likely that if there were 2 related gammaherpesviruses and not one 
as previously thought, the previous reports which considered them as only one type 
could contain misleading information.  In Chapter 6, EHV2 as opposed to EHV5, 
was associated with respiratory disease in 3 of 11 groups of weanling foals that 
were examined, present in 26 of 35 (74.2%) of foals with clinical respiratory 
symptoms, and it therefore appears to be associated with respiratory disease in 
younger animals in Western Australia.  In contrast, EHV2 was infrequently isolated 
from clinically normal foals, wherein it was detected in only 4 of 109 (3.6%) healthy 
foals without respiratory symptoms.  Whether the EHV2 was a primary cause of the 
respiratory disease or whether it acted in concert with other infectious agents 
remains to be determined, the data obtained only indicates that it was associated 
with respiratory disease.  It has been previously suggested that “EHV2” infection 
may predispose to infection by other viruses or bacteria (Palfi et al., 1978; Belak et 
al., 1980; Nordengrahn et al., 1996) perhaps acting as an immunosuppressive 
agent (Browning & Studdert, 1988; Murray et al., 1996).  Evidence of 
immunosuppression after both in vitro and in vivo infection with “EHV2” was 
reported by Fu et al. (1986), and “EHV2” has been proposed to act as a trans-
activating factor, which may either trigger or upregulate EHV1 and EHV4 expression 
from a latent state (Edington et al., 1994, Welch et al., 1992; Camarda et al., 1999, 
Purewal et al., 1992; Purewal et al., 1998). It has also been suggested that that 
EHV2, similarly to other gammaherpesviruses, encodes ORFs with significant 
homology to cellular immunomodulatory proteins (Telford et al., 1995; Camarda et 
al., 1999).    161
Attempts were made to produce respiratory disease in young horses by inoculation 
of cell-culture replicated EHV2 that had been isolated from one of 3 groups of foals 
with EHV2-associated respiratory disease (reported in Chapter 6).  Mild signs of 
respiratory disease were induced in the experimentally infected horses after they 
were infected intratracheally with the cultured virus.  While these results support the 
field evidence of the association of EHV2 with respiratory disease, and provide 
additional evidence that EHV2 is a potential cause of respiratory disease in young 
horses, the infection experiments should be repeated.  Problems associated with a 
background level of EHV5 and the possibility that EHV2 acts in concert with other 
infectious agents needs to be addressed.  In any horses used for experimental 
purposes, latent virus infections needs to be considered; it is possible that the stress 
associated with the purchase of the horses, with transportation of the horses, with 
the experimental infections, may reactivate other latent herpesvirus infections.  All 
the experimental horses used were infected with EHV5; this is such a common virus 
that it would be hard to put together a group of horses that were not infected, and 
the possibility of a synergism of EHV2 and EHV5 cannot be discounted.  
Reactivation of latent EHV1 and EHV4 was not observed in the horses 
experimentally infected with EHV2 and reported in Chapter 6.  
In contrast to EHV2, EHV5 was commonly detected in the NS and PBL of clinically 
normal horses (Chapter 4) and it was also commonly detected in normal weanling 
foals (Chapter 6).  It was the most common virus detected in horses, present in 
either the PBL or NS of 83.2% of normal horses <2 years of age (Chapter 4).  In 
normal horses >2 years of age the prevalence of EHV5 was less although it was still 
common and was detected in either the PBL or NS of 40% of these horses (Chapter 
4).  It was also detected in NS and/or PBL of 81% (89/109) of healthy weanling foals 
(Chapter 6).  These prevalence rates are higher than has been reported previously 
by Dunowska et al. (1999) and Dunowska et al. (2000).  The high prevalence of   162
EHV5 in normal horses suggests it is an unlikely cause of respiratory disease, and 
provides a possible explanation for why “EHV2” has been associated with a 
multitude of conditions in horses. 
A major problem in the interpretation of the EHV data reported in this thesis, 
however, and especially the data obtained from PBL, was that the techniques 
utilised did not differentiate whether the viruses detected represented actively 
replicating virus or latent virus infections.  It is presumed that the co-culture 
techniques would activate latent virus from PBL, and similarly that the PCR 
procedure would detect DNA that could have been associated with a lytic virus 
infection or with latent virus.  It is suggested that future studies could utilise direct 
PCR in conjunction with techniques that will differentiate lytic and latent virus 
infections.  The detection of mRNA encoding the structural proteins, by reverse-
transcriptase (RT) PCR, would be indicative of lytic virus infection, and the detection 
of latency associated transcripts (reviewed in Chapter 2) would be indicative of 
latent virus infection.  Latency-associated transcripts have been identified for EHV1 
and EHV4 (Baxi et al., 1995; Chesters et al., 1997; Borchers et al., 1999b) and need 
to be identified for the gammaherpesviruses.  The use of such techniques to 
determine the prevalence of latency and factors initiating re-activation would seem 
to be important in future epidemiological investigations of EHV infections.   
The high prevalence of EHV DNA and virus in NS and PBL of most clinical healthy 
horses is interesting and it remains to be determined if this represented continued 
(maybe low level) lytic infection of cells in the tissues sampled, or latent virus 
infection.  The site of latency of EHV5 has not been reported but the high 
prevalence rate of EHV5 DNA and the ability to reactivate EHV5 from PBL suggests 
PBL are a primary site of latency of EHV5.  Hopefully, future studies will produce 
methods that will discriminate between active and latent EHV5 infection to further 
our understanding of the pathogenesis of EHV5 infection in the horse.     163
Another valuable technique that needs to be developed for furthering our 
understanding of the different role of EHV2 and EHV5 in disease in the horse is the 
development of specific and sensitive serological techniques that will differentiate 
antibody to EHV2 and EHV5.  Currently available serological tests for determining 
the role of EHV2 as a cause of disease has been of minimal value (McGuire et al., 
1974; Rose et al., 1974; Jolly et al., 1986).  The two viruses cross-react 
antigenically and techniques such as serum neutralisation do not differentiate 
antibody to the 2 gammaherpesviruses, although they do possess type-specific 
epitopes (Agius et al., 1994).  In a limited study of neutralising antibody levels in the 
experimentally infected horses (Chapter 6) levels of neutralising antibody were low, 
there was no increase associated with EHV2 infection, and there was no 
discrimination between levels detected using EHV2 and EHV5 as antigens.   164
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